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GENERal baCkGROuNd
Medicine is decision making
Making decisions about the care of individual patients is fundamental to health care. For 
each patient, many decisions have to be made. In the emergency room, for example, a 
doctor should decide which patient to see first, decide whether an x-ray should be made of 
an injured ankle, and decide how this specific ankle fracture of this specific patient should 
be treated. Medical training is focused on acquiring the knowledge and experience to make 
such decisions. Other factors that are essential for patient care, including empathy and 
technical abilities, also involve decision making. For example, in the outpatient clinic, a 
trade-off is needed when one patient needs more time and empathy, but the waiting room 
is packed and the physician is an hour behind schedule. In the operating room, a surgeon 
must decide whether to proceed with a complicated laparoscopic procedure to remove a 
gall bladder, to convert to an open procedure, or to ask a more experienced surgeon for 
help.
Informal decision making is prone to error
In daily practice, most medical decisions are based on experience and judgment. Infor-
mally, an assessment is made of the probabilities and outcomes of each alternative, as well 
as the patient’s preference for each outcome. Unfortunately, human judgment is fallible: 
people (including professionals) can make severe errors in estimating probabilities and out-
comes.1 Therefore, patients may benefit from a formal assessment of the probabilities and 
outcomes involved in a medical decision. Many decisions are nowadays resolved by such a 
formal assessment. For example, whether to make an x-ray of an injured ankle is resolved 
based on a decision rule.2 On the other hand, a formal consideration of each individual 
decision with which a doctor is confronted seems infeasible.
Paradigms for formal assessment of decisions
Medical decision making (MDM) and evidence-based medicine (EBM) are separate para-
digms that provide tools for formal assessment of medical decisions. They were developed 
because of concerns about human judgment, practice variation, and the proliferation of 
diagnostic and treatment options.3 The mainstay of EBM is critical literature appraisal, 
starting with an answerable clinical question that is summarized in the mnemonic PICO: 
patient’s problem, intervention, compare with alternative intervention, and outcome. The 
results of such an appraisal still demand considerable informal judgment on the part of the 
clinician: for example, results may not apply very well to an individual patient or studies 
may have conflicting results. Moreover, patient preferences, rare events, and health care 
costs are typically ignored in EBM, meaning that informal judgment on the part of the cli-
nician still plays a role. MDM applies decision models to guide medical decisions and has 
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a strong foundation in decision theory.4 Decision models can bring together all available 
evidence relevant for a decision; for example, disease incidence from population statistics, 
treatment effects from meta-analyses, patient preferences and rare complications from 
observational studies, and costs from medical claims databases. The model has no limit 
to the number of alternatives compared or to the length of follow-up. The aim of MDM is 
to perform a complete formal assessment of every aspect that is relevant for a decision. 
The main drawback of decision models is that building them is very time consuming. As a 
result, EBM has a higher acceptance in daily patient care and MDM in guideline develop-
ment, health policy, and cost-effectiveness analysis.
Decision making and health care costs
Consideration of cost in addition to health benefits has more recently complicated decision 
making in health care. More beneficial health care interventions have become available 
than a health care system can afford. Priorities therefore have to be set. Most new interven-
tions are beneficial but also more costly. Implementing such interventions requires increas-
ing the overall health care budget or withholding other interventions. The latter seems fair 
only if the new intervention has a better value for money. The purpose of cost-effectiveness 
analysis is to provide information regarding the decision to implement new interventions by 
weighing the additional benefits against the additional costs. As a result, it may improve 
people’s health by setting the appropriate priorities. As Stinnett noted, “investing in a cost-
ineffective intervention is not simply an unwise use of money in some vague sense, but a 
foregone opportunity to achieve greater gains in people’s health”.5 The cost-effectiveness 
of interventions is evaluated in clinical trials or in decision models. Trials have appeal be-
cause of a high internal validity6, but only models can synthesize all available evidence.7 
The National Institute for Health and Clinical Excellence (NICE) makes recommendations 
on the adoption of health care interventions in the United Kingdom. In doing so it is re-
quired to explicitly consider cost-effectiveness.8 
Decision making and uncertainty
Decision making is further complicated by uncertainty about probabilities and outcomes. 
For example, clinical trials often lack power to draw definitive conclusions. Even if arbi-
trary levels of significance are reached (typically a p-value < 0.05), there remains a finite 
possibility that the supposedly optimal intervention is not the “true” optimal intervention. 
However, while tests of hypotheses are relevant for exploring scientific phenomena, they 
are less useful in decision making. A decision has to be made, regardless of the amount of 
evidence and the extent of uncertainty.
Uncertainty is an even larger problem if clinical trials also consider health care costs, be-
cause the variation in costs typically exceeds the variation in health outcomes, requiring 
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larger sample sizes. When most uncertainty has been resolved at the decision level, uncer-
tainty will remain at the patient level. For example, little doubt remains that a patient (in 
a good general condition) with a 7 cm aneurysm of the abdominal aorta is expected to be 
better off with elective repair of his aneurysm. However, it is still uncertain whether or not 
he will survive the intervention.
Various methods are used to present uncertainty. For clinical trials measuring efficacy, the 
consensus is that confidence intervals rather than p-values should be used to present the 
results. Confidence intervals don’t blend magnitude and precision of the results, allowing 
for assessment of medical relevance in addition to statistical significance.9 For cost-effec-
tiveness analyses, the presentation of uncertainty is more complicated, and no consensus 
exists. The analysis and presentation of uncertainty in cost-effectiveness analyses is the first 
main focus of this dissertation.
Decision making and Bayesian methods
When clinicians evaluate the results of a new clinical trial, they informally consider other 
relevant evidence and judgment. For example, most clinicians will demand stronger ex-
perimental evidence for a homeopathic drug, of which efficacy other than placebo would 
conflict with chemistry than for a drug that was developed based on understanding of 
biochemical pathways. Bayesian methods enable an explicitly quantitative use of external 
evidence and judgment when interpreting data from a study.10 This approach acknowledg-
es that most decisions will not be based exclusively on the results of a single study. Bayes' 
theorem is a formula that can determine how evidence and uncertainty about the effect of 
interventions are changed by a new study. Currently, Bayes’ theorem is not commonly used 
in interpreting the results of new studies. However, Bayesian methods are increasingly used 
in MDM. Moreover, Bayes’ theorem is applied informally on a daily basis by doctors when 
they interpret diagnostic test results. For example, for a patient with a typical presentation 
of acute appendicitis, a moderate leucocytosis may add up to sufficient evidence to pro-
ceed to surgery. In a patient with non-specific abdominal pain, the same leucocytosis may 
not justify immediate surgery. Both the leucocytosis and the outcome of a new clinical trial 
are interpreted in light of what is already known.
Uncertainty and the need for more research
Clinical trials often show no statistically significant difference between the treatments com-
pared. Two erroneous conclusions are common about the need for more research. Some 
authors conclude that the decision has been settled: the interventions are equivalent, and 
more research is not needed. However, it can and does occur that a clinically relevant 
difference is not found because the study did not have sufficient power to detect relevant 
differences.11 In a famous quote, Altman warned that “absence of evidence is not evidence 
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of absence”.12 Other authors conclude the exact opposite — more research is needed — 
based on a similar non-significant difference. They seem convinced that there must be 
a difference and because it wasn’t found with the current study, another (larger) study is 
needed. Phillips pointed out that the conclusion “more research is needed” requires some 
assessment of this research’s expected benefit for future patients in relation to the cost 
of the research. He observed that studies in health care typically conclude that “more re-
search is needed” without such an assessment.13 Value of information (VOI) analysis evalu-
ates uncertainty resulting in a formal assessment of the expected benefit and the cost of a 
proposed study.14 VOI analysis is the second main focus of this dissertation.
Uncertainty and sample size calculations
When more research seems justified, the investigator should choose an optimal sample size 
for the proposed study. Decision uncertainty will decrease with increasing sample size, but 
the study costs will increase. Most sample size calculations are based on arbitrary values 
for the minimal clinically relevant difference in treatment effect, the level of significance 
(typically ®=0.05) and desired power (typically 1-¯=0.8). In practice the input parameters 
are often chosen to result in a predetermined sample size that primarily reflects feasibility 
and cost.15 As an alternative to these arbitrary methods, VOI analysis can find the optimal 
sample size of a proposed study.
dEvElOPMENTS aNd ChallENGES
In this section we discuss the main developments regarding the analysis and presentation 
of uncertainty in cost-effectiveness analyses and VOI analysis. The analysis of uncertainty 
focuses on decision models. Developments regarding VOI analysis apply to both decision 
models and patient-level data from clinical trials.
Analyzing parameter uncertainty in decision models
The outcomes of a decision model depend on uncertain parameters, including probabili-
ties, health state utilities, and costs. Deterministic sensitivity analysis can explore how the 
model outcomes change when individual parameters are varied across an often arbitrary 
range. The conclusions of a model may appear robust when the optimal intervention is 
insensitive to these analyses. However, a change in optimal intervention may prove more 
likely if several parameters are varied simultaneously. Unfortunately, deterministic sensitiv-
ity analysis allowing more than two parameters to vary simultaneously is rather cumber-
some. Moreover, the analyses don’t present how likely each model outcome is.
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Probabilistic sensitivity analysis (PSA), also known as second-order Monte Carlo simulation, 
was introduced to evaluate uncertainty of all parameters simultaneously.16, 17 Probability 
distributions are assigned to each parameter and propagated through the model resulting 
in probability distributions for the model outcomes. A distribution of the expected outcome 
presents the range of possible outcomes as well as the probability of each outcome. The 
National Institute for Health and Clinical Excellence (NICE) in the United Kingdom requires 
PSA for the assessment of health technologies.18, 19
Stochastic uncertainty can complicate the assessment of uncertainty in decision models. A 
PSA in a patient-level model, also known as microsimulation model, requires a computer-
intensive two-level Monte Carlo simulation to obtain the distribution of the expected out-
come.20 The most common rationale for patient-level models is that events within the model 
influence subsequent probabilities, utilities, or costs. The simultaneous analysis of patient 
heterogeneity and parameter uncertainty poses another challenge.21 Subgroups should be 
evaluated because the cost-effectiveness of an intervention may vary across subgroups.
Presenting uncertainty of cost-effectiveness analyses
Guidelines for cost-effectiveness analyses require that a measure of uncertainty is pre-
sented in addition to point estimates.6 Typically the preferred measure of uncertainty is not 
specified because no consensus exists about the optimal measure. The cost-effectiveness 
plane (CE plane) may seem an attractive candidate because it presents the joint distribu-
tion of each intervention.22 For the comparison of two interventions, the CE plane can 
present the incremental joint distribution. The main drawback of the CE plane is that it can 
overestimate decision uncertainty when more than two interventions are compared and — 
additionally — the outcomes of the interventions are positively correlated. While clinical 
trials typically compare two interventions, comparing more than two positively correlated 
interventions is the rule rather than the exception in decision models.
In the search for alternatives, separate hypothesis tests for costs and effects were quickly 
dismissed.23 Instead, many methods were developed for inference about the incremental 
cost-effectiveness ratio (ICER).24, 25 However, it was soon realized that uncertainty intervals 
for the ICER are only valid when the incremental distribution is limited to the first or third 
quadrant of the CE plane.5 Inference about the ICER became less popular, because any 
decision requiring formal consideration has some uncertainty regarding the sign of either 
incremental cost or effect. Van Hout introduced the cost-effectiveness acceptability curve 
(CEAC) as an alternative to the discredited inference about the ICER.26 The curve provides 
a graphical presentation of the probability that an intervention is optimal, across a range 
of values of the willingness-to-pay (wtp). CEACs are created using bootstraps of patient-
level data or the results of a PSA in decision models. The main drawback of CEACs is that 
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they consider only the probability of selecting a suboptimal intervention and not the con-
sequences.
 
Stinnett introduced the net benefit framework as another alternative to analyze and pres-
ent uncertainty.5 The net health benefit (NHB) is defined as: NHB = health effect – cost/
willingness-to-pay. Standard statistical methods can now be applied to calculate point 
estimates and uncertainty intervals using patient-level data or PSA results of a decision 
model. For patient level data, the analyst can choose between assuming normality of the 
mean NHB — based on the central limit theorem — or non-parametric methods such as 
bootstrapping. The (incremental) NHB can be presented graphically including uncertainty 
boundaries across a range of values for the wtp, similar to a CEAC. The main drawback 
of this presentation is that it can overestimate decision uncertainty when more than two 
interventions are compared and — additionally — the outcomes of the interventions are 
positively correlated.
VOI analysis
The analysis of uncertainty is particularly relevant for the decision as to whether more 
quantitative research (e.g., a clinical trial) regarding the competing interventions is justi-
fied.27 A future study could reduce uncertainty, which is expected to benefit future patients 
or reduce health care costs. A cost-benefit trade-off should be made — before performing 
a study — between the expected cost and the expected benefit of a proposed clinical study. 
The trade-off assumes that money spent on either health care or research aims to improve 
the health of patients and that the funds come from the same limited resources. VOI analy-
sis can estimate the expected benefit of a proposed study using a decision model or the 
results of a clinical trial. The analysis involves integrating the probability of implementing 
a suboptimal intervention with the associated consequences in foregone health benefits or 
increased health care costs.
Investigators increasingly use VOI analysis to analyze and present uncertainty in medical 
decision making.28 VOI analysis was introduced by Grundy29 in the late fifties and developed 
by Raiffa and Schlaifer.4 Howard noted in 1966 that: “Placing a value on the reduction of 
uncertainty is the first step in experimental design, for only when we know what it is worth 
to reduce uncertainty do we have a basis for allocating our resources in experimentation 
designed to reduce the uncertainty.”30 In 2002, Claxton introduced the philosophy of VOI 
analysis to the clinical audience of the Lancet.14 Moreover, he demonstrated the feasibility 
of VOI analysis to guide the research priority setting of the National Health Service in the 
United Kingdom.31 Ades clarified the mathematical notation and algorithms for the various 
VOI analyses.32
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VOI analysis typically starts with estimating the total expected value of perfect informa-
tion (total EVPI). It is the expected benefit per patient of a study with an infinite sample 
size, resulting in perfect information about all (total) uncertain parameters. Such a study 
would eliminate all uncertainty, but is of course hypothetical. The population EVPI is the 
total EVPI per patient multiplied by the number of future patients expected to benefit from 
the results of a proposed study. More research is not justified if the population EVPI is less 
than the fixed costs of a future study. If the population EVPI exceeds the fixed costs, more 
research is potentially justified.
Currently, VOI applications using patient-level data or complex decision models typically 
don’t proceed beyond estimating the population EVPI.33, 34 However, VOI analysis can also 
help to identify the study that maximizes the difference between the expected benefit for 
future patients and the expected cost of the study. This optimal study is characterized by its 
design (e.g., randomized controlled trial), the subset of sampled parameters (e.g., quality 
of life only, or a selection of cost parameters), the sample size, and the associated study 
costs. Partial VOI analysis is performed to select the optimal subset of sampled parameters, 
representing key parameters that are responsible for most of the decision uncertainty. The 
expected value of sample information (EVSI) is estimated to find the optimal sample size of 
a study. The required methods to find the optimal study — estimating the partial EVPI and 
partial EVSI — were only recently resolved and require considerable computational time. 
These methods are typically applied to hypothetical data or simple decision models. These 
initial examples often used closed form solutions, while increasingly complex applications 
require simulation methods.28
OuTlINE Of ThIS dISSERTaTION
The research presented in this dissertation is divided over eight chapters. In general, Chap-
ters 2 to 6 have a more methodological character. Chapters 7 to 9 present applications of 
novel methodology to clinical problems.
In Chapter 2 we introduce cost-effectiveness analysis to a clinical audience of surgeons. 
New interventions in surgery typically provide small additional health benefits and are more 
expensive in comparison to current care. If a health care system cannot afford all beneficial 
new interventions, cost-effectiveness analysis can help set priorities. This article demon-
strates the basics of evaluating and performing cost-effectiveness analyses. In addition, 
we discuss various challenges for the application of cost-effectiveness analysis, including 
challenges specific to surgical interventions.
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Chapter 3 is a tutorial about uncertainty and patient heterogeneity in medical decision 
models. Parameter uncertainty, patient heterogeneity, and stochastic uncertainty of out-
comes are increasingly important concepts in medical decision models. We demonstrate 
the various methods to analyze uncertainty and patient heterogeneity in a decision model 
using a real-life example. Differences and analogies between the analyses are pointed out, 
as well as practical issues. The scope includes nested Monte Carlo simulations that are 
required in patient-level models for PSA and in nonlinear models for partial VOI analysis.
Chapter 4 focuses on the combined analysis of uncertainty and patient heterogeneity in 
medical decision models. When more than one type of uncertainty and heterogeneity is 
analyzed, the correct algorithm to obtain the model outcomes of interest can be com-
plicated. We distinguish eight model types, each dealing with a different combination of 
parameter uncertainty, patient heterogeneity, and stochastic uncertainty. The model out-
comes of interest include the expected outcome, the distribution of the expected outcome 
reflecting lack of perfect knowledge, the distribution of the expected outcome reflecting 
patient heterogeneity, and the distribution of the individual outcome. The analyses — re-
quired to obtain the model outcomes — are expressed in equations, explained in stepwise 
algorithms, and demonstrated in examples. Nested Monte Carlo simulations are necessary 
for most analyses.
In Chapter 5 we demonstrate the limitations of acceptability curves for presenting un-
certainty in cost-effectiveness analyses. Clinical journals increasingly illustrate uncertainty 
about the cost and effect of health care interventions using cost-effectiveness acceptability 
curves (CEACs). CEACs present the probability that each competing alternative is optimal 
across a range of values of the cost-effectiveness threshold. First, we discuss why uncer-
tainty is of interest to policy makers, since it may not be obvious that the evaluation of 
uncertainty results in better decisions. Next, we demonstrate and explain the various limita-
tions of CEACs. 
In Chapter 6 we evaluate two different approaches for estimating the partial expected value 
of perfect information (partial EVPI) to identify key parameters in cost-effectiveness analy-
sis. Both approaches have been described and applied in the literature, but they may result 
in different outcomes, and a different importance ranking of parameters. The objectives of 
this manuscript are to set out the correct methods to estimate partial EVPI and to explain 
and demonstrate why a generally recommended method is incorrect both conceptually and 
mathematically.
In Chapter 7 we apply VOI analysis to a decision model comparing various diagnostic tests 
for coronary heart disease. The objective is to design the optimal future study regarding 
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diagnostic tests for patients with chest pain. We estimated the partial EVPI for various study 
designs: observational studies for test characteristics and health state utilities, a cost study, 
and clinical trials measuring treatment effects. For the study measuring health state utilities 
we estimated the optimal sample size.
In Chapter 8 we apply VOI analysis to data from an economic clinical trial. Most published 
applications of VOI analysis have used decision models or hypothetical trial data. We ex-
plain how VOI analysis using patient-level data about costs and effects is simplified using 
several justifiable assumptions. As an example, we use data from a clinical trial comparing 
treatments of intermittent claudication. The objective of the VOI analysis is to design a 
future study that maximizes the difference between the expected benefit for future patients 
and the expected cost of the study. This optimal study is characterized by its design, the 
subset of sampled parameters, the sample size, and the associated study costs. 
In Chapter 9 we apply VOI analysis to guide future outcomes research regarding the use 
of MR imaging for patients with acute knee trauma in the emergency room setting. We 
estimate the total EVPI reflecting the expected value of eliminating all decision uncertainty 
that remained after completion of a clinical trial. In addition, we identify the parameters 
that are responsible for most of the decision uncertainty, evaluate the expected benefit of 
various study designs, and estimate their optimal sample size.
Finally, Chapter 10 summarizes the previous chapters, and Chapter 11 is an epilogue con-
taining some concluding thoughts and suggestions for future research.
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abSTRaCT
New interventions in surgery typically provide small additional health benefits and are more 
expensive in comparison to current care. If a health care system cannot afford all benefi-
cial new interventions, cost-effectiveness analysis can help set priorities. In this setting, 
surgeons increasingly encounter policy makers questioning the cost-effectiveness of the 
treatments they provide. Especially when writing guidelines, surgeons should understand 
cost-effectiveness analysis to evaluate the value for money of their interventions.
The value for money of a health care intervention can be expressed by its incremental 
cost-effectiveness ratio (ICER). The ICER is the ratio of the additional cost and the addi-
tional effect of an intervention (e.g., laparoscopic cholecystectomy) in comparison to an 
alternative intervention (e.g., open cholecystectomy) for the same patient. These costs and 
effects can be evaluated in randomized controlled trials or in decision models. This article 
demonstrates the basics of evaluating and performing cost-effectiveness analyses.
The application of cost-effectiveness analysis to help set priorities in health care faces sev-
eral challenges, including credibility, generalizability, and ethical implications. Additional 
challenges more specific to surgery include the learning curve for new surgical interven-
tions and the gradual improvement of surgical technology. Adherence to guidelines for 
cost-effectiveness analyses could address some challenges; other challenges simply reflect 
the difficulty of making decisions under uncertainty. Despite these challenges, priorities 
have to be set. In the UK cost-effectiveness is explicitly considered for the adoption of in-
terventions whereas in the US this is done more implicitly.
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INTROduCTION
“In 40 years of practice I never withheld a test or treatment that I thought would help my 
patients, even when I had to absorb the costs myself.”35 Like this surgeon, most surgeons 
want the best possible care for their patient, regardless of the costs. Surgeons, however, are 
increasingly likely to encounter value for money issues. Hospitals and insurance companies 
may interfere with their patient care when, for example, a PET scan is not reimbursed. In 
the development of novel technologies, such as laparoscopic procedures, surgeons often 
need to convince policy makers that the new interventions are good value for money. When 
writing guidelines, surgeons are expected to consider the value for money of their interven-
tions.
What has changed in recent decades is that more beneficial health care interventions have 
become available than a health care system can pay for. Priorities therefore have to be 
set. Interventions that are beneficial by reducing mortality or morbidity and save money 
are straightforward: They should be implemented. Most new interventions, however, are 
beneficial but more costly. Implementing such interventions requires increasing the health 
care budget – at the expense of, for example, welfare or education – or withholding other 
interventions. The latter seems only fair if the new intervention has a better value for 
money. Cost-effectiveness analysis aims to inform the decision to implement new interven-
tions by weighing the additional benefits against the additional costs. Its objective is not to 
cut health care costs. Cost-effectiveness analysis aims to improve the health of patients by 
setting the right priorities.
This article is organized as follows. First, we demonstrate the basic concepts of cost-effec-
tiveness analysis, using two recent examples from the surgical literature. We discuss how 
to find, evaluate, and perform cost-effectiveness analyses, especially in the field of surgery. 
We then address several important challenges for cost-effectiveness analysis, some specific 
to the analysis of surgical interventions. Finally, we address the current use and impact of 
cost-effectiveness analysis in the United States and the United Kingdom. 
chapter 2
24
COST-EffECTIvENESS aNalYSIS - ThE baSICS
Box 1 and 2 present summaries of two cost-effectiveness analyses that we use to illustrate 
some of the concepts in this section.
BOX 1: LUNG-VOLUME REDUCTION SURGERY
Methods
•	 Patients	with	severe	emphysema
•	 Lung-volume	reduction	surgery	vs.	medical	treatment
•	 Randomized	controlled	trial	–	1218	patients
•	 Societal	perspective
•	 Health	effects:	mortality,	exercise	capacity,	quality-of-life
•	 Cost:	medical	and	non-medical	costs,	based	on	resource	use	in	trial	and	Medicare	charges
•	 Time	horizon:	3	years	trial	data	plus	7	years	modeled
•	 Discounting:	both	cost	and	effects
Cost-effectiveness analysis
•	 Surgery	more	effective:	difference	of	0.19	QALYs
•	 Surgery	more	costly:	difference	of	36,000$
•	 ICER	of	190,000	$/QALY
Subgroups
•	 upper-lobe	emphysema	and	low	baseline	exercise	capacity:	ICER	of	98,000	$/QALY
•	 non-upper-lobe	emphysema	and	low	baseline	exercise	capacity:	ICER	of	330,000	$/QALY
•	 Substantial	uncertainty	for	subgroup	estimates
Model with 10 years time horizon
•	 at	10	years:	ICER	of	53,000	$/QALY
•	 Substantial	uncertainty	for	10-year	estimates
Conclusion
For patients with severe emphysema – esp. with upper-lobe disease and 
low baseline exercise capacity – lung-volume reduction surgery may be 
cost-effective as compared to medical treatment.
25
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Health effects
When evaluating surgical interventions, we are typically interested in more than one health 
effect or outcome. For example, the study on lung-volume reduction surgery considered 
both mortality and the exercise capacity of the patients (box 1).36, 37 The patient and the 
surgeon have the difficult task of aggregating and integrating these outcomes with the pa-
tient’s preferences. Using quality-of-life as the outcome measure has the advantage of ag-
gregating all health outcomes, except survival. Several methods are available to measure 
the quality-of-life.38 The study on lung-volume reduction surgery also measured quality-
of-life with a questionnaire at baseline, at 6 months, at 12 months, and yearly thereafter. 
The	outcome	quality-adjusted	life	expectancy	(QALE)	integrates	the	survival	data	with	the	
quality-of-life	and	is	expressed	in	quality-adjusted	life	years	(QALYs).	This	aggregate	mea-
sure is commonly used in cost-effectiveness analyses and facilitates the comparison of 
interventions.
BOX 2: PRIMARY HYPERPARATHYROIDISM (PHPT) 
Methods
•	 Observation	vs.	pharmacologic	vs.	parathyroidectomy	(PTX)
•	 Asymptomatic	60-year-old	patient	with	PHPT
•	 Decision	model
•	 Third-party-payer	perspective
•	 Health	effects:	QALYs
•	 Costs:	medical	costs	using	charges
•	 Time	horizon:	remaining	life	time
•	 Discounting:	both	cost	and	effects
Cost-effectiveness analysis
•	 PTX	more	effective	than	observation:	difference	of	0.16	QALYs
•	 PTX	more	costly	than	observation:	difference	of	$800
•	 ICER	–	PTX	vs.	observation:	$5,000	per	QALY
•	 Pharmacologic	more	effective	than	PTX:	difference	of	0.01	QALYs
•	 Pharmacologic	more	costly	than	PTX:	difference	of	$176,000
•	 ICER	–	pharmacologic	vs.	PTX:	$21,000,000	per	QALY
•	 Sensitivity	analysis:	robust	regarding	costs	and	complications,	sensitive	to	quality	of	 life	 improvement	
after	PTX
Conclusion
For	60-year-old	patients	with	asymptomatic	PHPT,	PTX	is	very	cost-effective	
as compared to observation and pharmacologic treatment is not cost-effective. 
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Costs
For an unbiased comparison of the costs of interventions, all short-term and long-term 
costs should be included. The study on primary hyperparathyroidism (box 2) included the 
costs of surgery, diagnostic tests, hospital stay, complications, medications, physician’s 
fees, and follow-up visits.39 Consideration of some costs depends on the perspective from 
which the analysis is conducted. From the societal perspective, non-medical costs – includ-
ing the costs of patient’s time and travel, as well as productivity loss during illness – are rel-
evant in addition to medical costs. However, they may not be relevant from the third-party 
payer’s perspective. The study on lung-volume reduction surgery (box 1) was performed 
from the societal perspective and included both medical and non-medical costs. Even if a 
study represents your perspective, the costs may not be representative for your setting. The 
study on lung-volume reduction surgery (box 1), for example, used US costs that may dif-
fer from costs in other countries. The source of the cost data is also important. The study 
on primary hyperparathyroidism (box 2), for example, used charges to represent the costs. 
Although data on charges are more readily available, they typically overestimate actual 
costs and require adjustments using cost-to-charge ratios.
Cost-effectiveness
An intervention is considered cost-effective when it has an additional health benefit deemed 
worth the additional cost.40 The value for money of a health care intervention is usually 
measured by its incremental cost-effectiveness ratio (ICER). The ICER is the ratio of the 
additional cost and the additional effect of an intervention (e.g., laparoscopic cholecystec-
tomy) in comparison with an alternative (e.g., no surgery or open cholecystectomy) for the 
same patient. The cost-effectiveness of an intervention can be expressed in, for example, 
cost per life-saved, cost per life-year saved, or cost per averted cancer. 
The study on primary hyperparathyroidism (box 2) estimated the cost per quality-adjusted 
life-year	(QALY)	of	each	intervention.	The	advantage	of	using	QALYs	to	measure	health	
effects is that it allows comparison of the value for money of preventive, diagnostic and 
therapeutic health care interventions for different indications or disease areas. For ex-
ample, the cost-effectiveness of parathyroidectomy for asymptomatic primary hyperpara-
thyroidism (box 2) can be compared directly with other commonly adopted interventions 
such as kidney dialysis. All health care interventions can be ranked according to their cost-
effectiveness. In theory, the greatest health of a population is reached when interventions 
are funded from the top of the cost-effectiveness ranking downward until the health care 
budget is exhausted. The state of Oregon has attempted to establish a priority list for its 
Medicaid benefit package following such a framework, although the final plan differs from 
its original conception after much controversy.41 Other factors than cost-effectiveness were 
important to policy makers; some of these issues will be discussed later.
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A	universally	agreed-upon	threshold	value	for	the	cost	per	QALY	does	not	exist,	despite	that	
several	figures	–	for	example,	$50,000	or	$100	000	per	QALY	gained	–	are	frequently	cited.	
In evaluating interventions in the developing world, the World Health Organization gives 
the following general guidance: an ICER of less than the GDP (gross domestic product) per 
capita is very cost-effective, between 1 and 3 times GDP per capita is cost-effective, and 
more than 3 times GDP per capita is not cost-effective.42 For the US in 2007 these values 
would	 be	 $46,000/QALY,	 between	 $46,000	 and	 $138,000/QALY,	 and	 $138,000/QALY	
respectively.43	Alternatively,	the	cost	per	QALY	can	be	compared	with	established	ICERs	of	
generally accepted interventions. For example, the ICER for kidney dialysis and statins are 
often used to advocate adoption of interventions with lower or similar cost-effectiveness.
Study design
Surgeons often encounter cost-effectiveness analyses as part of a randomized controlled 
trial. Data on resource use (e.g., the number of hospital days) is collected for each pa-
tient together with health outcomes. The study on lung-volume reduction surgery (box 1) 
used this design. Randomization minimizes confounding on both cost and effectiveness 
estimates, resulting in high internal validity. Patients in clinical trials, however, often differ 
from the general patient population in demographics or disease severity and may receive 
care different from normal practice, resulting in lower external validity (or generalizability). 
Moreover, the follow-up period in trials is often insufficient to observe all relevant costs and 
effects. For example, endovascular repair of abdominal aortic aneurysms results in more 
re-interventions in the long-term than open repair. Not considering the cost and harm of 
these re-interventions can lead to a bias favouring endovascular repair. Another poten-
tial drawback of trials is that they are often under-powered to capture differences in rare 
complications44 – for example, injury to the common bile duct in open versus laparoscopic 
cholecystectomy. 
An alternative study design is to use a decision model to assess cost-effectiveness. These 
models aim to bring together all available evidence from various sources – for example, 
disease incidence from population statistics, treatment effects from meta-analyses, rare 
complications from observational studies, and costs from medical claims databases. The 
model has no limit for the number of alternatives compared or the length of follow-up. 
However, in building a model many assumptions – sometimes implicit – are made. Conse-
quently, models that consider the same interventions may show large variation in incremen-
tal cost-effectiveness ratios, as has been demonstrated for screening for abdominal aortic 
aneurysms.45 Advocates for economic trials continue to emphasize their internal validity, 
while advocates for models stress their external validity and consideration of all available 
evidence. Their relative value depends on the decision at hand and the available evidence.
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Time horizon and discounting
Cost-effectiveness analyses must have an appropriate time horizon to include all relevant 
(immediate and future) costs and effects associated with the interventions. For example, 
the study on primary hyperparathyroidism (box 2) considered the lifetime costs of calcitriol 
when surgery inadvertently resulted in hypoparathyroidism. Such future costs should be 
discounted to “present values”. The rationale behind discounting costs is that people would 
rather pay a bill in 10 years than today. Surgical interventions typically incur most costs up-
front, whereas medical treatments may involve long-term cost. As a result, parathyroidec-
tomy for primary hyperparathyroidism appears less cost-effective compared with medical 
treatment when costs are discounted than if costs are undiscounted. Analogously, future 
health effects are discounted because people also prefer immediate health gains over the 
same gains occurring in the future. For example, a screening program for colon cancer ap-
pears less cost-effective when the future health benefits are discounted than if discounting 
is omitted. Often analysts present both undiscounted and discounted results.
Uncertainty
Just like other clinical outcome measures, ICERs calculated from randomized controlled 
trials are imprecise because of the finite sample size. This uncertainty is often presented 
as the probability that an intervention is cost-effective, under different threshold criteria 
of cost-effectiveness. In decision models uncertainty is typically explored using sensitiv-
ity analysis. Key parameters are varied across a plausible range and the impact on the 
ICER is presented graphically. The study of primary hyperparathyroidism (box 2) performed 
Figure Sensitivity analysis for the quality-of-life (or quality adjustment 
factor) for asymptomatic hyperparathyroidism. The reference case is the 
best estimate for the quality-of-life that was used for the main results. 
Surgery would be the preferred intervention for values for the quality-of-
life	below	0.998,	assuming	a	threshold	for	acceptable	ICERs	of	$50,000	
per	QALY.	–	reprinted	with	permission	from	Surgery	2006;140:874-81.
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sensitivity analyses and found that the conclusion is sensitive to the assumption on the 
quality-of-life improvement expected after parathyroidectomy in asymptomatic 60-year-
old patients (Figure). However, the cost-effectiveness of parathyroidectomy is quite stable 
given a plausible range of costs and complication rate estimates. This indicates that further 
research yielding more precise estimates of the quality-of-life improvement would make the 
model more robust.
Checklist and read more
Box 3 presents a concise checklist for evaluating and performing a cost-effectiveness analy-
sis. It summarizes the issues that we have discussed in this section. More extensive guide-
lines for reporting cost-effectiveness analyses have been published.46, 47 Moreover, many 
textbooks are available about decision making in general, and about economic evaluation 
alongside clinical trials or using decision models.38, 48-50 Eddy has written an excellent series 
in the Journal of the American Medical Association in which he explains cost-effectiveness 
analysis to his father, a retired surgeon.35, 51-53 The Users’ Guides on Evidence-based Medi-
cine include 2 articles about economic analysis in clinical practice, which are also avail-
BOX 3: COST-EFFECTIVENESS ANALYSIS – CHECKLIST
Validity of the results
•	 Is	the	population	of	interest	well-defined?
•	 Are	all	relevant	alternatives	well-defined	and	considered?
•	 Is	the	perspective	stated	and	are	all	relevant	costs	included?
•	 Is	the	source	of	the	effect	provided?
•	 Is	the	measurement	of	the	quality-of-life	stated?
•	 Is	the	source	of	the	costs	provided?
•	 Is	time	horizon	sufficient	for	all	relevant	costs	and	effects?
•	 Is	discounting	applied	to	both	costs	and	effects?
•	 Regarding	models:	Are	the	structure,	data,	and	assumptions	disclosed	and	valid?
The results
Did the analysis consider;
•	 Incremental	costs	and	effects	for	each	strategy?
•	 Incremental	cost-effectiveness	ratio?
•	 Sensitivity	analyses	and	subgroup	analyses?
Applying results to my patient
•	 Does	the	study	reflect	my	patient	population?
•	 Does	the	study	reflect	my	perspective	and	setting?
•	 Which	intervention	should	I	adopt?	
chapter 2
30
able from the website of the Centre for 
Health Evidence in Canada.54-56 
COST-EffECTIvENESS 
aNalYSES IN ThE 
SuRGICal lITERaTuRE
Cost-effectiveness analyses of surgi-
cal interventions are increasingly per-
formed, although the absolute numbers 
are still low in comparison with other 
fields in health care.57 Kruper et al. 
found only 110 cost-effectiveness anal-
yses of surgical procedures between 
1995 and 2004.58 The Table presents 
some cost-effectiveness analyses of 
surgical interventions with their ICER.
Quality of cost-effectiveness 
analyses for surgical 
interventions
A good research study should comply 
with certain methodologic criteria to 
allow for evaluation of its validity. For 
example, most journals require authors 
to adhere to the CONSORT statement 
(www.consort-statement.org) for re-
porting trials. In the previous section we 
discussed similar methodologic check-
lists for cost-effectiveness analyses.46, 47 
A recent study evaluated cost-effective-
ness analyses of surgical procedures 
using a list of Blackmore et al. with 10 
basic methodologic principles.59 On 
average these studies adhered to only 
4 out of 10 principles: The perspective 
of the study is rarely defined, relevant P
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long-term costs are often not included, the outcome measure is sometimes unclear, and 
the source of the cost data is sometimes not explained.58 These observations present room 
for improvements for future cost-effectiveness analyses in the surgical literature.
Finding a cost-effectiveness analysis
Cost-effectiveness analyses of surgical interventions can be found in Medline (www.pubmed.
gov) using the Medical Subject Heading (MeSH) term “cost-benefit analysis”, which in-
cludes “cost effectiveness” as an entry term. In addition, 2 databases are accessible on the 
internet free of charge. The Economic Evaluation Database of the British National Health 
Service (www.crd.york.ac.uk/crdweb) contains over 7000 abstracts of quality assessed eco-
nomic evaluations. The same database is also available through the Cochrane Library. 
The Cost-effectiveness analysis Registry of Tufts Medical Center in Boston, MA (https://
research.tufts-nemc.org/cear/default.aspx) provides access to a comprehensive database 
of cost-effectiveness ratios in the medical literature. 
ChallENGES fOR COST-EffECTIvENESS aNalYSES
We will discuss several challenges for cost-effectiveness analysis of surgical procedures. 
Most of these challenges are also encountered with other types of studies and outside sur-
gery. The last 2 challenges are more unique to the applications in surgery.
Credibility of the cost-effectiveness analysis
Cost-effectiveness analyses are often performed using decision models. Surgeons may per-
ceive a decision model as a “black box”. Lack of transparency regarding data sources and 
assumptions is sometimes responsible for this perception. Therefore, researchers should 
clearly state all data sources and assumptions in a comprehensive and transparent fashion, 
as recommended by guidelines for cost-effectiveness analysis. Sensitivity analyses are also 
vital to enhance the credibility. The unfamiliarity with decision models, as compared with, 
for example, regression analyses, may also contribute to the perceived lack of credibility. 
Credibility concerns can also emerge when analysts using different decision models report 
diverging results for the same research question.45 The diverging results are explained by 
differences in data sources and assumptions. A vast amount of evidence from clinical and 
laboratory research is typically available pertaining to a medical decision and multiple 
assumptions may be reasonable. Small changes in these assumptions may have a large 
impact on the estimated cost-effectiveness of an intervention. Often, the diverging results 
simply reflect the uncertainty and disagreement about which data sources and assump-
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tions are most appropriate. However, the credibility of some cost-effectiveness analyses 
sponsored by the industry was recently challenged because they were more likely to report 
a favourable cost-effectiveness for the new intervention.60
Generalizability of the ICER
The results of a cost-effectiveness analysis may not be generalizable to the local setting of 
a surgeon. The analysis may be of limited use if the perspective (e.g., society or hospital) 
or the setting (e.g., UK or US cost data) is different. Sometimes this limitation can be over-
come by presenting the results for multiple perspectives or by providing details on relevant 
inputs to allow readers to adjust the calculations based on their own settings. Another con-
cern is that the results from a cost-effectiveness analysis may not apply to a specific patient. 
The cost-effectiveness of a surgical intervention depends on characteristics such as age, se-
verity of disease, and co-morbidities of the target population. A cost-effectiveness analysis 
typically reports the ICER for a so-called “base-case” analysis, for example, a 60-year-old 
white male with no co-morbidities. The reported cost-effectiveness may be different for an 
individual patient undergoing the same operation in your practice. Generalizability can be 
improved by reporting separate ICERs for all relevant subgroups. For example, in the study 
of lung-volume reduction surgery, surgery was only cost-effective for some subgroups of 
patients but not others.37
Ethical Implications
The theoretical foundations of the cost-effectiveness analysis framework often provoke 
debates on equity, fairness and ethics. For example, cost-effectiveness analysis may favour 
interventions that benefit younger people over interventions that benefit the elderly. A life-
saving treatment (e.g., an appendectomy) will be deemed more cost-effective for a patient 
with	a	 long	 life	 expectancy	 since	more	QALYs	 can	be	gained	 compared	with	 saving	an	
elderly patient. Cost-effectiveness analysis may also favour interventions for diseases for 
otherwise	healthy	patients:	More	QALYs	can	be	gained	compared	with	 saving	a	patient	
with	multiple	 co-morbidities.	 Furthermore,	 although	 the	QALY	measure	 captures	 health	
improvements in both quantity and quality of life, it does not distinguish between large 
gains for a small number of individuals versus small gains for a large number of individuals. 
The distribution of costs and health burdens across the population is not considered, which 
apparently disregards any societal preference for equity.
Cost-effectiveness analysis, therefore, aims to inform decisions; a program’s cost-effective-
ness should not be the only determinant of its adoption decision. The National Institute for 
Health and Clinical Excellence (NICE) in the United Kingdom considers factors other than 
cost-effectiveness for adoption.61 For example, an intervention is more likely to be adopted 
in spite of a high ICER given a high burden of disease, such as multiple sclerosis.
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Variation in quality of surgical care
Variation in outcome across surgeons has been well demonstrated.62 This variation is rel-
evant for both costs and health effects. For example, the cost-effectiveness of parathyroi-
dectomy depends on the rate of recurrent laryngeal nerve damage, which varies between 
surgeons. In addition, most new surgical interventions – for example, laparoscopic hemi-
colectomy - demonstrate a learning curve resulting in a period of suboptimal outcomes, 
possibly both in higher costs and in inferior clinical outcomes. Ideally, randomized con-
trolled trials should start only after reaching the plateau of the learning curve to obtain 
the appropriate ICER for these interventions. On the other hand, one could argue that 
the higher costs and complication rates associated with the surgical training are real and 
should be considered in adoption decisions. The cost-effectiveness also depends on varia-
tion in the details of the surgical procedure. A precise description of a surgical intervention 
is important to replicate the study results in daily patient care.
Gradual advances in surgery
The gradual improvement of surgical technique and technology causes another challenge 
more specific to surgery. Advances in surgery often occur from a series of small modifi-
cations to existing techniques. The effect of small changes may not become apparent in 
randomized controlled trial settings. As a result, by the time long-term results of a new 
technology are available, the current surgical intervention may differ from the evaluated 
intervention. For example, the cost-effectiveness of endovascular repair of abdominal an-
eurysms depends greatly on the long-term rate of re-interventions. When these long-term 
results become available, the technology of stents may have improved, requiring fewer re-
interventions. Consequently, the actual cost-effectiveness changes over time and remains 
uncertain.
dISCuSSION
New interventions in surgery typically provide small additional health benefits and are more 
expensive in comparison to current care. If a health care system cannot adopt all beneficial 
interventions, priorities have to be set by considering value for money. In this setting, sur-
geons are increasingly likely to encounter policy makers questioning the cost-effectiveness 
of their interventions. Surgeons must understand cost-effectiveness analysis to make guide-
lines for surgical diseases and interventions.
Several challenges exist for conducting and applying cost-effectiveness analysis in surgery. 
The challenge regarding generalizability, and to some extent credibility can be dealt with 
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by adherence to published methodologic guidelines. Other challenges do not represent a 
problem of cost-effectiveness analysis itself, but reflect the difficulty of making decisions 
under uncertainty. The ethical challenge emphasizes that cost-effectiveness analysis should 
not be the only factor in determining adoption of health care interventions. Despite these 
challenges, priorities have to be set.
The National Institute for Health and Clinical Excellence (NICE) makes recommendations 
on the adoption of health care interventions in the United Kingdom. In doing so, it is re-
quired to explicitly consider cost-effectiveness in addition to effectiveness.8 The cost per 
QALY	figure	is	used	to	inform,	but	not	determine,	their	decisions.	Medicare	in	the	United	
States – providing coverage to the elderly and disabled – does not explicitly consider cost-
effectiveness. Its reimbursement is limited to health care interventions that are “reasonable 
and necessary”.63 Efforts to explicitly consider cost-effectiveness in the United States have 
not been successful owing to methodologic challenges and the resistance from the phar-
maceutical and medical-device industry.64 Moreover, political risks are perceived because 
of a pervasive discomfort with medical decisions being influenced by anyone else than the 
patient and his or her physician.65 Considering cost-effectiveness, however, is inevitable to 
achieve the greatest health care benefit from any given level of Medicare spending. More 
open consideration of cost-effectiveness may happen in the United States after political 
change or increasing pressure on health care resources.66
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Uncertainty and patient 
heterogeneity in medical decision 
models
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abSTRaCT
Parameter uncertainty, patient heterogeneity, and stochastic uncertainty of outcomes are 
increasingly important concepts in medical decision models. The purpose of this paper is 
to demonstrate the various methods to analyze uncertainty and patient heterogeneity in 
a decision model. We distinguish various purposes of medical decision modeling, serving 
various stakeholders. Differences and analogies between the analyses are pointed out, as 
well as practical issues. The analyses are demonstrated with an example comparing im-
aging tests for patients with chest pain. For complicated analyses step-by-step algorithms 
are provided. The focus is on Monte Carlo simulation and value of information analysis. 
Increasing model complexity is a major challenge for probabilistic sensitivity analysis and 
value of information analysis. We discuss nested analyses that are required in patient-level 
models, and in nonlinear models for analyses of partial value of information analysis.
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INTROduCTION
Uncertainty and patient heterogeneity are receiving increasing attention in medical decision 
modeling. The National Institute of Health and Clinical Excellence (NICE) in the UK has ad-
vocated the use of probabilistic sensitivity analysis to assess parameter uncertainty.77 Value 
of information analysis has been introduced to estimate the expected benefit of future re-
search, reducing parameter uncertainty.14 At the same time, decision models have become 
increasingly complex, often requiring patient-level simulation which introduces stochastic 
uncertainty. Uncertainty about the model structure further complicates decision modeling. 
78, 79 Finally, patient heterogeneity is relevant, for example, to identify subgroups for which a 
new intervention is cost-effective.
The objective of this paper is to demonstrate the various methods to analyze uncertainty 
and patient heterogeneity in a decision model. We illustrate these methods with an example 
comparing imaging tests for patients with chest pain. Tutorials on uncertainty or patient 
heterogeneity in decision modeling have typically focused on a single methodology: for ex-
ample, probabilistic sensitivity analysis 16, 17, 80, or the expected value of perfect information81, 
82. A broader view avoids confusion about similar methods, such as first-order and second-
order Monte Carlo simulation. Moreover, appreciating value of information analysis, for ex-
ample, is facilitated when its relation with other methods addressing parameter uncertainty 
is understood. Our focus is on Monte Carlo simulation and value of information analysis. 
The scope of this paper also includes various nested simulations to accommodate multiple 
levels of uncertainty and patient heterogeneity.
We will distinguish various purposes of medical decision modeling, serving various stake-
holders. Before the advent of cost-effectiveness analysis, the patient and his doctor were the 
main stakeholders of medical decision modeling. Initially decision models were developed 
to improve the care of specific patients. Nowadays, many models in health care consider 
costs in addition to health effects and policy makers have become stakeholders too. NICE 
uses the cost-effectiveness outcomes of typically a base case cohort analysis to inform re-
imbursement decisions. We will demonstrate how analyses, other than the base case cohort 
analysis, using the same decision model, can serve additional purposes or stake holders.
In the next section we give a brief description of the decision problem, including a determin-
istic analysis, used as the primary example for the methods presented in this paper. In the 
sections that follow, we consider stochastic uncertainty, parameter uncertainty, model un-
certainty, and patient heterogeneity. For each analysis we provide step-by-step instructions. 
We provide verbal explanations of the analyses to avoid the hurdle imposed by mathemati-
cal notation. In appendix 2 we present the relevant equations. We assume familiarity with 
Markov cohort analysis and probability distributions.38, 83
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1. REal lIfE EXaMPlE
1.1 Decision problem: diagnostic strategies for patients with chest 
pain
Conventional catheter coronary angiography (CA) is considered the reference standard 
test that can distinguish patients with coronary heart disease (CHD) from patients without 
CHD. Unfortunately, CA has considerable drawbacks: it has a risk of mortality and morbid-
ity, and it is expensive. Multidetector computed tomographic angiography (CTA) is less ex-
pensive and has a minimal risk. Its test characteristics (sensitivity and specificity), however, 
are imperfect: CTA misclassifies both patients with CHD and those without CHD. The initial 
risk and cost of CA versus the harm and cost of misclassifying patients with chest pain is 
the main trade-off when choosing between these imaging tests.
Each year 400,000 patients in the USA newly present with chest pain that may be caused 
by coronary heart disease (CHD).84, 85 It is important to identify patients with CHD, since 
they can benefit from a coronary arterial bypass graft (CABG) or a percutaneous coronary 
intervention (PCI). The current decision problem is to find the optimal imaging test to di-
agnose CHD in patients with chest pain.
The available evidence regarding the costs and effects of imaging tests for diagnosing 
CHD was synthesized into a Markov model from the health care system perspective. The 
model extrapolated the evidence on costs and effects over the entire remaining lifetime of 
patients. Although earlier versions of the model compared various imaging strategies77, 86, 
for illustrative purposes we will now only compare CA with CTA. For comparison we will 
consider a third strategy, in which patients with chest pain receive medical therapy without 
an imaging test.
1.2 Decision model
In the model we assume that if a CTA test result was positive or uninterpretable, a CA fol-
lowed. Patients with a positive CA receive a PCI for one or two vessel disease and a CABG 
for three-vessel disease and left main disease. Both treatments have an associated disutility 
and a short-term risk of mortality and myocardial infarction. The beneficial effects of treat-
ment are three-fold: reduction in long-term mortality, reduction in long-term risk of myo-
cardial infarction, and reduction of chest pain severity. Age- and gender-specific life tables 
were used to model the subsequent lifetime outcomes using Markov models.87 Three chest 
pain states were distinguished in the model: no, mild, and severe chest pain. Moreover, 
each year patients may suffer a myocardial infarction or undergo a CABG or PCI, depend-
ing on the extent of the coronary heart disease and treatment history. We modeled the 
cost of tests and treatments, as well as the annual cost – depending on chest pain severity 
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and left ventricular ejection fraction – for patients with CHD. The model outcomes of each 
imaging	test	were	quality-adjusted	life	expectancy	(QALE)	and	expected	lifetime	costs.	We	
applied a half-cycle correction for all analyses.38 Tables 1 to 3 in appendix 3 present all 
model parameters with their 95% uncertainty interval and sources.
1.3 Deterministic analysis
We performed a Markov cohort analysis for 55-year old men (representing men aged 50 
to 59) with atypical chest pain. Table 1 presents the results of this deterministic analy-
sis, including incremental cost-effectiveness ratios (ICERs). Policy makers can conclude 
that	for	a	willingness-to-pay	(WTP)	of	less	than	$31,000/QALY	both	imaging	tests	are	not	
cost-effective.	CA	is	cost-effective	if	the	WTP	is	$85,000/QALY	or	more.	In	between	these	
threshold values, CTA is cost-effective.
 
2. STOChaSTIC uNCERTaINTY
Stochastic uncertainty – also known as first-order uncertainty or individual patient vari-
ability – represents the uncertainty in patient-level outcomes.88 This uncertainty is entirely 
due to chance.89 In decision models each chance node contributes to this uncertainty. For 
example, at a specific chance node a patient has an estimated probability of 3.2% that he 
will die from surgery. Stochastic uncertainty reflects the uncertainty related to the actual 
outcome - a patient may or may not fall within the 3.2% of patients that die – which should 
be distinguished from uncertainty around the 3.2% due to the limited sample of patients 
in which the value was estimated (i.e., parameter uncertainty) and from uncertainty about 
whether the 3.2% applies to this particular type of patient (i.e., patient heterogeneity). 
We evaluated stochastic uncertainty using first-order Monte Carlo analysis (a.k.a. micro-
simulation).38, 83 This analysis should not be confused with second-order Monte Carlo analy-
sis dealing with parameter uncertainty, which we discuss in section 3.2. A first-order Monte 
Carlo analysis simulates subjects one-by-one. Probabilities at chance nodes and a random 
number generator result in a subject’s path along the chance nodes. This path is called a 
Strategy Cost Incr Cost Effect Incr Effect ICER
No imaging test 26953 12.96567
CTA 34997 8044 13.22813 0.262 30649
CA 35153 156 13.22997 0.002 84836
Table 1 Results	of	the	deterministic	analysis	of	the	example	model.	All	costs	are	in	US$,	all	
effects in quality-adjusted life years. 
Incr, incremental; ICER, Incremental Cost-Effectiveness Ratio; CTA, multidetector computed 
tomographic angiography. CA, conventional catheter coronary angiography.
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random walk or a “trial”. Counters (a.k.a. tracker variables) can record the accumulated 
(quality-adjusted) lifetime and costs, as well as events along the subject’s path. When the 
subject dies, the simulation restarts with a new subject. We performed 10,000 random 
walks in the example model. Using the results of this analysis we can calculate, for ex-
ample, that the probability that a 55-year-old man with atypical chest pain lives at least 
another 10 years is 82%. Patients are typically interested in such outcomes in addition to 
expected outcomes.
While the analysis of stochastic uncertainty can serve patients as stake holders it is not the 
most common rationale for its use 90. In so-called patient-level models, a first-order Mon-
te Carlo simulation (i.e., microsimulation) is necessary to estimate expected outcomes.20 
First-order Monte Carlo simulation allows modeling of the influence of patient history on 
subsequent events. For example, when a subject suffers a myocardial infarction, his future 
mortality rate will increase. Although Markov cohort models can include patient history 
in the definition of health states, this requires expanding the number of states which can 
become unwieldy.38 
If a stakeholder is uninterested in individual patient outcomes, then the analysis of stochas-
tic uncertainty in patient-level models only contributes noise to the expected outcomes. 
Instead of a single Markov cohort analysis, many trials are required to obtain a precise esti-
mate of the expected outcomes. Evaluating more trials of the model will improve precision 
but also requires more computing time. The precision of these expected outcomes could be 
assessed by the standard error of the mean (sem). The sem is calculated as the standard 
deviation of the trial outcomes divided by the square root of the number of trials. Gaussian 
process modeling has been suggested as a time-efficient alternative to first-order Monte 
Carlo simulation 91, but such methodology is still in the developmental stage. Griffin et al. 
discussed how patient-level modeling can be avoided in certain circumstances.90
 
3. PaRaMETER uNCERTaINTY
3.1 Deterministic sensitivity analysis
Deterministic sensitivity analysis evaluates the influence of uncertainty in one or more pa-
rameters on the expected outcomes. In univariable (one-way) sensitivity analysis, the out-
come of each strategy is calculated over a justifiable range of one parameter, for example, 
the 95% uncertainty interval based on the results of a study. A tornado diagram presents 
the results of many one-way sensitivity analyses. In a tornado diagram a horizontal bar rep-
resents the range of expected outcomes at the decision node (across all strategies) given 
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the range of each selected estimated parameter (e.g., the 95% uncertainty interval). The 
tornado shape arises by ordering the bars by width, starting with the widest at the top. A 
mark can indicate where the optimal strategy changes across the range of a parameter.
600 610 620 630 640 650
utility of nonspec. angina
utility of mild angina
RR of dying w ith 1 or 2 VD (compared to no CAD)
utility of severe angina
RR of dying w ith LMD (compared to no CAD)
annual cost of mild angina pt w ith normal LVEF
RR of dying w ith 3VD (compared to no CAD)
reduction in mort. after CABG in LMD
cost CABG
cost PCI
Net Monetary Benefit in K$
Figure 1 Tornado diagram for the ten most influential estimated parameters (A). “Influential” 
means that they have the highest impact on the expected outcome at the decision node. Of 
the 80 assessed parameters, 3 additional parameters changed the optimal strategy within 
their range (B). 
RR, relative risk; VD, vessel disease; CAD, coronary arterial disease; LMD, left main disease; 
LVEF, left ventricular ejection fraction; CABG, coronary arterial bypass graft; PCI, percutane-
ous coronary intervention; WTP, willingness-to-pay; CTA, computed tomographic angiogra-
phy.”
A
B
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We built a tornado diagram of all estimated parameters, with the exception of parameters 
that are correlated, such as Dirichlet distributions.92 We used net monetary benefit (NMB) 
as the expected outcome, combining the outcomes cost and effect: NMB = effect * WTP 
– cost.5 Figure 1A presents a tornado diagram for the ten estimated parameters with the 
largest impact on the expected outcome (i.e., NMB) at the decision node, given a WTP of 
$50,000/QALY.	The	black	mark	in	the	top	bar	demonstrates	that	only	this	parameter	–	the	
utility of non-specific chest pain – causes a change in optimal strategy at the lower end of 
its range. Three other parameters changed the optimal strategy within their range. These 
are presented in the tornado diagram of Figure 1B.
3.2 Probabilistic sensitivity analysis
PSA or second-order Monte Carlo analysis, evaluates the joint effect of uncertainty about 
all estimated parameter values in the model.16, 17 The uncertainty about the parameter 
values is represented by probability distributions and propagated in the model resulting in 
a probability distribution of the expected outcome for each strategy. The probability distri-
butions of the parameters are often obtained using traditional parametric statistical meth-
ods. Briggs et al. give guidance on selecting the appropriate distributions.80 Alternatively, 
bootstrapping has the advantage that the analyst does not have to make parametrical 
assumptions about the parameter distribution.93, 94 However, standard bootstrapping meth-
ods may lead to misleading inferences, for example, when cost data exhibit highly skewed 
distributions.95 Correlations between parameters can be modeled by drawing values from 
Sample NMB
(CTA)
NMB
(No test )
NMB
(CA)
sample 
best
sample 
max
baseline 
max
opportunity  
loss
1 $598,104 $588,775 $597,540 CTA $598,104 $598,104 $0
2 $608,478 $606,464 $608,743 CA $608,743 $608,478 $265
3 $609,489 $606,648 $602,758 CTA $609,489 $609,489 $0
4 $624,283 $624,815 $624,614 no test $624,815 $624,283 $532
5 $636,035 $626,805 $633,813 CTA $636,035 $636,035 $0
6 $635,034 $625,744 $636,382 CA $636,382 $635,034 $1,348
7 $638,400 $630,043 $637,928 CTA $638,400 $638,400 $0
8 $637,761 $628,196 $632,105 CTA $637,761 $637,761 $0
9 $655,188 $640,486 $655,815 CA $655,815 $655,188 $627
10 $622,801 $617,226 $623,182 CA $623,182 $622,801 $381
Average $626,557 $619,520 $625,288 50% CTA $626,873 $626,557 Total EVPI  = $315
Table 2 Results of the probabilistic sensitivity analysis (columns 1-5) and expected value of information analysis 
(columns 1-8). 
WTP,	willingness-to-pay	=	$50,000/QALY;	CTA,	multidetector	computed	tomographic	angiography;	No	test,	no	imaging	test;	
CA, conventional catheter coronary angiography; sample best, the strategy with the highest net benefit of the sample; baseline 
max, the outcome of the strategy with the overall optimal outcome; sample max, the outcome of the strategy with the highest 
net benefit of the sample.
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joint distributions of the correlated parameters. Bayesian Markov chain Monte Carlo meth-
ods are increasingly used to model correlations, but require dedicated software such as 
WinBUGS. 7, 27-30
We performed PSA by randomly drawing a value for each parameter from its probability 
distribution. This set of values is commonly referred to as a “sample”. The model was then 
recalculated for this sample using a Markov cohort analysis. We repeated this for 10,000 
samples. Table 2 (column 1-4) presents ten samples of the PSA. In column 5, for each 
sample we identified the optimal alternative as the strategy with the highest net benefit. 
The probability that CTA is the “true” optimal strategy is the percentage of samples in 
which it has the highest net benefit. Table 2 shows that CTA is optimal in 50% of the ten 
samples. Out of 10,000 samples, CTA was optimal in 54%. 
Acceptability curves (Figure 2) 26, 96-99 demonstrate that the probability that CTA is cost-ef-
fective is less than 55% for any reasonable value of the WTP. Note also that the probability 
that CA is cost-effective is smaller than the probability that CTA is cost-effective for any WTP, 
even when the expected net benefit of CA exceeds the expected net benefit of CTA (i.e., for 
Acceptability Curve
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Figure 2 Cost-effectiveness acceptability curves. The probability is presented that each strat-
egy is the “true” optimal strategy across a range of values for the willingness-to-pay. For each 
value of the willingness-to-pay the total probability adds to 1.
CTA, computed tomographic angiography; No test, no imaging test; CA, coronary angiog-
raphy.
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WTP>$85,000/QALY,	see	Table	1).	The	cost-effectiveness	acceptability	frontier	(CEAF)	has	
been introduced within acceptability curves to indicate the intervention with the highest 
expected net benefit.100
Next, we estimate the 95% uncertainty interval for the incremental net benefit of CTA 
versus CA from the results of the PSA. For each sample we calculate the difference in net 
benefit between the two strategies. The 95% uncertainty interval for the incremental net 
benefit	of	CTA	versus	CA	 is	 –$430	 to	+$516,	with	an	expected	difference	of	$64.	The	
equivalent	values	in	quality-adjusted	life	days	are	-3	to	+4	days,	with	an	expected	differ-
ence of half a day. These values are small, but typical for incremental benefits of diagnostic 
tests and screening programs.
The use of PSA also has a more technical justification. A deterministic analysis is valid only 
if the expected outcome of the model (f) equals the model outcome when evaluated in the 
expected values of the parameters (x): E [f(x)] = f (E[x]). Correlated parameters in which 
the model is linear do not require sampling from their probability distribution to obtain 
unbiased expected outcomes. A linear function of parameters x1, x2,…xn is defined as a 
function of the form a1*x1+	a2*x2+	…	+an*xn for certain constants a1, a2,…an. Uncorre-
lated parameters in which the model is multilinear also do not require sampling from their 
probability distribution to obtain unbiased expected outcomes. A function is multilinear if 
it is a linear function of each parameter when the other parameters are given fixed values. 
BOX 2: TOTAL EVPI
1. Perform a second-order Monte Carlo simulation, sampling all estimated parameters.
2. For each sample of the PSA, calculate the opportunity loss as the difference between the maximum 
expected benefit of the sample and the sample’s expected benefit of the baseline optimal strategy.
3. The total EVPI is the average opportunity loss.
BOX 1: SECOND-ORDER MONTE CARLO SIMULATION (PSA) IN PATIENT-LEVEL MODEL.
1. Draw a sample from all parameter distributions.
2. Plug in the sampled values and perform a first-order Monte Carlo simulation with N trials.
3. Calculate the expected outcome of the N trials for each strategy.
4. Repeat steps 1 to 3 M times.
5. The M expected outcomes obtained at step 3 represent the distribution of the expected outcome char-
acterizing parameter uncertainty.
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Nonlinearity is the rule rather than exception: in Markov models the transition probabilities 
are multiplied by themselves repeatedly in the calculation of expected outcomes. The same 
issue arises in section 3.4 when we estimate the partial expected value of perfect informa-
tion. In appendix 1 we present a numerical example. Although the expected outcomes of 
the Markov cohort analysis in section 1 are biased in theory, we could not detect this bias: a 
PSA of 100,000 samples found expected outcomes similar to the deterministic analyses.
A PSA becomes more complicated in patient-level models (see section 2) that do not allow 
for Markov cohort analyses. Instead, the recalculation for each sample requires an entire 
first-order Monte Carlo simulation (e.g., 1,000 trials). The PSA represents an outer loop of 
BOX 3: PARTIAL EVPI – ONE-LEVEL ALGORITHM
1. Perform a second-order Monte Carlo simulation, but sample only the parameters of interest. The pa-
rameters not-of-interest remain fixed at their mean values.
2. For each sample, calculate the opportunity loss as the difference between the maximum expected be-
nefit of the sample and the sample’s expected benefit of the baseline optimal strategy.
3. The partial EVPI is the average opportunity loss.
Figure 3 The population expected value of sample information (population EVSI), the re-
search cost, and the expected net benefit of sampling information (ENBS) as functions of 
the sample size of a future observational study gathering data on the utilities of the angina 
states. The maximum ENBS corresponds with an optimal sample size of about 4,000 patients 
for each strategy.
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M samples; the first-order Monte Carlo simulation represents an inner loop of N trials. This 
is sometimes called the “M by N problem” and it is a major obstacle to performing PSA be-
cause of the time-consuming calculations required.19, 20, 90, 101 Confusion often exists about 
performing a PSA of a patient-level model. Box 1 presents a step-by-step algorithm.
3.3 Total EVPI
Information obtained in future quantitative research – for example, a randomized con-
trolled trial – can reduce parameter uncertainty. A decrease in parameter uncertainty may 
avoid reimbursement of suboptimal interventions, and consequently is expected to benefit 
patients and/or reduce costs. Value of information analyses explicitly estimate the expected 
benefit of collecting information in future research. The value of information is not the 
BOX 4: PARTIAL EVPI – TwO-LEVEL ALGORITHM
1. Draw a sample from the distributions of the parameters of interest.
2. Draw a sample from the distributions of those parameters not-of-interest,
•	 in	which	the	model	is	nonlinear,
•	 in	which	the	model	is	multilinear	and	that	are	correlated	with	other	parameters	not	of	interest,
•	 that	are	correlated	with	parameters	of	interest	and	for	which	an	analytic	expression	for	the	conditional	
mean value is not available.
 All other parameters not-of-interest may be fixed at their mean values.
3. Recalculate the model performing a cohort analysis for the values of step 1 and 2.
4. Repeat step 2 and 3 K times. – inner loop
 Calculate the expected benefit of each strategy.
5. Calculate the opportunity loss as the difference between the maximum expected benefit in step 4 and 
the expected benefit in step 4 of the baseline optimal strategy.
6. Repeat step 1 to 5 J times. – outer loop
7. The partial EVPI is the average opportunity loss.
BOX 5: ALGORITHM PARTIAL EVSI – PARAMETERS OF INTEREST wITH A BETA DISTRIBUTION
1. Draw a sample µI
j
  from the prior distributions Beta(a,b) of the parameters of interest.
2. Select a sample size n for the proposed data collection.
3. Draw a sample r
j
 from the binomial distribution (µI
j
 , n).
4. Obtain the posterior distribution of each parameter of interest: Beta(a+	r
j
,b+n - r
j
).
5. Recalculate the model using the posterior distributions of the parameters of interest. 
 All nonlinear and correlated multilinear parameters should be sampled in a nested second-order Monte 
Carlo simulation. – inner loop
6. Calculate the opportunity loss.
7. Repeat steps 1-6 J times. – outer loop
8. The partial EVSI is the average opportunity loss.
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actual value of future research – which we will only learn after performing future research 
– but the “expected” value of future research, ex ante. It is expressed in the same units 
as the model outcome, typically net monetary benefit. Value of information analysis was 
introduced by Grundy29 in the late fifties and developed by Raiffa and Schlaifer.102, 103 Since 
the late eighties it has received increasing attention in the risk analysis literature and more 
recently in health care.14, 28, 81, 104
The total EVPI is the expected benefit per patient of a hypothetical study with an infinite 
sample size that would eliminate all parameter uncertainty. It is estimated by the average 
opportunity loss of the samples of the PSA (Table 2).105 The opportunity loss of a sample is 
defined as the difference between the maximum expected benefit of that sample (sample 
max) and the sample’s expected benefit of the baseline optimal strategy (baseline max).106 
For example, the maximum expected benefit of the second sample in Table 2 is the ex-
pected	benefit	of	CA:	$608,743.	CTA	is	the	baseline	optimal	strategy;	the	expected	benefit	
of	CTA	 in	sample	2	 is	$608,478.	The	opportunity	 loss	of	sample	2	 is	 the	difference	be-
tween	these	values:	$608,743	–	$608,478	=	$265.	The	final	column	of	Table	2	presents	
the	opportunity	loss	for	each	sample.	The	average	opportunity	loss	of	all	samples	is	$315	
per patient and is an estimate of the total EVPI per patient. See Box 2 for a step-by-step 
parameter pEPVI Tornado rank
utility of nonspecific angina 42 1
cost CA 32 15
cost CTA 25 34
TPR CTA 14 39
utility of mild angina 0.001 2
annual costs of mild angina pat with normal LVEF 0 6
cost CABG 0 9
cost PCI 0 10
reduction in mortality after CABG in LMD 0 8
RR of dying with 1 or 2 VD (compared to no CAD) 0 3
RR of dying with 3 VD (compared to no CAD) 0 7
RR of dying with LMD (compared to no CAD) 0 5
utility of severe angina 0 4
Table 3 Individual model parameters ranked by partial expected value of perfect informa-
tion (pEVPI) as a measure for the importance of uncertainty. The Tornado rank in the third 
column demonstrates that it is not a valid proxy for the importance of uncertainty. All param-
eters not in this table had a zero pEVPI.
pEVPI, partial expected value of perfect information; CA, coronary angiography; CTA, com-
puted tomographic angiography; TPR, true positive rate; LVEF, left ventricular ejection frac-
tion; CABG, coronary arterial bypass graft; PCI, percutaneous coronary intervention; LMD, 
left main disease; RR, relative risk; VD, vessel disease; CAD, coronary artery disease.
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algorithm. Using 10,000 samples instead of the 10 samples of Table 2, we obtained a more 
precise	 estimate	 of	 the	 total	 EVPI:	 $294	 per	 patient.	 This	means	 that	 after	 eliminating	
uncertainty	we	can	expect	an	improvement	in	net	monetary	benefit	of	$294	per	patient.	
The probability that the actual value is zero is 54%, identical to the current probability that 
CTA is the optimal strategy. This result also implies that the current expected harm due 
to	uncertainty	is	$294	per	patient,	with	a	health	equivalent	of	2	quality-adjusted	life	days	
(WTP=$50,000/QALY).
More research to decrease uncertainty is justified if the expected benefit to future patients 
exceeds the cost of research. The population EVPI represents the expected benefit to all 
future patients. It is estimated as the product of the total EVPI per patient and the popula-
tion that is expected to benefit from future research, discounting expected benefit in future 
years. The population EVPI is a ceiling level for the expected return on investment of re-
search. If research is more expensive than the population EVPI, it is a bad investment: the 
uncertainty is not important enough to be resolved. The annual population to benefit is 
usually ambiguous, because it is not obvious whether we should consider the local setting, 
one country, or all patients worldwide. Moreover, the period that patients will benefit from 
the proposed data collection is typically uncertain because of future improvements, novel 
interventions, or new insights. These ambiguities, however, are not drawbacks of value of 
information analysis in itself, but inherent to the problem of allocating resources wisely.
We estimated the annual population to benefit (males aged 50-59 years with atypical chest 
pain) for the US at 44,000 patients (i.e., 11% of 400,000).84, 85 Assuming a period of 5 
years	and	a	discount	rate	of	3%,	we	found	a	total	EVPI	for	the	population	to	benefit	of	$61	
million. 
3.4 Partial EVPI
Instead of estimating the total EVPI of all parameters, we can estimate the partial EVPI 
of one or more parameters (i.e., the parameters of interest). First, we demonstrate the so-
called one-level algorithm.82, 105 Analogous to the estimation of total EVPI, a second-order 
Monte Carlo simulation is performed, but only the parameters of interest are sampled from 
their distributions. The parameters not-of-interest (i.e., all other parameters) remain fixed 
at their mean values. For each sample the model is recalculated and the opportunity loss is 
estimated analogous to the estimation of total EVPI. The average opportunity loss of many 
samples is an estimate of the partial EVPI of the parameters of interest. See Box 3 for a 
step-by-step algorithm of the one-level algorithm.
Keeping the parameters not-of-interest fixed at their mean value may result in the same 
bias that we discussed in section 3.2 (technical justification of PSA). In a two-level algo-
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rithm, a second-order Monte Carlo simulation is performed for each sample of the param-
eters of interest, to avoid this bias. All parameters of interest are sampled in the outer loop 
second-order Monte Carlo simulation; selected parameters not-of-interest are sampled in 
the inner loop second-order Monte Carlo simulation. The criteria to decide if a parameter 
not-of-interest requires sampling in the inner loop are the same as the criteria of section 3.2 
to avoid a bias when obtaining expected outcomes of a model. If correlations exist between 
parameters of interest and a parameter not-of-interest, the latter should also be sampled in 
the inner loop when an analytic expression for the conditional mean value is not available. 
See Box 4 for a step-by-step algorithm of the two-level algorithm.
The outer loop – sampling the parameters of interest – determines the precision of the 
estimate of the partial EVPI. More samples in the inner loop – recalculating the model by 
sampling the parameters not-of-interest – yields less biased results. Brennan et al. recom-
mend a 1 to 5 ratio of samples of the outer versus the inner loop.82 The correct order of 
magnitude was found with a minimum of 100 samples in the outer loop.
In a tornado diagram we identified four parameters that have the capability to change 
the optimal strategy somewhere along their range of likely values. We first estimated the 
partial EVPI of these parameters because they should exceed zero. We divided the remain-
ing parameters into several groups. Most groups have a zero partial EVPI, and therefore 
all constituent parameters have a zero partial EVPI. The tornado diagram identified four 
out of five parameters with a nonzero partial EVPI. The ranking in the tornado diagram, 
however, is not a good predictor of the importance of uncertainty as reflected by the partial 
EVPI. Table 3 presents the ranked results for partial EVPIs with their rankings in the tornado 
diagram. Note that the sum of the partial EVPIs of individual parameters generally does not 
equal the total EVPI.106, 107
To assess whether more research is justified we should estimate the partial EVPI of a set of 
parameters that could be measured in a specific study. Parameters with a partial EVPI of 
zero may seem useless to consider in future research. A combination of such parameters, 
however, may jointly have a nonzero partial EVPI. We analyzed the partial EVPI of eight 
study designs. Six of these were observational studies, measuring, respectively: test charac-
teristics of CTA, complications of coronary angiography, utilities of chest pain states, costs 
of interventions, complications of PCI, and complications of CABG. The other two study 
designs were randomized trials: medical treatment versus PCI in one- or two-vessel disease 
and medical treatment versus CABG in three-vessel disease or left main disease. For the 
observational	study	measuring	utilities	we	found	the	highest	partial	EVPI:	$91	per	patient,	
with	a	population	EVPI	of	$19	million.	The	cost	study	had	a	partial	EVPI	of	$48	per	patient,	
and	the	diagnostic	study	for	test	characteristics	of	CTA	had	a	partial	EVPI	of	$31	per	pa-
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tient. All other study designs, including the two RCTs had a (near) zero partial EVPI.
The (partial) expected value of sample information (EVSI) estimates the expected value of 
obtaining information for finite sample sizes.47-50 With increasing sample size, the partial 
EVSI will reach a ceiling: the partial EVPI, representing an infinite sample size. At the same 
time, the cost of research increases with increasing sample size. The expected net benefit 
of sampling (ENBS) is defined as the difference between the EVSI and the cost of research. 
The maximum ENBS is associated with the optimal sample size of a proposed study design. 
We refer to Ades et al. for an extensive coverage of EVSI.32 
4. MOdEl STRuCTuRE uNCERTaINTY
The structure of a model typically depends on assumptions about the natural course of a 
disease and how medical interventions may influence this course. The amount and form 
of available data will also determine the model structure. Moreover, analysts can opt for 
more or less model complexity: for example, a simple decision tree versus a Markov model. 
This may depend on the research question, available time, and the required validity and 
precision of the results. Consequently, different teams of experts may come up with differ-
ent models to represent the same decision problem. Campbell et al. demonstrated how 
this can result in large variation in the outcomes.45 Evaluating only the plausible single best 
model may result in an underestimation of uncertainty.78 Ideally, analysts should build a 
model for every imaginable set of assumptions regarding a decision. In real life most ana-
lysts settle for using their single best model. Claxton et al. pointed out that more research is 
needed regarding the trade-off between the realism of the model and the available time.19 
If alternative modeling assumptions may affect the decision, more evidence to justify the 
use of one assumption instead of the others should be found. If this is impossible, the re-
sults of each model can be presented, and the policy maker can decide. Sometimes model 
structure uncertainty can be dealt with using parameterization.108 Finally, some sources 
of uncertainty are not covered by parameter or structural uncertainty: for example, un-
certainty about the appropriate evidence sources, and uncertainty about the selection of 
interventions.
We performed a structural sensitivity analysis by assuming an additive mortality function. 
The	CTA	strategy	remained	the	optimal	strategy	at	a	WTP	of	$50,000/QALY,	with	an	ICER	
of	$28,000	compared	to	no	imaging	test.	The	ICER	differed	about	9%	from	the	ICER	using	
the multiplicative model.
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5. PaTIENT hETEROGENEITY
Patient heterogeneity is usually analyzed to identify differences in the optimal strategy 
for subgroups of patients.109 Clinical guidelines and reimbursement decisions reflect these 
differences between subgroups. Moreover, a strategy could have a high incremental cost-
effectiveness ratio for the total population, but a low ratio for a certain subgroup; the mean 
value may obscure the cost-effectiveness of a strategy for a subgroup. Baseline patient 
characteristics can influence each estimated parameter in the model: for example, we can 
distinguish heterogeneity in treatment effects, heterogeneity in costs, and heterogeneity in 
utilities. In practice it is often difficult to determine whether a difference between subgroups 
is genuine or simply reflects noise in the data. Criteria are being developed to decide when 
it is justified to model heterogeneity in a parameter.110
Sensitivity analysis may evaluate the optimal strategy for various subgroups and involves 
repeated analysis of a model for, for example, different age groups. If patient heteroge-
neity is modeled using a continuous or ordinal variable, sensitivity analysis can calculate 
the expected outcomes over a range of values for the patient characteristic, analogous to 
deterministic sensitivity analysis of parameters representing parameter uncertainty.
Differences in setting - as opposed to differences in patient characteristics – can also cause 
heterogeneity in parameter values. This type of heterogeneity arises, for example, when a 
model developed based on data from one country is used to make inferences for another 
country. For example, the cost of an appendectomy or the sensitivity of ultrasound for ap-
pendicitis can differ across countries or hospitals. A policy maker should be able to assess 
what the model implies for a situation that may be identical to the base-case assumptions 
of the model except for a limited set of parameter values. 
In our example model, gender, age, and type of chest pain are the most relevant patient 
characteristics. We assessed 30 subgroups: 5 age groups, both genders, and 3 chest pain 
groups. The higher the prior probability of CHD the more likely it is that CA is cost-effective. 
The prior probability of CHD is increased by advanced age, male gender, and typical in-
stead of nonspecific or atypical chest pain. CTA is cost-effective for intermediate-risk pa-
tients, no imaging for low-risk patients.
The analysis of patient heterogeneity is also required when uniform decisions are con-
sidered for rather heterogeneous populations. For example, policy makers may want to 
know the overall ICER of a colon cancer screening program for everyone over 50 years. 
For population-level decisions it is important that the heterogeneity of the target popula-
tion is reflected in the model. Patient heterogeneity can be represented by distributions for 
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each patient characteristic or by bootstrapping “real” subjects from a study population. 
The expected outcome for the heterogeneous population is the average outcome of many 
randomly drawn patients performing a random walk in the model. Typically this requires a 
patient-level first-order Monte Carlo simulation. Nijhuis et al. used this approach to model 
a heterogeneous population using data from a large study population. 111 Parameter un-
certainty in such models adds an additional level of complexity.112
 
dISCuSSION
We demonstrated various methods to analyze uncertainty and patient heterogeneity in de-
cision models. The analyses resulted in outcomes serving various purposes and stakehold-
ers. Policy makers (e.g., NICE) determine the optimal strategy by combining these results 
with (typically) unmodeled considerations such as ethical viewpoints or the transition costs 
of a new intervention.8 More recently, research-funding agencies can use the results of 
value of information analyses to guide future research. Patients and doctors also combine 
model results with their preferences regarding health states and risk attitude, as well as 
specific patient characteristics that are often not accounted for in the model.
The analysis of uncertainty and patient heterogeneity faces several challenges. Increasing 
model complexity impedes probabilistic sensitivity analysis and value of information analy-
sis. Nested analyses are required in patient-level models, and for partial value of informa-
tion analyses in nonlinear models. The required calculation time in decision analytic soft-
ware using personal computers is prohibitive. Linear cohort models (i.e., no Markov nodes, 
no patient-level simulation) avoid nested simulations, but could be an unrealistic represen-
tation of the decision problem. Accounting for correlations between estimated parameters 
is another challenge. Correlations are influential on the value of information, but often no 
data is available to model this. Thirdly, it is not feasible to consider the characteristics and 
preferences of each individual patient in a decision model. However, doctors rarely see 
patients that match the base case analysis of a cost-effectiveness study. Instead, doctors 
care for a variety of patients each with their own unique set of risks and preferences. Finally, 
model structure uncertainty remains problematic, because more than one structure may 
be reasonable. We often lack time to build various models, and placing a weight on each 
model is an arbitrary choice.
Despite these challenges, decisions regarding current implementation and future research 
have to be made. We hope this paper will stimulate and help analysts and policy makers 
evaluating uncertainty and patient heterogeneity to inform these decisions.
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abSTRaCT
The analysis of both parameter uncertainty and patient heterogeneity in decision models 
is increasingly recommended to improve decision making. In addition, the complexity of 
current medical decision models commonly requires simulating individual subjects, which 
introduces stochastic uncertainty. The combined analysis of uncertainty and heterogeneity 
often involves complex nested Monte Carlo simulations to obtain the model outcomes of 
interest.
In this paper we distinguish eight model types, each dealing with a different combination 
of patient heterogeneity, parameter uncertainty, and stochastic uncertainty. The model out-
comes of interest include the expected outcome, the distribution of the expected outcome 
reflecting lack of perfect knowledge, the distribution of the expected outcome reflecting 
patient heterogeneity, and the distribution of the individual outcome. The analyses that are 
required to obtain these model outcomes are expressed in equations, explained in step-
wise algorithms, and demonstrated in examples. Patient heterogeneity is represented by 
frequency distributions and analyzed with Monte Carlo simulation. Parameter uncertainty 
is represented by probability distributions and analyzed with second-order Monte Carlo 
simulation (i.e., probabilistic sensitivity analysis). Stochastic uncertainty is analyzed with 
first-order Monte Carlo simulation (i.e., trials or random walks). This article can be used as 
a reference for analyzing complex models with more than one type of uncertainty and with 
patient heterogeneity.
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INTROduCTION
Policy making in health care can benefit from the evaluation of uncertainty and patient het-
erogeneity in decision models. Organizations and journals therefore increasingly demand 
a probabilistic analysis of parameter uncertainty.18 Modeling patient heterogeneity is also 
recommended, because the optimal intervention may depend on patient characteristics.110 
In addition, analysts are forced to deal with stochastic uncertainty in models that require 
the simulation of individual subjects. 
Nevertheless, many published models consider neither uncertainty nor patient heterogene-
ity, and hardly any consider all 3 types of uncertainty and heterogeneity simulteneously.89 
When more than one type of uncertainty and/or patient heterogeneity is modeled, the 
correct algorithm to obtain the model outcomes of interest can be complicated. Nested 
Monte Carlo simulations, for example, may be necessary. The purpose of this paper is to 
demonstrate the combined analysis of uncertainty and patient heterogeneity in medical 
decision models.
In section 1 we discuss the terminology for uncertainty and patient heterogeneity, as well as 
various decision model outcomes of interest. In sections 2 and 3 we demonstrate how the 
outcomes of interest are estimated in eight models, each exhibiting a different combination 
of parameter uncertainty, stochastic uncertainty, and patient heterogeneity. We distinguish 
models in which the analysis of stochastic uncertainty is not required (section 2 – “macro-
simulations”) from models in which the analysis of stochastic uncertainty is required (sec-
tion 3 – “microsimulations”). The analyses are expressed in equations, and explained in 
stepwise algorithms. In section 4 we demonstrate some of the analyses with an example. 
We adopt a Bayesian approach, treating model parameters as random variables, and with 
probability distributions representing uncertainty. The focus is on Monte Carlo methods to 
perform the analyses. We assume some familiarity with Markov models and Monte Carlo 
simulation.38, 83, 113 
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1. TERMINOlOGY
Typically a cohort analysis of a deterministic model is performed to obtain the mean value 
of the outcome, or expected outcome. Introducing stochastic uncertainty, parameter uncer-
tainty and/or patient heterogeneity into a model complicates the estimation of the expected 
outcome. At the same time, it allows the estimation of other model outcomes in addition 
to the expected outcome:
•	 stochastic	uncertainty:	distribution	of	the	individual	outcome	in	a	cohort	or	population,	
reflecting randomness,
•	 parameter	uncertainty:	distribution	of	the	expected	outcome,	reflecting	lack	of	perfect	
knowledge, and
•	 patient	heterogeneity:	distribution	of	the	expected	outcome,	reflecting	patient	hetero-
geneity.
Stochastic uncertainty
Stochastic uncertainty is the uncertainty about the outcome of an individual due to chance. 
This uncertainty is also referred to as first-order uncertainty.88, 114 The analysis of stochastic 
uncertainty results in a distribution of the individual outcome in a cohort of population. This 
distribution may be of interest, in addition to the expected outcome, if a decision maker 
is concerned about minimizing the risk of an unfavorable outcome due to risk aversion. 
Moreover, the individual-level uncertainty might be of interest to patients for purely prog-
nostic reasons.
The analysis of stochastic uncertainty, however, is applied primarily to estimate the ex-
pected outcome in so-called microsimulation (i.e., patient-level) models.20 Chance occur-
rences within these models determine the value of downstream parameters. For example, 
after experiencing a myocardial infarction, a patient’s annual probability of mortality will 
increase. Because the model is required to “memorize” such previous events in order to set 
parameter values, subjects must be simulated one at a time. Adding more Markov states to 
deterministic models to retain memory of previous events may result in prohibitively large 
models.101 Therefore, microsimulation models may be used because of computational ne-
cessity, rather than because of an interest in patient-level uncertainty.
A disadvantage of microsimulation is the noise introduced by stochastic uncertainty in the 
estimate of the expected outcome. This noise can only be resolved by simulating an infi-
nitely large number of subjects. The standard error of the mean outcome can be used to 
ascertain that sufficient simulations were performed. In contrast, the standard deviation of 
the outcome is a measure of uncertainty at the patient-level.
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Parameter uncertainty
Parameter uncertainty arises from lack of perfect knowledge. The “true” value of an input 
parameter (e.g., a relative risk, a treatment efficacy, or a utility) will remain unknown, un-
less it was estimated in an infinitely large sample. This uncertainty is also referred to as 
second-order uncertainty and is typically represented by a probability distribution for each 
parameter.88 Parameter uncertainty can be propagated through the model, resulting in a 
distribution of the expected outcome reflecting lack of perfect knowledge.
The probabilistic analysis of parameter uncertainty has several objectives: it quantifies the 
confidence in the expected outcome, it enables the synthesis of model results with risk at-
titude, and it is required for value of information analysis – analysis of the value of obtain-
ing evidence that can reduce the uncertainty and guide future decisions.14, 32, 115 Moreover, 
in models where the outcome is a nonlinear function of parameters (e.g., probabilities in 
a Markov model), a probabilistic analysis is required to obtain unbiased estimates of the 
expected outcome, even if the uncertainty is not of interest in its own right.115
Patient heterogeneity
Patient heterogeneity (also known as variability) concerns patient characteristics that can 
influence the expected outcome of a decision model. Because of patient heterogeneity, 
the optimal intervention may vary across individuals. Unlike parameter uncertainty, patient 
heterogeneity cannot be reduced with better data.116 Heterogeneity can be modeled using 
discrete subgroups (e.g. age ranges), within which all individuals are assumed identical. 
The analyst can assign subgroup-specific parameter values, resulting in subgroup-specific 
expected outcomes. When using discrete subgroups, patient heterogeneity is represented 
by a (discrete) distribution of the expected outcome.
Infinitely many subgroups arise when patient heterogeneity is modeled using continuous 
covariates.111 The frequency distribution of a covariate can represent patient heterogeneity. 
For example, the annual probability of developing a stroke depends on cholesterol level, 
and a frequency distribution can represent how the cholesterol level varies across individu-
als. These frequency distributions should be distinguished from the probability distributions 
representing parameter uncertainty. The importance of the covariate(s) can be illustrated 
by a (continuous) distribution of the expected outcome reflecting its dependence on the 
covariate(s).
The analysis of patient heterogeneity is needed in order to identify the optimal intervention 
for different subgroups. For example, annual mammography screening could be recom-
mended for women aged 40 to 79, but not for other ages. However, sometimes a policy 
maker has to make a uniform recommendation for a heterogeneous population, as in the 
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choice of contrast media for imaging tests. In that case, the expected outcome averaged 
over the heterogeneous population is required in order to evaluate the optimal course of 
action for the population as a whole.
 
2. MaCROSIMulaTIONS
In this section we discuss models for which the cohort is the fundamental unit of the analy-
ses. We use the term macrosimulations for these models, as opposed to microsimulations 
that require simulation of individual subjects (Table 1). In macrosimulation models, Markov 
cohort analysis can be applied to calculate the expected outcome for a set of parameter 
values and patient characteristics. The analysis of stochastic uncertainty will be demon-
strated later, in the microsimulation section. We first introduce some notation.
Let M be the expected outcome of a model, for example, the life expectancy. M is a func-
tion of patient characteristics (X) and model parameters (B). X is a vector of covariates 
and B a vector of parameters. The patient characteristics vary within the population of in-
terest according to some joint probability distribution, f(x), reflecting patient heterogeneity. 
Parameter uncertainty is also reflected by a joint probability distribution, g(b). We denote 
X
i
 as a subgroup of patients and b
j
 as a possible set of values for the parameters.
Model Parameter uncertainty Patient heterogeneity
Macrosimulation
D - -
H - +
P + -
PH + +
Microsimulation
S - -
HS - +
PS + -
PHS + +
Table 1 Model complexity
D: deterministic
H: patient heterogeneity
P: parameter uncertainty
S: stochastic uncertainty
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If patient heterogeneity is not modeled, then patients are assumed to be identical, and 
f(x) resolves at a single point, which we will refer to as x*. If parameter uncertainty is not 
modeled, then parameter values are assumed to be certain and g(b) resolves at a single 
point, which we will refer to as b*. Thus, we can distinguish four macrosimulation models 
(Table 1): deterministic models that consider neither patient heterogeneity nor parameter 
uncertainty (model D), models that consider patient heterogeneity only (model H), models 
that consider parameter uncertainty only (model P), and models that consider both patient 
heterogeneity and parameter uncertainty (model PH). We now demonstrate how to evalu-
ate the appropriate outcomes of interest for each of these models.
Model D: deterministic model
The simplest model is a deterministic model: 
 M=h(x*, b*)
This model type is probably the most prevalent model type in the literature. The expected 
outcome, M, is typically calculated using a single (Markov) cohort analysis. Patient hetero-
geneity can still be evaluated by analyzing the model for discrete subgroups, and param-
eter uncertainty can be considered by using deterministic sensitivity analysis.
Model H: patient heterogeneity
In this model, the expected outcome is subject to patient heterogeneity only: 
 M=h(X, b*).
The expected outcome, M, in this model varies across the possible patient characteristics, 
X, which are distributed according to a frequency distribution, f(X). M
i
 is the expected 
outcome given the patient characteristics x
i
.
Cohort analysis can be applied to calculate the expected outcome for any subgroup x
i
: 
M
i
=h(x
i
, b*). With second-order Monte Carlo simulation we can obtain the distribution 
(P
X
) of the expected outcome, reflecting patient heterogeneity: P
X
[M]. For each randomly 
drawn set of values, x
i
, a cohort analysis is performed to calculate M
i
=h(x
i
, b*). A distribu-
tion is then made of the results of the cohort analyses.
If we want to make a decision for a heterogeneous population, our primary interest is in the 
expected outcome of the aforementioned distribution: E
X
[M]. The expected outcome (for 
a heterogeneous population) is estimated as the average outcome of the Monte Carlo sim-
ulation that resulted in P
X
[M]. When the patient characteristics can be quantified numeri-
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cally (such as age in years, or diastolic blood pressure in mmHg), this average outcome 
may not equal the expected outcome for patients whose characteristics are at the mean of 
their distributions. That is, E
X
[M] = E
X
[h (X, b*)] may differ from h(E[X], b*). This is true 
in particular when the outcome is a nonlinear function of the characteristic, X. Therefore, 
avoiding Monte Carlo simulation by using the mean values of the patient characteristics 
may result in a biased expected outcome.
Model P: parameter uncertainty
When parameter uncertainty is modeled and patient heterogeneity is not, the expected 
outcome is subject to parameter uncertainty only: 
 M=h(x*, B).
M
j
 is the expected outcome if b
j
 represents the “true” set of parameter values. Second-
order Monte Carlo simulation (i.e., probabilistic sensitivity analysis) is typically applied to 
obtain the distribution of the expected outcome (reflecting lack of perfect knowledge): 
P
B
[M].16, 17, 80 For each randomly drawn set of values, b
j
, a cohort analysis is performed to 
obtain M
j
=h(x*, b
j
). The distribution of the expected outcome is then built from the re-
sults of the cohort analyses. The expected value of this distribution is E
B
[M]. In nonlinear 
models, this expected outcome may not equal the expected outcome that would result if 
all parameters were fixed at their mean values: E
B
[M] = E
B
[h (x*, B)] is unequal to h(x*, 
E[B]). Therefore, avoiding Monte Carlo simulation by using the mean values for the un-
certain model parameters – as practiced in deterministic models – may result in a biased 
expected outcome.
Model PH: parameter uncertainty and patient heterogeneity
The analyses become more complicated when the expected outcome is subject to both 
parameter uncertainty and patient heterogeneity: 
 M=h(X, B).
In this model, the outcome M varies across both patient characteristics, X, and the 
para meter space, B. For each set of values (x
i
, b
j
) we can calculate the expected out-
come, 
 M
ij
=h(x
i
, b
j
).
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Expected outcome: heterogeneous population
If we want to make a decision for a heterogeneous population, our main interest is in the 
expected outcome given both parameter uncertainty and patient heterogeneity: 
 E
X,B=[M].
Second-order Monte Carlo simulation can be applied to estimate this expected outcome. 
For each set of values (x
i
, b
j
)	−	randomly	drawn	from	the	distributions	of	X and B	−	a	
cohort analysis is performed to obtain M
ij
=h(x
i
, b
j
). The expected outcome of the model 
is estimated by the average outcome of many cohort analyses. The step-by-step algorithm 
is:
1. Draw a value for (x
i
, b
j
).
2. Calculate M
ij
=h(x
i
, b
j
), for example, using cohort analysis.
3. Repeat steps 1 and 2 many times.
4. Calculate the average of the expected outcomes, M
ij
, obtained at step 2.
Distribution of the expected outcome, reflecting lack of perfect knowledge
In addition, we may be interested in the distribution of the expected outcome reflecting lack 
of perfect knowledge, for a heterogeneous population: 
 P
B
[E
X
 [M]]. [equation 1]
This is the same distribution as in model P, but now for a heterogeneous population. The 
analysis requires a nested Monte Carlo simulation: for each parameter value, b
j
, we have 
to average over X. For each b
j
 the expected outcome is a function of X: M
j
=h(X, b
j
). The 
algorithm to obtain this distribution consists of the following steps:
1. Draw a value b
j
.
2. Draw a value x
i
.
3. Calculate M
ij
=h(x
i
, b
j
), for example, using cohort analysis.
4. Repeat steps 2 and 3 many times, for the same value b
j
.
5. Calculate the average of the expected outcomes, M
ij
, obtained at step 3.
6. Repeat steps 1 to 5 many times.
7. Make a probability distribution of the averages at step 5.
The mean of this distribution is E
B
[E
X
 [M]] = E
X,B [M]: if we are only interested in the 
expected outcome, the nested simulation is not necessary, and the method described in the 
previous section (“Expected outcome: heterogeneous population”) would apply.
chapter 4
66
Distribution of the expected outcome, reflecting the impact of patient 
heterogeneity
To obtain the expected outcome for a subgroup, a second-order Monte Carlo simulation 
is performed to average over the parameter space B for the subgroup x
i
:E
B
 [MjX = x
i
]. 
For each, the expected outcome is a function of B:M
i
 = h(x
i
,B). The distribution of the 
expected outcome reflects the impact of patient heterogeneity:
 P
X
(E
B
[M]). [equation 2]
This is the same distribution as in model H, but averaged over B for each x
i
. The algorithm 
for P
X
 is identical to the algorithm for P
B
 in this model, except for a reversed order of steps 
one and two and correspondingly different interpretations of the result.
The mean of this distribution is E
X
[E
B
 [M]] = E
X,B [M]: the same expected outcome for a 
heterogeneous population is obtained, independent of the order of the nested Monte Carlo 
simulation. 
3. MICROSIMulaTIONS
In this section we demonstrate models that require the simulation of individual subjects 
(Table 1). The setup of this section is analogous to the previous section on macrosimula-
tions. The simulation of individual subjects, however, adds a layer of complexity. Instead 
of a cohort analysis, a first-order Monte Carlo simulation is now required to estimate the 
expected outcome given the patient characteristics and parameter values. In addition, the 
simulation of individual subjects enables the estimation of the distribution of the individual 
outcome. Whereas M was the expected model outcome in the previous section, in this 
section L is the model outcome of an individual. Like M, L is a function of X and B. For 
given values of X and B, however, L is uncertain at the patient level. We denote a realized 
value for L as l
k
.
We can distinguish four microsimulation models, all of which are subject to stochastic un-
certainty (Table 2): stochastic models that are subject to neither patient heterogeneity nor 
parameter uncertainty (model S), models that consider patient heterogeneity (model HS), 
models that consider parameter uncertainty (model PS), and models that consider both 
patient heterogeneity and parameter uncertainty (model PHS).
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Model S: stochastic uncertainty
When parameter uncertainty and patient heterogeneity are not modeled, the outcome of 
an individual is subject only to stochastic uncertainty:
 L=h(x*, b*).
The distribution of the individual outcome P[L] can be obtained with first-order Monte 
Carlo simulation.83, 113 The Monte Carlo simulation involves many random walks, each 
resulting in a realized value (l
k
) for L. The expected outcome, E[L], is estimated as the 
average individual outcome across many random walks.
Model HS: patient heterogeneity and stochastic uncertainty
In this model, the outcome for an individual is subject to patient heterogeneity and sto-
chastic uncertainty:
 L=h(X, b*)
For any patient with characteristics x
i
, L
i
=h(x
i
, b*) represents the range of values that have 
a defined probability of being realized.
Distribution of the individual outcome
The distribution of the individual outcome is P
X,L[L]. The algorithm to obtain this distribu-
tion is:
1. Draw a value x
i
.
2. Draw a value l
k
 (i.e., perform a random walk) given x
i
.
3. Repeat steps 1 and 2 many times.
4. Make a probability distribution of the individual outcomes, l
k
, obtained at step 2.
Expected outcome (heterogeneous population)
If we are interested in the expected outcome in a heterogeneous population we can esti-
mate E
X,L[L]. The expected outcome is estimated as the average of the previous distribu-
tion.
Distribution of the expected outcome, reflecting patient heterogeneity
The expected outcome of a subgroup x
i
 is: E
L
 [LjX = x
i
]. This can be estimated with a 
first-order Monte Carlo simulation. The patient heterogeneity in the expected outcome is 
presented as a probability distribution:
 P
X
 [E
L
[L]].
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This distribution can be estimated with a nested Monte Carlo simulation. The algorithm 
is:
1. Draw a value x
i
.
2. Draw a value l
k
 (i.e., perform a random walk) given x
i
.
3. Repeat step 2 many times.
4. Calculate the average of the random walks, l
k
, obtained at step 2.
5. Repeat steps 1 to 4 many times.
6. Make a probability distribution of the averages at step 4.
Model PS: parameter uncertainty and stochastic uncertainty
In this model, the outcome of an individual is subject to both parameter uncertainty and 
stochastic uncertainty:
 L=h(x*, B).
For any set of parameter values, b
j
 L
j
=h(x*, b
j
) represents the range of values that have a 
defined probability of being realized.
Distribution of the individual outcome
The distribution of the individual outcome is P
B,L[L]. This distribution can be obtained by 
performing first-order and second-order Monte Carlo simulation simultaneously. The algo-
rithm is:
1. Draw a value b
j
.
2. Draw a value l
k
 (i.e., perform a random walk) given b
j
.
3. Repeat steps 1 and 2 many times.
4. Make a probability distribution of the individual outcomes at step 3.
This distribution reflects uncertainty about the individual outcome due to both randomness 
(stochastic uncertainty) and the lack of perfect knowledge (parameter uncertainty).
Distribution of the expected outcome, reflecting lack of perfect knowledge
The expected value of the previous distribution is the expected outcome of the model: 
E
B,L(L). A nested Monte Carlo simulation is needed in order to obtain a probability distribu-
tion for the expected outcome:
 P
B
 [E
L
[L]].
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The algorithm is:
1. Draw a value b
j
.
2. Draw a value l
k
 (i.e., perform a random walk) given b
j
.
3. Repeat step 2 many times.
4. Calculate the average of the random walks at step 2.
5. Repeat steps 1 to 4 many times.
6. Make a probability distribution of the averages at step 4.
Model PHS: parameter uncertainty, patient heterogeneity, and 
stochastic uncertainty
In this model, the outcome of an individual is subject to patient heterogeneity, parameter 
uncertainty, and stochastic uncertainty:
 L=h(X, B).
Distribution of the individual outcome
The distribution for the outcome of an individual with unknown patient characteristics is: 
 P
X,B,L[L].
This distribution can be estimated with a combined first-order and second-order Monte 
Carlo simulation. The algorithm is:
1. Draw values for (x
i
, b
j
).
2. Draw a value l
k
 (i.e., perform a random walk), given (x
i
, b
j
), drawn in step 1.
3. Repeat steps 1 and 2 many times.
4. Make a distribution of the outcomes found at step 2.
This distribution reflects uncertainty about the individual outcome due to randomness (sto-
chastic uncertainty), the lack of perfect knowledge (parameter uncertainty), and unknown 
patient characteristics (patient heterogeneity).
Distribution of the expected outcome, reflecting lack of perfect knowledge
If we want to make a decision for a heterogeneous population, we can estimate the expect-
ed outcome of the heterogeneous population as the average of the previous distribution:
 E
X,B,L[L].
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The probability distribution for the expected outcome reflecting lack of perfect knowledge 
is:
 P
B [EX,L[L]].
We can estimate this distribution using both first-order and second-order Monte Carlo 
simulation. The expected outcome is estimated for B = b
j
, for , j = 1,..., N by averaging 
over X and L. The step-by-step algorithm is:
1. Draw a value b
j
.
2. Draw a value x
i
.
3. Draw a value l
k
 (i.e., perform a random walk), given the values b
j
 and x
i
 drawn in steps 
1 and 2.
4. Repeat steps 2 and 3 many times, for the same value of b
j
.
5. Calculate the average found at step 3.
6. Repeat steps 1 to 5 many times.
7. Make a probability distribution of the averages found at step 5.
Distribution of the expected outcome, reflecting the impact of patient heterogeneity
To obtain the expected outcome for a subgroup, we can estimate:
 E
B,L[LjX = xi].
The algorithm to estimate this expectation using Monte Carlo simulation is:
1. Draw a value b
j
.
2. Draw a value l
k
 (i.e., perform a random walk), given b
j
 from step 1 and x
i
.
3. Repeat steps 1 and 2 many times.
4. Calculate the average of the outcomes found at step 2.
The distribution of the expected outcome that reflects the impact of patient heterogeneity 
is:
 P
X [EB,L[L]].
The algorithm is identical to the algorithm for equation 3, but with steps 1 and 2 
switched.
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4. EXaMPlE
A multivariable risk function to predict the risk of cardiovascular disease (CVD) is a key 
component of many CVD decision models. D’Agostino used data from the Framingham 
Heart Study to build such a function to predict the 10-year risk of developing a first CVD 
event.117 Cox proportional hazards regression resulted in an equation for the 10-year risk 
(p):
                                                                                                                                                                                                                           ,
where S
o
(10) is the baseline 10-year survival, ¯
i
 is the ith estimated regression coefficient 
(log hazard ratio), X
i
 is the (log-transformed) ith covariate, and     is the (log-transformed) 
MODEL
Parameter -mean beta-sem mean X
Age (log) 3.061 0.214 3.856
Total cholesterol (log) 1.124 0.207 5.342
HDL (log) -0.933 0.142 3.769
SBP if untreated (log)* 1.933 0.290 4.354
SBP if treated (log)# 1.999 0.286 0.502
Smoking 0.655 0.078 0.352
Diabetes 0.574 0.110 0.065
SUMMARY STATISTICS FRAMINGHAM COHORT
Covariate mean Sd proportion yes
Age 48.5 10.8 -
Total cholesterol 212.5 39.3 -
HDL 44.9 12.2 -
SBP (log) 129.7 17.6 -
Antihypertensive treatment - - 402/3969=0.10
Smoking: 0=no 1=yes - - 1398/3969=0.35
Diabetes: 0=no 1=yes - - 258/3969=0.18
Table 2 Multivariable risk function to predict the 10-year risk of cardiovascular disease in men.
SBP: systolic blood pressure
sem: standard error of the mean
sd: standard deviation
Total cholesterol and HDL in mg/dL
* The covariate associated with the regression coefficient "SBP if untreated" is 0 if an individual 
has antihypertensive treatment, and it is log (SBP) if an individual has no antihypertensive treat-
ment.
‡ The covariate associated with the regression coefficient "SBP if treated" is log (SBP) if an 
individual has antihypertensive treatment, and it is 0 if an individual has no antihypertensive 
treatment. 
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mean value of the ith covariate. The regression coefficients ¯
i
 can be represented by distri-
butions, reflecting parameter uncertainty. The covariates X
i
 reflect patient heterogeneity. 
Table 2 presents the covariates and coefficients; appendix 4 demonstrates the calculation.
We now demonstrate the analyses described in section 2 in models whose patient hetero-
geneity consists only of variations in the covariates of this risk function. Both a spreadsheet 
and dedicated decision analysis software are suitable for the analyses.118, 119 We performed 
1,000,000 runs for single Monte Carlo simulations and 10,000*10,000 runs for nested 
Monte Carlo simulations.
In a deterministic model (model D) we only need the mean estimates of the regression 
coefficients. Next, a base case analysis is usually performed involving a patient with a typi-
cal set of covariates. For our example (see appendix 4), we considered a non-smoker, non-
diabetic patient with the mean values of the other covariates in Table 2. The 10-year risk 
for the base case is 22%. In addition to the base case analysis we can estimate the 10-year 
risk for any set of covariates. Sensitivity analyses are typically performed to evaluate the 
importance of uncertainty about the regression coefficients. Sensitivity analyses can also 
assess the impact of a covariate on the outcome. For example, a sensitivity analysis across 
the frequency distribution of the total cholesterol level (keeping all other covariates fixed at 
their base-case values) resulted in a range of the ten-year risk of 14% to 30%.
Patient heterogeneity is introduced by using distributions instead of fixed values for the 
covariates, resulting in model H. A second-order Monte Carlo simulation resulted in the 
expected outcome of a heterogeneous population or the expected outcome of a patient 
with random values for the covariates: 20%. The 95% uncertainty interval of the simula-
tion outcomes was [2%;61%]. This is the uncertainty interval of the distribution of the 
expected outcome reflecting the impact of patient heterogeneity. Such wide intervals re-
flecting patient heterogeneity mandate separate analyses for subgroups, which may result 
in subgroup-specific guidelines.
Parameter uncertainty is introduced into a deterministic model by using distributions instead 
of mean values for the regression coefficients, resulting in model P. Standard errors of the 
individual coefficient estimates – or ideally the joint variance-covariance matrix of the coef-
ficient estimates – can be used to generate these parameter distributions. A second-order 
Monte Carlo simulation (probabilistic sensitivity analysis) resulted in the same 10-year risk 
of 22% as was found using model D. Note that only if the outcome is a linear function of 
the regression coefficients (which is approximately the case in this example) will the mean 
of the outcome of the probabilistic sensitivity analysis be identical to the expected outcome 
of the deterministic model. The 95% uncertainty interval of the simulation outcomes was 
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[20%;24%]. This is the uncertainty interval of the distribution of the expected outcome 
reflecting lack of perfect knowledge.
Finally, we introduced distributions for both regression coefficients and covariates, result-
ing in model PH. A second-order Monte Carlo simulation that sampled both the regression 
coefficients and the covariates resulted in the expected outcome of a patient with random 
values for the covariates: 20%. The expected outcome was identical to the expected out-
come in model H because the outcome is approximately a linear function of the regres-
sion coefficients. To determine the distribution of the expected outcome reflecting lack of 
perfect knowledge, for a heterogeneous population, we performed a two-level simulation. 
In the outer loop the regression coefficients were sampled, and in the inner loop the cova-
riates were sampled (as in equation 1 in the section on model PH). The 95% uncertainty 
interval of the simulation was [18%;21%]. To determine the distribution of the expected 
outcome reflecting the impact of patient heterogeneity, taking parameter uncertainty into 
account, we performed a similar two-level simulation. However, this time in the outer loop 
the covariates were sampled, and in the inner loop the regression coefficients (as in equa-
tion 2 in the section on model PH). We found a 95% uncertainty interval of [2%;61%]. The 
interval is identical to the interval of model H, because in our example the model outcome 
is approximately a linear function of the regression coefficients.
 
dISCuSSION
We have reviewed the methods for the combined analyses of uncertainty and patient het-
erogeneity in medical decision models. To the best of our knowledge a comprehensive 
overview of decision models that are subject to more than one type of uncertainty or patient 
heterogeneity does not exist in the literature. However, several applications of the analysis 
of parameter uncertainty in microsimulation models are available in the literature.20, 101 A 
debate in this journal concerning the correct combined analysis of parameter uncertainty 
and stochastic uncertainty exemplified that such combined analyses are not straightfor-
ward.101, 120, 121
The combined analysis of patient heterogeneity and uncertainty has drawn increasing atten-
tion in the risk analysis literature since the early nineties.122-125 Nested (or two-dimensional) 
simulations were suggested for quantifying both patient heterogeneity and uncertainty in 
the assessment of risks.123, 126 In addition, a decomposition of the total variance into com-
ponents attributable to parameter uncertainty and patient heterogeneity was proposed in 
the risk analysis literature, and more recently in the statistical literature.112, 127
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Decision models are built primarily to inform policy makers about the expected outcomes 
of competing strategies.90 We demonstrated that the expected outcome and the distribu-
tion of the individual outcome can always be obtained in a single Monte Carlo simulation 
(i.e., without using nested Monte Carlo simulations). Nested Monte Carlo simulations are 
inevitable if we are interested in the distribution of the expected outcome (reflecting lack 
of perfect knowledge) for a heterogeneous population or or in microsimulation models. 
In addition, nested analyses should be performed to obtain the distribution of the expect-
ed outcome reflecting patient heterogeneity, both in microsimulation models and models 
with parameter uncertainty. These nested Monte Carlo simulations are computer-intensive. 
More time-efficient methods, such as Gaussian process modeling, have been developed, 
but few applications have been published.91 The importance of such time-efficient methods 
will depend on the balance between increasing model complexity and increasing computer 
performance.
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abSTRaCT
Clinical journals increasingly illustrate uncertainty about the cost and effect of health care 
interventions using cost-effectiveness acceptability curves (CEACs). CEACs present the 
probability that each competing alternative is optimal for a range of values of the cost-
effectiveness threshold. The objective of this manuscript is to demonstrate the limitations 
of CEACs for presenting uncertainty in cost-effectiveness analyses. 
These limitations arise because the CEAC is unable to distinguish dramatically different 
joint distributions of incremental cost and effect. A CEAC is not sensitive to any change of 
the incremental joint distribution in the upper-left and lower right quadrant of the cost-ef-
fectiveness plane, neither is it sensitive to radial shift of the incremental joint distribution in 
the upper-right and lower-left quadrants. As a result, CEACs are ambiguous to risk-averse 
policy makers, inhibit integration with risk-attitude, hamper synthesis with other evidence 
or opinions, and are unhelpful to assess the need for more research. Moreover, CEACs may 
mislead policy makers and can incorrectly suggest medical importance. Both for guiding 
immediate decisions and for prioritizing future research, these considerable drawbacks of 
CEACs should make us rethink their use in communicating uncertainty.
As opposed to CEACs, confidence and credible intervals do not conflate magnitude and 
precision of the net benefit of health care interventions. Therefore, they allow (in)formal 
synthesis of study results with risk attitude and other evidence or opinions. Presenting the 
value of information in addition to these intervals allows policy makers to evaluate the need 
for more empirical research. 
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INTROduCTION
Clinical journals increasingly present the uncertainty about the costs and effects of health 
care interventions using cost-effectiveness acceptability curves (CEACs). The British Medi-
cal Journal, for example, has published 16 cost-effectiveness analyses – decision models as 
well as economic trials – that presented a CEAC.128-143 These CEACs present the probability 
that each evaluated intervention is optimal, for varying values of the willingness-to-pay 
(WTP)	per	quality-adjusted	life	year	(QALY).	Decision	making	is	assumed	to	improve	when	
CEACs are presented in addition to point estimates of the incremental cost-effectiveness 
ratios (ICERs).
The ICER is typically considered the most important outcome of economic trials and deci-
sion models. It allows for comparison of the “value for money” of the interventions under 
evaluation with other unrelated health care interventions, whether preventive, diagnostic, 
or therapeutic. Organizations and journals increasingly recommend that uncertainty about 
the cost-effectiveness of interventions be evaluated. Because inference for the ICER is 
associated with statistical problems,5 CEACs were introduced in 1994 to assess the uncer-
tainty surrounding the ICER.26 Unfortunately, CEACs have several noteworthy limitations 
that have received little attention in the literature.
The objective of this manuscript is to demonstrate the limitations of CEACs for presenting 
uncertainty in cost-effectiveness analyses. In the next section, we first review the relevant 
background, including the cost-effectiveness plane, the WTP, the net benefit framework, 
uncertainty about costs and effects, and the construction of CEACs. Then we discuss why 
uncertainty is of interest to policy makers because it may not be obvious that the evaluation 
of uncertainty results in better decisions. The limitations of CEACs for presenting uncer-
tainty are then examined. Finally, we will discuss alternative presentations of uncertainty.
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baCkGROuNd
Cost-effectiveness plane
Cost-effectiveness analyses in health care typically result in 2 outcome measures for each 
competing	alternative:	the	costs	per	patient	and	an	effect	measure,	for	example,	QALYs	or	
symptom-free days per patient. The cost-effectiveness plane (CE-plane) was introduced to 
illustrate the resulting 2-dimensional “health policy space”.22 Figure 1 presents a CE-plane 
with the expected costs and effects of alternatives A to F each compared to a common 
comparator strategy. None of the alternatives is dominant – that is, more effective and less 
costly than all other alternatives. A policy maker will therefore need to be explicit about 
how she or he values costs compared to effects. Because novel health care interventions 
are often both more effective and more costly, a trade-off between costs and effects has 
to be made.
Threshold WTP and the Net benefit framework
The threshold WTP has been introduced as the substitution rate at which society is indif-
ferent to “trade” costs for effects or vice-versa. It is typically assumed that the WTP is inde-
pendent of the value of costs or effects. Using the substitution rate (i.e., the WTP), we can 
express the cost of each alternative in a health equivalent. Cost and effects can then be 
combined in a single outcome measure, net health benefit (NHB):5
 
NHB = effect – cost/WTP.
Figure 1 Cost-effectiveness plane with the 
expected costs (C) and expected effects (E) 
of six alternatives each compared to a com-
mon comparator strategy. The WTP line is 
indicated through the origin for a WTP of 
$20,000	 per	 QALY.	 The	 parallel	 lines	 are	
indifference curves, connecting points with 
the same net benefit. The NHB of the in-
difference curves corresponds to the value 
of the x-axis where the indifference curves 
intersect the x-axis. A to F represent the 
cost and effects of 6 alternatives: B is the 
preferred alternative.
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Analogously, we can express the effect of each alternative in a monetary equivalent, result-
ing in the net monetary benefit (NMB):
 NMB = effect*WTP – cost.
Identifying the preferred alternative is now simplified to selecting the strategy with the 
maximum net benefit (NHB or NMB).
We can also present this graphically. The slope of the straight line through the origin of 
the	CE-plane	in	Figure	1	equals	the	WTP	per	unit	of	the	effect	measure	(e.g.,	$20,000	per	
QALY).	Rotating	the	WTP	line	around	the	origin	varies	the	WTP.	As	we	rotate	the	WTP	line	
counterclockwise from horizontal to vertical, the WTP increases from 0 to infinity. Alterna-
tives to the lower right of the WTP line are preferred over alternatives to the upper left of 
the WTP line.
Alternatives with the same net benefit lie on the same line parallel to the WTP line. Because 
society is assumed to be indifferent between alternatives with the same net benefit, these 
parallel lines are indifference curves.87 The indifference curves create a preference gradi-
ent, from large negative net benefits in the upper left corner of the CE-plane to large posi-
tive net benefits in the lower right corner. The NHB of the indifference curves corresponds 
to the x-value, where the curves intersect the x-axis: the NMB of the indifference curves 
corresponds to the y-value, where the curves intersect the y-axis. The WTP line through the 
origin represents a net benefit of 0. The indifference curves illustrate that alternative B is 
the	most	preferred,	given	a	WTP	of	$20,000	per	QALY.
Uncertainty about costs and effects
Estimates of the mean costs and effects are uncertain, because trials have limited sample 
sizes, and model parameters are not known with absolute certainty. This uncertainty is the 
uncertainty about the mean outcomes (cf. standard error of the mean), and is different 
from the uncertainty about individual outcomes (cf. standard deviation). Although uncer-
tainty about individual outcomes may affect decision making through consideration of 
equity, the focus of this article is on uncertainty about mean outcomes.
In an economic trial, the costs and effects are measured for each patient. By drawing boot-
strap replicates from the trial data, we can derive the joint distribution of the mean costs 
and effects of each alternative to represent uncertainty.24 These joint distributions take cor-
relations between costs and effects into account.
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In a decision model, probabilistic sensitivity analysis (also known as second-order Monte 
Carlo simulation) can be applied to obtain the joint distribution of the mean costs and ef-
fects.17, 38, 80 This involves 3 steps: first, many samples are drawn from the joint probability 
distribution of the input parameters (e.g., transition probabilities, utilities, and costs). Next, 
using the model, the expected costs and effects are calculated for each alternative, for 
each sample. Finally, the expected costs and effects for each alternative and each sample 
are plotted in the CE-plane. The expected costs and effects can be correlated within and 
between alternatives: for example, a transition probability in the model can impact several 
alternatives.
Figure 2 Cost-effectiveness plane with the 
joint distribution of the incremental expect-
ed costs and incremental expected effects 
of two competing alternatives. The word 
“incremental” refers to the difference be-
tween two alternatives (e.g., alternative B 
minus alternative A). 
Figure 3 Cost-effectiveness acceptability 
curves for both alternatives. The ascend-
ing curve presents the probability that the 
net benefit (NB) of alternative B exceeds 
the net benefit of alternative A: Pr [NB(B) 
> NB(A)]. The descending curve presents 
the probability that the net benefit (NB) 
of alternative A exceeds the net benefit of 
alternative B: Pr [NB(A) > NB(B)].  Often 
only the ascending curve is presented.
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If only 2 alternatives are considered, the joint distribution of the incremental costs and 
effects can be presented. In Figure 2, for each sample of a probabilistic sensitivity analy-
sis, the difference in expected costs and effects is plotted. Note that the axes of Figure 2 
present incremental costs and effects, whereas the axes of Figure 1 present the costs and 
effects of each alternative compared to a common comparator strategy. The incremental 
distribution reflects correlations between the outcomes of the 2 alternatives. The outcomes 
of alternatives in economic trials, however, are not correlated – with the exception of cross-
over trials. To create an incremental joint distribution of the cost and effects of an economic 
trial, it is typically assumed that no correlation exists between the alternatives.
Constructing CEACs for 2 alternatives: graphically
CEACs present uncertainty as the probability that each alternative has the greatest net ben-
efit as a function of the WTP. CEACs were introduced to present uncertainty about a choice 
between 2 alternatives (e.g., alternative A representing standard care and alternative B 
representing a new treatment).26 The probability that one alternative (B) is preferred over 
the other (A) is represented graphically in Figure 2 as the proportion of the incremental 
joint distribution to the lower-right of the WTP line. We can estimate this proportion repeat-
edly while rotating the WTP line counterclockwise from horizontal (i.e., WTP = 0) to verti-
cal (i.e., WTP = infinity). The ascending curve in Figure 3 presents the probability that al-
ternative B is preferred over alternative A for a range of values for the WTP. The probability 
Sample A B C preferred
1 -0.14 0.06 -0.02 B
2 -0.27 0.07 0.05 B
3 -0.08 0.10 0.05 B
4 -0.12 0.05 0.02 B
5 -0.07 0.06 0.04 B
6 0.04 0.18 0.19 C
7 -0.15 0.04 0.02 B
8 -0.36 -0.05 -0.01 C
9 0.06 -0.02 -0.02 A
10 -0.06 0.07 0.06 B
Average -0.11 0.06 0.04 B
Table 1 The	NHB	(in	QALYs)	for	ten	samples	are	presented	for	the	alternatives	
A, B, and C. Alternative B is the preferred alternative with the maximum average 
NHB (i.e., 0.06). Alternative B is preferred in 70% of the samples, alternative C in 
20%, and alternative A in 10%. Estimating these proportions over a range of the 
WTP will result in the CEACs. More samples will result in more precise estimates 
of the probabilities.
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that alternative A is preferred over alternative B is 1 minus the probability that alternative 
B is preferred over alternative A (descending curve in Figure 3). When only 2 alternatives 
are compared, the CEAC typically presents only the ascending curve.
Constructing CEACs for 2 or more alternatives: numerically
The net benefit framework enables the construction of CEACs for any number of alterna-
tives.5, 96 Table 1 presents the hypothetical results in NHB of a probabilistic sensitivity analy-
sis of a model with 3 alternatives. Each row represents a sample from the joint distribution 
of the input parameters with the resulting net benefit of the model for each alternative. 
Each row is equally likely to be “true”. For each row, we can determine the alternative 
with the maximum NHB. The probability that each alternative is preferred is the fraction 
of rows in which it is the alternative with the maximum NHB: (A;B;C) = (10%;70%;20%). 
The estimated fractions become more precise with more replications than the 10 samples 
in Table 1. Repeating this process for a range of values for the WTP yields the CEACs for 
each of the alternatives. The probabilities that each alternative is optimal – for a given 
WTP – sum to 1.
WhY POlICY MakERS CaRE abOuT uNCERTaINTY
Uncertainty about the outcome (e.g., net health benefit) has been considered irrelevant, 
assuming that the preferred alternative is simply the alternative with the highest expected 
outcome.27, 144 The analysis and presentation of uncertainty may, therefore, seem point-
less. A study, however, showed that reimbursement decisions of the National Institute of 
Clinical Excellence (NICE) in the UK were considerably influenced by uncertainty about 
the expected outcome.61 We will discuss 3 rationales for presenting uncertainty about the 
outcomes of economic randomized controlled trials (RCTs) and decision models. Two ad-
ditional rationales to evaluate uncertainty are especially relevant to decision models. 
Integrate uncertainty with risk attitude
Analysts typically assume that policy makers are risk neutral. In reality, however, policy 
makers (as representatives of society at large) tend to be risk averse rather than simply 
expected outcome maximizers. They are especially worried about new interventions with a 
nonnegligible probability of being very harmful. For example, an established drug with a 
small but certain benefit may be preferred over a new drug with a higher – but uncertain 
–benefit. When the cost of a new intervention is particularly uncertain, policy makers may 
worry about budgetary problems. If considerable uncertainty exists about the cost-effec-
tiveness of the alternative with the most favorable cost-effectiveness ratio, future evidence 
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may show that another alternative is actually preferred. Policy makers may be reluctant 
to reimburse a new alternative with uncertain cost-effectiveness because changing policy 
and practice costs time and effort and commonly meets resistance from those involved in 
delivering and receiving care. For example, repeatedly starting and discontinuing a breast 
cancer screening program whenever the evidence tips the balance may be unacceptable to 
both providers and the public.
In evaluating uncertainty, risk-averse policy makers consider 2 aspects of uncertainty: the 
probability of not selecting the “true” preferred alternative and the possible consequences 
of not selecting the “true” preferred alternative. No matter how precisely estimated the net 
benefits of the alternatives are, the preferred alternative - based on available evidence - 
has a non-zero probability of not being the “true” preferred alternative. The difference in 
net benefit between the “true” preferred alternative and the selected alternative is the con-
sequence or harm of not selecting the “true” preferred alternative. A policy maker can only 
appraise uncertainty when both the probability and the consequences of not selecting the 
“true” preferred alternative are presented. A decision with a 4% probability of being wrong, 
for example, may be perceived as very uncertain if the consequences could be devastating 
(e.g., outbreak of an epidemic). On the other hand, for a 50% probability of being wrong, 
little uncertainty may be perceived when the consequences of being wrong are negligible 
(e.g., 2 drugs with precise and nearly equal benefit). Because of the “flat maximum prin-
ciple" the latter scenario is not entirely hypothetical in current day Western medical care: 
differences between competing alternatives tend to be small.145
An unambiguous presentation of uncertainty enables policy makers to combine the results 
of a cost-effectiveness analysis implicitly with their attitude towards risk. If desired, we could 
elicit a utility function for costs and effects for each policy maker and integrate uncertainty 
and risk attitude explicitly.87 The decision is then simplified to selecting the alternative with 
the maximum expected utility.
Integrate uncertainty with other evidence and opinions
A quantitative analysis is rarely the only or final word on a decision.115, 146 This is especially 
true for a single economic trial. Policy makers will wish to combine the results of the analy-
sis with other (future) evidence and opinions. A quantitative statement of the uncertainty 
about the results will enable policy makers to weigh the results implicitly in combining them 
with other evidence and opinions. This synthesis could take place in a more formal Bayes-
ian framework, if desired.73
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Uncertainty and the need for more research
In addition to selecting the preferred alternative, policy makers have to decide whether 
to perform more empirical research (e.g., a trial) regarding the decision. The decision to 
perform more research can be considered as an independent decision from the selection of 
the preferred alternative.14 Regarding the comparison of the current treatment and a new 
drug, for example, a policy maker can decide to:
1. implement the new drug and obtain more research,
2. implement the new drug and not obtain more research,
3. not implement the new drug and obtain more research, or
4. not implement the new drug and not obtain more research.
In the 2 previous subsections, we discussed how uncertainty influences policy makers in 
selecting the preferred alternative. Uncertainty, however, is also responsible for the policy 
maker’s perception of the need for more research. Policy makers should compare the 
expected benefit of research with the expected research costs because collecting primary 
data is typically expensive. Value of information analysis is a method to explicitly estimate 
the expected benefit of research.14, 27, 28, 32, 81, 105, 115, 146, 147 It considers both the probability 
and the consequences of not selecting the “true” preferred alternative.
Moral obligation
Scientists may feel a moral obligation to be clear about the lack of absolute certainty in 
their results.115 The analysis of uncertainty serves this accountability by quantifying the 
confidence in the outcomes. Moreover, if uncertainty is not explicitly modeled, it is possible 
that investigators or institutions might (subconsciously) select values from the ranges of 
uncertainty that fit their preferences best.
Non-linearity
This rationale for assessing uncertainty about model parameter values in decision models 
has a mathematical nature and is often unappreciated. Ignoring uncertainty may result 
in a biased estimate of the expected net benefits of alternatives, when a nonlinear rela-
tion exists between the expected net benefit and the uncertain parameters. For example, 
a Markov model is nonlinear in the annual constant mortality rate. More generally we can 
state that a model outcome, f(b), is a nonlinear function of an uncertain model parameter, 
b, if the expected value of f(b) is not equal to the function of the expected value of b:
E[f(b)]	≠	f(E[b]).
To account for such nonlinearities, nonlinear model parameters should ideally be modeled 
with probability distributions instead of point estimates.17 
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lIMITaTIONS Of CEaCS
In this section we discuss how CEACs perform in addressing the first 3 rationales – discussed 
in section 2 – for presenting uncertainty. In addition, we draw attention to 2 situations in 
which CEACs are easily misinterpreted and, as a result, could mislead policy makers. First, 
we demonstrate how dramatically different incremental joint distributions of 2 alternatives 
may result in the exact same CEAC. The limitations of CEACs arise because of this inability 
to distinguish completely different incremental joint distributions.
CEACs don’t distinguish dramatically different incremental joint 
distributions
CEACs are identical if the proportion of the incremental joint distribution to the lower-right 
of the WTP line is the same for all values of the WTP. This allows points of the incremental 
joint distribution in the upper left or lower right quadrant to move anywhere else within the 
same quadrant, without changing the CEAC. The CEAC remains unchanged, because the 
proportion of the incremental joint distribution to the lower right of the WTP line for any 
value of the WTP remains unchanged. Consequently, if 1 alternative could be more costly 
and less effective, CEACs ignore whether the adverse health effect and budgetary impact 
could be tiny or giant. Moreover, CEACs are not affected when points of the incremental 
joint distribution in the upper right and lower left quadrants move radially toward or away 
from the origin. The CEAC remains unchanged because the proportion of the incremental 
joint distribution to the lower right of the WTP line for any value of the WTP remains un-
changed.
Figure 4 The CE-plane in Figure 4A reflects small expected incremental costs and effects, and some uncertainty. The arrows 
represent (hypothetical) changes in the distribution that would not modify the CEAC of this CE-plane. Points in the upper-left 
or lower-right quadrant can move anywhere else within the same quadrant, without changing the CEAC. Points in the two other 
quadrants can move radially towards or away from the origin, again without changing the CEAC. In Figure 4B the points have 
moved, resulting in a different distribution with a large expected incremental costs and effects and more uncertainty. However, 
the CEACs of Figure 4A and B are identical.
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Figure 4 illustrates 2 remarkably different incremental joint distributions with identical 
CEAC, presented in Figure 3. The distributions represent 2 different (hypothetical) datasets 
regarding the same competing health care interventions. The distribution in Figure 4A has 
small	incremental	expected	costs	and	effects	(1100	euro	and	0.05	QALYs),	some	uncer-
tainty	 (standard	errors	of	1100	euro	and	0.05	QALYs),	and	no	correlations.	The	arrows	
represent hypothetical changes in the incremental distribution that would not modify the 
CEAC. Regarding the upper left and lower right quadrants the arrows represent shift of 
points of the incremental distribution to anywhere within the same quadrant. In the upper-
right and lower-left quadrants, they represent radial shift within the same quadrant. Figure 
4B (identical to Figure 2) presents such a change in the distribution, resulting in large in-
cremental	expected	costs	and	effects	(11,000	euro	and	0.5	QALYs),	increased	uncertainty	
(standard	errors	of	11,000	euro	and	0.5	QALYs),	and	no	correlations.	We	will	use	these	2	
sets of hypothetical results to illustrate the drawbacks of CEACs and some advantages of 
others methods.
CEACs are useless to risk-neutral and ambiguous to risk-averse 
policy makers
Risk-neutral policy makers don’t need CEACs. They will prefer the alternative with the maxi-
mum expected net benefit, no matter what the probability is that this alternative is optimal. 
To a risk-averse policy maker, the probability of not selecting the “true” preferred alterna-
tive – as presented by the CEAC – is ambiguous for assessing the importance of uncertainty 
without knowing the consequences (as explained earlier). As a result, any cut-off value for 
this probability is an ambiguous criterion to risk-averse policy makers for making decisions. 
Figure 4 illustrates that CEACs fail to capture the importance of uncertainty. Uncertainty is 
clearly more important in B than in A: possible consequences of making the wrong decision 
(in retrospect) are several times larger in Figure 4B, compared to Figure 4A. Therefore, 
a risk-averse decision maker would be more worried about the uncertainty in Figure 4B. 
However, the incremental distributions of Figure 4A and 4B have identical CEACs. 
The risk-attitude of a policy maker - as reflected by a utility function - applies to the uncer-
tain net benefits of the alternatives. We can formally integrate the risk attitude of a policy 
maker with the uncertain outcome of each alternative, to identify the alternative with the 
maximum expected utility.87 Because CEACs only present the probability of not selecting 
the “true” preferred alternative – and not the consequences– they imply that policy mak-
ers have a binary utility function: a value of 1 is assigned if the preferred alternative is the 
“true” preferred alternative and a value of 0 if the preferred alternative is not the “true” 
preferred alternative. Policy makers are unlikely to care only about the probability that an 
alternative is best with no consideration of how much better or worse it may be.
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CEACs hamper synthesis of study results with other evidence and 
opinions
To integrate a CEAC with existing evidence and opinions, we need to choose an appropriate 
weight for the evidence presented by the CEAC. The weight depends on the precision and 
validity of the evidence. Unfortunately, we cannot tell whether results presented as a CEAC 
are precise. CEACs conflate the precision of the net benefit estimates of each alternative 
with the magnitude of the estimates. For the same CEAC, the precision and magnitude may 
both be small as in Figure 4A, or large as in Figure 4B. Because a CEAC does not reveal the 
precision of estimates, we cannot assign a meaningful weight to the evidence contained in 
the cost-effectiveness study. 
The conflation of magnitude and precision has an analogy in epidemiology. For decades, 
statisticians have tried to convince the medical research field that estimation (i.e., report-
ing confidence intervals) is better than hypothesis testing (i.e., reporting p-values).9, 148 Hy-
pothesis testing only provides an indication of statistical significance, which is not the same 
as medical importance. A confidence interval conveys the (im)precision of an estimate in 
addition to its magnitude. 
CEACs are unhelpful in value of information analysis
CEACs provide a measure of uncertainty. It has therefore been argued that creating a CEAC 
is an appropriate first step towards the evaluation of the need for more research.96 How-
ever, CEACs do not reflect the importance of uncertainty (i.e., the value of information), 
because they ignore the consequences of not selecting the “true” preferred alternative. 
For a probability of 65% that an alternative is the “true” preferred alternative, the value of 
information could be negligible or enormous. The same holds for a probability of 99%. The 
incremental distributions in Figure 4 share the same CEAC, but have an expected value of 
perfect	 information	 (EVPI)	of	0.03	QALYs	and	0.32	QALYs	 respectively	 (WTP=20,000).	
CEACs are therefore unreliable to evaluate the need for future research. Because a prob-
ability of 65% may suggest the need for more research, and 99% may suggest minimal 
value from more research, CEACs can even be considered potentially misleading regarding 
the need for more research.
CEACs may mislead policy makers regarding the preferred 
alternative
The CEACs do not report which alternative has the maximum expected benefit given the 
WTP. Policy makers may be easily misled to believe that the alternative with the maximum 
probability of having the maximum benefit is the alternative with the maximum expected 
benefit. However, outcomes from decision models typically have asymmetric distributions. 
If the distribution of the incremental net benefit is asymmetric, the alternative with the 
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maximum probability of having the maximum benefit may not have the maximum ex-
pected benefit. To overcome this interpretation problem, the CEAC frontier was recently 
introduced: the alternative with the maximum expected benefit is highlighted for all values 
of the WTP.96 This “fix”, however, may be confusing for the policy maker unfamiliar with 
these concepts.
CEACs may incorrectly suggest medical urgency or importance
When a CEAC presents a high probability (e.g., 99%) that a new drug is the “true” pre-
ferred alternative, a need for immediate action may be perceived for this seemingly con-
vincing breakthrough drug. The high statistical significance is easily equated to medical 
importance. The additional benefit of the new drug compared to current standards, how-
ever, cannot be determined from the CEAC or the ICER. The mean expected benefit may 
in fact be negligible and not even justify the implementation costs.
 
OThER REPRESENTaTIONS Of uNCERTaINTY
Cost-effectiveness plane
The joint distribution of costs and effects for each alternative illustrates the comprehensive 
results of a cost-effectiveness analysis. Policy makers interested in cost or effects, in par-
ticular, can get an impression of the expected costs and effects, as well as their uncertainty 
intervals for each alternative. If only 2 alternatives are considered, the incremental joint 
distribution can be presented. The results can be combined qualitatively with risk-attitude, 
other evidence, and implementation costs. Moreover, the incremental joint distribution 
gives an unbiased impression of the value of more information. 
If more than 2 alternatives are presented, however, the CE-plane is ambiguous about 
the value of information and therefore about the importance of uncertainty. Correlations 
between more than 2 alternatives cannot be presented in the CE-plane, but have a large 
impact on the value of information. The uncertain outcomes of alternatives in a decision 
model are often correlated because the same uncertain parameter may influence the out-
come of several alternatives. When 2 alternatives are compared in a cross-over RCT or a 
decision model, the incremental joint distribution in the CE-plane captures the correlation 
between the alternatives. When more than 2 correlated alternatives are compared, the CE-
plane can present the joint distributions of each alternative. Overlapping joint distributions 
may then be incorrectly interpreted as a reflection of important decision uncertainty. Cor-
relations between overlapping alternatives, however, may cause one alternative to always 
dominate the others. This misperceived uncertainty, however, does not deter the selection 
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of the preferred alternative with the maximum expected outcome or expected utility for 
risk-averse policy makers.
The CE-plane has been recommended as a visual presentation of the results of a cost-
effectiveness analysis. Summary measures may be useful in addition to the CE-plane.
Intervals for the ICER
Confidence or credible intervals for the ICER are ambiguous when the incremental joint dis-
tributions are not confined to either the upper right or the lower left quadrant. This is because 
the interpretation of the ICER varies across the quadrants. Unfortunately virtually all decisions 
worth formal consideration extend into more than 1 quadrant: uncertainty about the sign of 
incremental cost and effects is the rule rather than the exception. Interventions in the upper 
right quadrant of the CE-plane are more effective and more costly: a low ICER is preferred. 
Interventions in the lower left quadrant are less effective and cost saving: a high ICER is pre-
ferred.149, 150 ICERs in the other 2 quadrants lack an inherent hierarchy, because they are a 
ratio of something good (i.e., positive effect or negative cost) and something bad (i.e., posi-
tive cost or negative effect). If incremental effects are positive and equal, we prefer an ICER 
of	-$10,000	over	an	ICER	of	-$5,000,	because	the	former	has	a	higher	negative	incremental	
cost. If incremental costs are negative and equal, however, we do not prefer an ICER of 
-$10,000	over	an	ICER	of	-$5,000,	because	the	former	has	a	smaller	incremental	effect.
The question now arises, whether a valid ICER interval helps policy makers in dealing with 
uncertainty. The interval limits do not seem particularly informative to the risk-averse policy 
maker, because the incremental net benefit, the incremental effect, and the incremental 
costs per patient remain indeterminate from an ICER. The same upper limit of an ICER 
interval	 (e.g.,	$100,000	per	QALY)	could	 represent	an	outcome	with	a	small	change	 in	
incremental net benefit, or a huge change. It is therefore impossible to predict how bad – 
considering both health and costs – it would be if the ICER would resolve at the upper limit. 
Moreover, ICER intervals are not informative for the weight the current study should get for 
synthesis with other evidence, or for the value of more research.
In both Figure 4A and B about 13% of the distribution falls in the upper left, and about 13% 
in the lower right quadrant. As explained earlier, a hierarchy for the ICER in these quadrants 
does not exist.
Intervals for the net benefit
A confidence or credible interval for the net benefit of each alternative provides policy 
makers with information about the precision of the outcomes. Intervals enable risk-averse 
policy makers to weigh the precision with their risk attitude implicitly. If desired, they can 
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explicitly integrate their single-attribute utility function with the distribution of the net ben-
efit for each alternative to identify the preferred alternative. The separate presentation of 
the magnitude and the precision of the outcomes also allows policy makers to weigh the 
results with other evidence and opinions. Moreover, when 2 alternatives are compared, 
the interval for the incremental net benefit provides an impression of the value of more 
information. If considerable uncertainty exists about the WTP, the intervals for net benefit 
can be presented across a range of values for the WTP. The intervals of the net benefit can 
be presented in addition to separate intervals for the cost and effects of each alternative. 
Policy makers may be more risk averse for harmful effects or high costs than is reflected in 
the net benefit framework.
This presentation has several additional advantages. The benefit of each alternative can 
be easily extrapolated to the population level by multiplying the benefit per individual with 
the appropriate number of patients. The population benefit enables comparison with im-
plementation or transition costs. Analogously, the interval limits can be multiplied with 
the appropriate number of patients. Moreover, policy makers and clinicians are used to 
confidence/credible intervals to present uncertainty: results of RCTs and meta-analyses are 
typically presented as confidence intervals.
The 95% confidence intervals for the incremental net benefit of the joint distributions are 
–0.15	to	0.14	QALYs	(Figure	4A)	and	–1.5	to	1.4	QALYs	(Figure	4B).	
Expected value of perfect information (EVPI)
When 2 alternatives are compared, the incremental distribution on the CE-plane and in-
tervals for the INB provide only an impression of the EVPI. When more than 2 alternatives 
are compared, CE-planes and incremental intervals do not reflect correlations between 
the outcomes of alternatives. Such correlations often arise in decision models and are in-
fluential on the EVPI. The EVPI is therefore valuable to policy makers, in addition to other 
presentations of uncertainty, to evaluate the need for more research.
 
dISCuSSION
We have demonstrated some of the limitations of cost-effectiveness acceptability curves 
(CEACs), which are increasingly applied to represent uncertainty about the choice between 
competing alternatives. Policy makers are interested in uncertainty in order to assimilate 
study results with their risk attitude and other evidence and opinions in choosing the pre-
ferred alternative. In addition, they evaluate uncertainty to decide whether more quantita-
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tive research regarding the decision uncertainty is justified. We have shown that CEACs do 
not allow integration with risk attitude or other evidence and opinions. Moreover, they are 
ambiguous regarding the need for more research.
It is not clear why CEACs are so popular in the light of these limitations. The analogy of 
CEACs with hypothesis testing - which is still widely used to present uncertainty in the health 
care literature instead of confidence (or credible) intervals - may explain its popularity. It 
has also been argued that CEACs are preferred over the probability distribution of net ben-
efits, because they do not require the selection of a value for the WTP. However, the net 
benefit can be presented over a range of values for the WTP, analogous to CEACs. Other 
research fields that apply decision analysis seem to prefer the net benefit framework to 
present uncertainty over CEACs. For example, we are not aware of a single example of the 
use of CEACs in the environmental risk analysis and cost benefit literature.
We have discussed several alternative presentations of uncertainty. The cost-effectiveness 
plane is useful to visualize the joint distributions of the competing alternatives. In addi-
tion, summary measures of the CE-plane can help policy makers. Confidence and credible 
intervals for the net benefit allow integration with risk attitude as well as other evidence 
and opinions. They clearly separate the magnitude of outcomes from the precision of out-
comes. Intervals for costs and effects can be presented separately, if the preferences of the 
policy maker are not represented by a constant WTP. Presenting the EVPI enables policy 
makers to evaluate the need for more quantitative research.
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abSTRaCT
Decisions in health care must be made, despite uncertainty about benefits, risks, and costs. 
Value of information analysis is a theoretically sound method to estimate the expected 
value of future quantitative research pertaining to an uncertain decision. If the expected 
value of future research does not exceed the cost of research, additional research is not 
justified, and decisions should be based on current evidence, despite the uncertainty.
To assess the importance of individual parameters relevant to a decision, different value of 
information methods have been suggested. The generally recommended method assumes 
that the expected value of perfect knowledge concerning a parameter is estimated as the 
reduction in expected opportunity loss. This method, however, results in biased expected 
values and incorrect importance ranking of parameters. The objective of this manuscript is 
to set out the correct methods to estimate the partial expected value of perfect information 
and to demonstrate why the generally recommended method is incorrect conceptually and 
mathematically.
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INTROduCTION
Decision makers in health care face two separate decisions when confronted with results 
from economic trials or decision models.14 First, they have to decide which strategy to 
adopt. Next, the question arises whether more clinical research regarding the decision is 
desirable. More research is expected to have a benefit, since it usually decreases decision 
uncertainty and therefore the probability and harm of making the wrong decision. At the 
same time, research also has a financial cost and may result in harm because of forgone 
benefits from delaying adoption of beneficial interventions. More research is only justified 
if the expected benefit exceeds the cost.
Different methods are used to communicate (decision) uncertainty, for example, confi-
dence intervals, Bayesian credible intervals, or acceptability curves. It is increasingly ac-
knowledged that, when assessing uncertainty, value of information (VOI) analysis is the 
only method that explicitly estimates the expected benefit of future research.151 The total 
expected value of perfect information (total EVPI) estimates the value of simultaneously 
eliminating all uncertainty of all uncertain parameters related to the decision. Estimation of 
partial expected value of perfect information (partial EVPI) can identify the key parameters, 
whose uncertainty drives the decision uncertainty. Other importance measures for param-
eters, such as rank correlation, n-way sensitivity analysis, elasticity or standardized regres-
sion coefficient, do not directly consider the expected net benefit per patient of further 
information.151, 152 Since increasing expected net benefit per patient is the main objective of 
health care, VOI analysis has a sound theoretical basis.
Brennan et al. noticed that two different approaches for estimating partial EVPI using simu-
lation have been described and applied in the literature.153 The generally recommended 
approach assumes that a parameter is important if the reduction in expected opportunity 
loss as a result of obtaining its “true” value is high. 107, 144, 151, 154-156 The correct approach 
assumes that a parameter is important if the expected value of obtaining its “true” value 
is high. These approaches can result in large differences in outcome, and a different im-
portance ranking. The objective of this manuscript is to set out the correct methods to esti-
mate partial EVPI and to demonstrate why the generally recommended method is incorrect 
conceptually and mathematically. Before focusing on partial EVPI, we will first define some 
notation in a net benefit framework and start with total EVPI. This notation was recently 
applied by Ades and Claxton in their work about the more complicated expected value of 
sample information (EVSI).32 
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Net benefit framework
The net benefit (B) is a function of the strategy (a) and the uncertain parameters (µ): 
B(a,µ). It has two components, both functions of a and µ:	an	effectiveness	component	(Q	
in	QALY)	and	a	cost	component	(C	in	Dollars).	In	order	to	express	effectiveness	and	costs	in	
the	same	units,	we	express	costs	in	quality	adjusted	life	years	(QALY)	by	dividing	the	costs	
by	the	willingness-to-pay	for	a	QALY	(λ) to obtain the net health benefit:5
 B(a,µ) = Q(a,µ) – C(a,µ)/ λ.
Since µ is uncertain, the benefit of a strategy is uncertain. However, for each strategy we 
can calculate the expected benefit over the joint probability distribution of the parameters 
µ (E for expectation):
 E
µ
B(a,µ). (1)
This expectation is typically estimated using Monte Carlo simulation. The first step in Monte 
Carlo simulation is to randomly draw a value of µ (i.e., a vector with one value for each 
parameter) from the joint distribution of µ. Next, we calculate the benefit of strategy a, 
given the value of µ. The expected benefit of a strategy is estimated as the average benefit 
over many randomly drawn values of µ. If we then maximize over a, we obtain the expected 
benefit of the optimal strategy, without additional information:
 max
a
 E
µ
B(a,µ). (2)
The optimal strategy without additional information is also referred to as the optimal base-
line decision or a*. If B(a,µ) is a linear function of µ and the parameters µ are not corre-
lated, we obtain the correct expected benefit by setting all parameters at their mean value: 
max
a
 B(a,E(µ)). This linearity is usually assumed implicitly in decision modeling where the 
analysis is called deterministic. Likewise, when the integral of B(a,µ) over the joint distribu-
tion of µ can be solved analytically, simulation is not necessary.
Total expected value of perfect information (EVPI)
The total EVPI is the expected value of obtaining perfect knowledge of the “true” values of 
all parameters (µ).106 With perfect information there is no uncertainty, so we would know 
the “true” value of µ and make the correct decision. The expected benefit if we would know 
the “true” value of µ is obtained by integrating over µ:
 E
µ
 max
a
 B(a,µ). (3)
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Notice that the only difference between the equations (2) and (3) is the order of expecta-
tion and maximization. We can estimate equation 3 using Monte Carlo simulation. For 
each randomly drawn value of µ, we can imagine it is the “true” set of parameter values, 
and calculate the benefit of the optimal strategy given these values: max
a
 B(a,µ). The aver-
age benefit over many randomly drawn values of µ is an estimate of the expected benefit 
with perfect information. The total expected value of perfect information (total EVPI) is the 
difference between the expected value with perfect information and the expected value 
without information:
 total EVPI = E
µ
 max
a
 B(a,µ) - max
a
 E
µ
B(a,µ).  (4)
In words, the total EVPI is the difference between the expected value of the optimal deci-
sion we would make if we knew the “true” parameter values (equation 3), and the expected 
value of the strategy we would choose if we had to choose under conditions of uncertainty 
about the parameters (equation 2). If B(a,µ) is normally distributed, the total EVPI can be 
calculated analytically.157
Opportunity loss
An equally valid way of estimating and interpreting value of information is from the oppor-
tunity loss perspective.158 In this section we demonstrate that the expected opportunity loss 
is equal to the expected value of information.
The opportunity loss is the difference between the benefit of the strategy that is optimal 
given the “true” value of µ and the benefit of the strategy that was optimal at baseline (a*). 
The expected opportunity loss over the joint probability distribution of the parameters µ is:
E
µ
 [opportunity loss]  = E
µ
 [max
a
 B(a,µ) – B(a*,µ)]
 = E
µ
 max
a
 B(a,µ) – E
µ
B(a*,µ)
 = E
µ
 max
a
 B(a,µ) – max
a
 E
µ
B(a,µ).
Note that the final step results in the total EVPI as in equation 4. With Monte Carlo simula-
tion we can estimate the expected opportunity loss. For each randomly drawn value of µ we 
can imagine it is the “true” value. We then calculate the difference in benefit between the 
strategy that is optimal given this value of µ and the strategy that was optimal at baseline 
(a*). The expected opportunity loss is estimated as the average benefit over many randomly 
drawn values of µ.
An example illustrates the equivalence of these definitions of EVPI. Table 1 presents the 
results of a Monte Carlo simulation to estimate the total EVPI of a decision between strate-
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gies	A	and	B.	The	bottom	row,	which	gives	the	expected	net	benefit	expressed	in	QALYs,	
shows that strategy A is optimal without additional information, resulting in an expected 
net	benefit	of	3	QALYs,	compared	to	2	QALYs	for	strategy	B.	The	expected	net	benefit	if	we	
know the “true” value of µ is estimated as the average of the maximum net benefit across 
many (N) randomly drawn values of µ. In our example, this average is 3.5: the mean of 
the	fourth	column	in	Table	1.	The	total	EVPI	therefore	is	3.5-3=0.5	QALYs,	analogous	to	
equation 4. The fifth column calculates the opportunity loss for each value of µ, analogous 
to	the	equation	for	the	opportunity	loss.	The	average	opportunity	loss	is	also	0.5	QALYs.
In the following sections we will explain several methods to estimate partial EVPI. We begin 
with the correct methods, based on the definition of partial EVPI. Then we will clarify why 
the reduction in expected opportunity loss approach is incorrect. 
 
Partial EVPI as the increase in expected value
If the total EVPI suggests that more research is justified, the analysis of partial EVPI can 
identify the key parameters. For example, in an economic evaluation of alternative treat-
ments, it is possible that only a few parameters – such as the waning of treatment benefits 
after the end of a clinical trial or the costs of components of resource use – account for 
virtually all decision uncertainty. Analogously, in a decision model comparing diagnostic 
tests, partial EVPI could indicate that future research is most valuable on health state utili-
ties, rather than test characteristics.
Corresponding to the definition of the total EVPI, the partial EVPI is defined as the expected 
value of obtaining perfect knowledge about the “true” values of one or more parameters. 
Future research aims to increase the expected value of a decision. The higher this increase 
in expected value is, the more important the parameter is. To calculate partial EVPI we will 
explain a generally valid method (two-level method) and a short-cut method that is valid 
under certain conditions (one-level method).
µ strategy A strategy B sample max opportunity loss
1 4 0 4 4-4=0
2 1 2 2 2-1=1
3 3 1 3 3-3=0
4 4 5 5 5-4=1
… … … … …
N   max(a,b) max(a,b)-a
mean 3 2 3.5 0.5
Table 1 Estimating total EVPI. Values are net benefits in QALYs.
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Two-level method
For a subset of one or more parameters, µ
I
 (the parameters of interest), we estimate the 
expected value of learning their “true” values. The complementary set of parameters we 
refer to as µC. The expected benefit of the optimal strategy given values of µI is:
 max
a
 EµC|µI B(a,µ).
Here the expectation is over the conditional distribution of µC, given the values of µI. The 
expected benefit with perfect information on µ
I
 is the expectation of this quantity over the 
distribution of µ
I
:
 Eµ
I
 max
a
 EµC|µI B(a,µ).
The partial expected value of perfect information on µ
I
 is the difference between the ex-
pected benefit with perfect information on µ
I
 and the expected benefit without informa-
tion:
 pEVPI(µ
I
) = Eµ
I
 max
a
 EµC|µI B(a,µ) - maxa EµB(a,µ).
 81, 159 (5)
Again, we can estimate this expected benefit using Monte Carlo simulation. Because of the 
two expectations, we need a two-level Monte Carlo simulation. Box 1 presents a stepwise 
algorithm.
Based on the reasoning in this section, equation 5 is the correct definition of partial EVPI. 
Therefore, any definition of partial EVPI that is not mathematically equivalent to equation 
5 is incorrect.
BOX 1: TwO-LEVEL MONTE CARLO SIMULATION.
1. Draw a value for µ
I
.
2. Draw a value for µC (draw from the conditional distribution given µI, if µI and µC are correlated).
3. Calculate the benefit for each strategy.
4. Repeat steps 2-3 many times (i.e.,µ
I
 remains fixed at value drawn at step 1).
5. Calculate, for each strategy, the average of the benefits calculated at step 3, and identify the optimal 
strategy.
6. Repeat steps 1-5 many times.
7. Calculate the average of the benefits of the optimal strategies calculated at step 5.
8. The partial EVPI is the difference between the average at step 7 and the benefit of the optimal baseline 
strategy.
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One-level method
Because of the double expectation in equation 5, the Monte Carlo simulation is computer-
intensive. However, if B(a,µ) is a linear function of µC, or a multilinear function of µC and 
the parameters µC are not correlated, a one-level Monte Carlo simulation is mathematically 
equivalent (linearity assumption). A utility is an example of a parameter in which B is linear, 
a transition probability in a Markov decision model is an example of a parameter in which 
B is not linear.
Similar to the two-level method, we want to know the expected value of obtaining the 
“true” values of one or more parameters (µ
I
). Under the above-mentioned conditions, it is 
valid to move the inner expectation of equation 5 within the net benefit formula:
 Eµ
I
 max
a
 B(a, µ
I
, E(µC|µI)).
If µ
I
 and µC are independent this can be simplified as:
 Eµ
I
 max
a
 B(a, µ
I
, E(µC)).
The resulting partial EVPI is mathematically equivalent to equation 5 if the linearity assump-
tion holds. To distinguish this definition from equation 5, we use the suffix “short-cut”.
 pEVPI(µ
I
)short-cut = EµI maxa B(a,µI,E(µC|µI)) - maxa EµB(a,µ).
81, 159, 160        (6)
Box 2 presents a stepwise algorithm for the simulation.
BOX 2: ONE-LEVEL MONTE CARLO SIMULATION.
1. Draw a value for µ
I
.
2. Calculate the mean for µC (use the conditional mean given µI, if µI and µC are correlated).
3. Calculate the benefit for each strategy, and identify the optimal strategy.
4. Repeat steps 1-3 many times.
5. Calculate the average of the benefits of the optimal strategies calculated at step 3.
6. The partial EVPI is the difference between the average at step 5 and the benefit of the optimal baseline 
strategy.
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Partial EVPI as the reduction in expected opportunity loss
Reduction in expected opportunity loss approach
In the literature, many authors assume that the objective of future research is to reduce the 
expected opportunity loss, instead of increasing the expected value.107, 144, 151, 154-156 There-
fore, partial EVPI has been defined as a reduction in expected opportunity loss, which is 
equivalent to a reduction in EVPI as we showed in the section on opportunity loss. Defin-
ing total EVPI as a reduction in expected opportunity loss results in the same total EVPI 
as equation 4. Regarding partial EVPI, however, this approach results in a bias as we will 
demonstrate. To distinguish this alternative definition of partial EVPI from the correct defi-
nition we use the suffix “red” (for “reduction”):
pEVPI(µ
I
)red  = reduction in expected opportunity loss 
 = reduction in EVPI
 = total EVPI – [EVPI | µ
I
=E(µ
I
)]
 = total EVPI – [EVPI of µC | µI=E(µI)].                     (7)
The total EVPI, the first term on the right hand side in equation 7, is the same as in equa-
tion 4. The second (bracketed) term is the total EVPI, but keeping µ
I
 fixed at its mean value 
during the entire analysis. But since µ
I
 is fixed at its mean, this term is the same as what we 
have referred to as pEVPI(µC)short-cut in equation 6:
pEVPI(µ
I
)red,short-cut  = total EVPI – [EVPI of µC | µI=E(µI)] 
 = total EVPI - pEVPI(µC)short-cut
 = [E
µ
 max
a
 B(a,µ) - max
a
 E
µ
B(a,µ)] – [EµC maxa B(a,E(µI),µC) – 
   max
a
 E
µ
B(a,µ)]
 = E
µ
 max
a
 B(a,µ) - EµC maxa B(a,E(µI),µC).      (8)
This estimation of pEVPI(µC)short-cut would be valid as an estimate of pEVPI(µC) if the linearity 
assumption holds. If this condition is not met, we should estimate pEVPI(µC) instead, as in 
equation 5:
pEVPI(µ
I
)red  = total EVPI - pEVPI(µC)
 = E
µ
 max
a
 B(a,µ) - EµC maxa EµC|µI B(a,µ).                   (9)
Equation 8 has been described and applied by many investigators.144, 151, 153-156 However, 
neither equation 8 nor equation 9 correctly estimates the partial EVPI of µ
I
. The reason, 
which we will demonstrate, is that they depend on the incorrect premise that partial EVPIs 
add up to the total EVPI.107
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The bias explained
In this subsection we clarify why the reduction methods represented by equation 8 and 9 
result in biased estimates of the partial EVPI as defined in their correct analogues, equa-
tions 6 and 5, respectively. Equation 
6, and not equation 8, is correct if the 
linearity assumption holds. Equation 
5, and not equation 9, is correct in 
the general case.
Figure 1 shows different paths, rep-
resented by the arrows, from no ad-
ditional information to total perfect 
information. For the total EVPI we go 
directly from no information to per-
fect information, learning the “true” 
values of all parameters µ. The quan-
tity pEVPI(µ
I
) in Figure 1 is the partial EVPI of µ
I
 as estimated correctly in equation 5, or 
equation 6 if the linearity assumption holds. It is the expected value of perfect information 
if we start out with no information and obtain perfect information on µ
I
. If from no informa-
tion we would first gather perfect information on µC, then pEVPI(µC) would be the expected 
value of perfect information on µC.
With perfect information on µ
I
 we arrive at A in Figure 1. From A, we can proceed to total 
perfect information by gathering perfect information on µC. The expected value of infor-
mation when moving from A to total perfect information is conditional on the values for 
µ
I
, and therefore not the same as the pEVPI(µC). Consequently, the sum of pEVPI(µI) and 
pEVPI(µC) is usually not equal to the total EVPI. If we know the “true” values for µI, we 
can directly estimate the expected value of perfect information on µC, conditional on the 
“true” values for µ
I
: pEVPI(µC|µI). If we have not yet gathered additional information on µI, 
we can use the joint distribution of µ
I
 to estimate the expected pEVPI(µC|µI), which is EµI 
pEVPI(µC|µI). Analogously, EµCpEVPI(µI|µC) is the expected value of perfect information on 
µ
I
, given perfect information on µC. Intuitively, the sum of the value of information going 
from no information to total perfect information is independent of the path taken (see Ap-
pendix 5 for a mathematical proof):
total EVPI  = pEVPI(µ
I
) + Eµ
I
 pEVPI(µC|µI)         (10)
 = pEVPI(µC) + EµC pEVPI(µI|µC).
Figure 1 Partial EVPI: the order of gathering information matters.
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From equation 10,
 pEVPI(µ
I
) = total EVPI - Eµ
I
 pEVPI(µC|µI),
but from equation 9,
 pEVPI(µ
I
)red = total EVPI - pEVPI(µC).
Therefore, pEVPI(µ
I
) and pEVPI(µ
I
)red are equal if and only if:
 pEVPI(µC) = EµI pEVPI(µC|µI).          (11)
In general, this equality will not hold. The left-hand side is the partial EVPI of µC starting 
with no information on µ
I
, whereas the right-hand side is the partial EVPI on µC starting with 
perfect information on µ
I
. In Figure 1, the left-hand side of equation 11 is the left portion of 
the bottom path, whereas the right-hand side of equation 11 is the right portion of the top 
path. These quantities need not be equal, and we give an intuitive counterexample below.
There is a way to fix the reduction in expected opportunity loss approach. We can define 
the reduction in expected opportunity loss as:
 pEVPI(µ
I
)red = total EVPI - EµI pEVPI(µC|µI).                               (12)
For this fix, we defined the second term on the right-hand side of equation 12 as the EVPI 
conditional on perfect information on µ
I
. If interpreted this way, the reduction in expected 
opportunity loss equals the expected value of information. However, this is not the method 
of defining reduction in expected opportunity loss that is usually applied. Furthermore, 
equation 12 is clearly not the most direct path to estimate pEVPI(µ
I
).
A simplified example
This example will demonstrate and help understanding why the generally recommended 
approach to calculating partial EVPI is incorrect, and likely to result in substantially biased 
outcomes and conclusions.
Figure 2 shows the decision tree for a decision between surgery and medication for a cer-
tain disease in newborns. If newborns receive medication, the expected net health benefit 
is	76	QALYs.	With	successful	 surgery,	 the	expected	net	health	benefit	 is	extended	 to	80	
QALYs.	However,	undergoing	surgery	will	expose	newborns	to	two	independent	risks.	First,	
they face a risk of surgical mortality. If the newborn survives surgery, there is a risk of be-
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coming so severely disabled that the utility equals zero. The “true” values of the probabili-
ties of surgical mortality (m) and permanent disability (d) are uncertain. However, we know 
that they have identical and independent dichotomous distributions: 50% that the “true” 
value is 0, and 50% that the “true” value is 0.1. Since m and d are independent, and since 
the benefit is a linear function of each of these parameters, we can calculate the expected 
benefit of surgery using the mean values for m and d: 
Expected net health benefit of surgery  = (1-m)*(1-d)*80 
 = (1-0.05)*(1-0.05)*80 = 72.2 QALYs.
Surgery seems too risky for the newborns. However, with value of information analysis we 
can assess whether more research is justified and if so, whether we should obtain more 
precise estimates of m, d, or both. Since the uncertain parameters in this example have 
dichotomous distributions, expected benefits can be calculated algebraically and simula-
tion is not necessary. Moreover, since B is linear in both parameters, the short-cut method 
is valid (see Appendix B for the calculations). Using equation 4, we find a total EVPI of 1 
QALY.	This	 implies,	 that	 if	 future	research	could	determine	the	“true”	values	for	both	m	
and	d,	the	expected	benefit	of	this	knowledge	would	be	1	QALY,	and	the	quality	adjusted	
life	expectancy	would	become	76+1=77	years.	However,	the	partial	EVPI	of	both	m	and	d	
equals 0 (equation 5 or 6). This is because the optimal decision would be medication even 
if the uncertainty about either m or d – but not both – were resolved favorably. This means 
that obtaining a more precise estimate of only m or only d has no expected benefit. 
The reduction in EVPI methods (equations 8 and 9) both result in partial EVPI’s of 1 for m 
and d. These methods incorrectly recommend obtaining more information on m or d only. 
Notice	also	that	the	correct	partial	EVPIs	(both	equal	to	0	QALY)	don’t	add	up	to	the	total	
EVPI	 (equal	 to	1	QALY).	However,	pEVPI(µ
I
)=0 and Eµ
I
 pEVPI(µC|µI)=1 do add up to the 
total EVPI, conforming to Figure 1 and equation 10. Using beta distributions for the uncer-
tain probabilities instead of our artificial dichotomized distributions would result in similarly 
biased results for the reduction in EVPI approach.
 
newborn 
surgery 
medication 
surgical 
survive surgery 
permanent disability 
successful surgery 
0 QALYs 
80 QALYs 76 QALYs 
m 
1-m 
d 
1-d 
 0 QALYs 
Figure 2 Decision tree for partial EVPI example.
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 dISCuSSION
In this manuscript we have explained and demonstrated that the generally recommended 
method to estimate partial EVPI is incorrect: it estimates partial EVPI as the reduction in 
expected opportunity loss instead of the increase in expected value. We have demonstrated 
the correct method to estimate partial EVPI, using a two-level Monte Carlo simulation. A 
computationally efficient one-level Monte Carlo simulation is mathematically equivalent if 
the outcome is a linear function of each parameter not of interest, or a multilinear function 
of each parameter not of interest, and the parameters not of interest are uncorrelated. 
Because many models are Markov models, the one-level method will typically result in a 
biased estimate of the partial EVPI. A numerical algorithm would be useful to determine 
whether the one-level method results in an acceptable approximation of the partial EVPI 
– when these conditions are not met. We are unaware of such algorithms in the literature, 
but hope that numerical mathematicians will develop them in coming years.
Some authors have suggested to empirically ascertain which one-level approach is better to 
estimate partial EVPI.154 Based on this manuscript, we can conclude that there is no need to 
do such experiments. With analytic proof, we showed that methods to estimate partial EVPI 
as reduction in EVPI are conceptually and mathematically wrong. It has been suggested to 
use a one-level Monte Carlo simulation – when it fails to hold – as a rapid screening of all 
parameters.151 The direction and magnitude of the bias, however, are uncertain. 
Computation time of the two-level Monte Carlo simulation can be limited by selecting the 
appropriate number of runs for the inner and outer loop of the Monte Carlo simulation. 
Few runs in the inner loop results in a biased estimate of the partial EVPI, few runs in the 
outer loop in a lack of precision. Tappenden et al. built a practical method for calculating 
the necessary number of runs for the inner loop.161 Confidence or credible intervals for 
any number of runs for the inner loop can be calculated once the simulation has been 
performed for a small number of runs. Nevertheless, computation time may still be imprac-
tical. Therefore, meta-models have been used to approximate partial EVPIs in complex 
decision models. A linear regression meta-model or a Gaussian process meta-model is a 
simplified version of the original model, which results in a substantial reduction of compu-
tation time. Applications of these meta-models and a tutorial of Gaussian processes have 
been published in the literature or are available on the internet.161-163
Estimating total EVPI and partial EVPI are only initial steps in guiding future research. Since 
perfect information is impossible, the next step assesses the expected value of sample in-
formation (EVSI).157 Regarding EVSI, the same conclusion holds, that we should estimate 
the expected benefit of information, not the reduction in EVPI with information.
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As the only method with a theoretically sound basis, we foresee an important role for value 
of information analysis in guiding future research by setting priorities amongst clinical 
research proposals, identifying key parameters, suggesting study designs, and estimating 
optimal sample sizes. Recently, Claxton et al. demonstrated the feasibility of value of infor-
mation analysis to guide the research priority setting of the National Health Service in the 
United Kingdom. In a few months time they synthesized available evidence, built probabi-
listic models, and estimated the value of information to guide future research for several 
decision problems in health care.31, 164 Synthesizing evidence and building probabilistic 
models is what many investigators have done. Value of information analysis is a logical 
and relatively simple additional step: the mathematics are straightforward, including only 
maximization and expectation. However, the concept needs time to gain familiarity and 
intuitive understanding.
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abSTRaCT
Objective: To design the optimal study comparing endovascular revascularization and su-
pervised exercise training for patients with intermittent claudication, and 2) To demonstrate 
value of information (VOI) analysis of patient-level data from an economic randomized 
controlled trial to guide future research. 
Methods: We applied a net benefit framework to patient-level data on costs and quality-of-
life of a previous randomized controlled trial. VOI analyses were performed using Monte 
Carlo simulation. We estimated the total expected value of perfect information (total EVPI), 
the total expected value of sample information (total EVSI), the partial expected value of 
perfect information (partial EVPI), and the partial expected value of sample information 
(partial EVSI). These VOI analyses identified the key parameters and the optimal sample 
size of future study designs. Sensitivity analyses were performed to explore the robustness 
of our assumptions about the population to benefit, the willingness-to-pay threshold and 
the study costs. The VOI analyses are demonstrated in statistical software (R) and a spread-
sheet (Excel) allowing other investigators to apply VOI analysis to their patient-level data.
Results: The optimal study design for the treatment of intermittent claudication involves 
a randomized controlled trial collecting data on the quality-adjusted life expectancy and 
additional admission costs for 525 patients per treatment arm. The optimal sample size re-
mained between 400 and 600 patients for a willingness-to-pay threshold between €30,000 
and	€100,000	/QALY,	for	even	extreme	assumptions	about	the	study	costs,	and	for	a	range	
of 3 to 7 years that future patients will benefit from the results of the proposed study.
Conclusions: 1) The optimal study for patients with intermittent claudication collects data 
on 2 key parameters for 525 patients per trial arm, and 2) we have shown that value of 
information analysis provides an explicit framework to determine the optimal sample size 
and identify key parameters for the design of future clinical trials.
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INTROduCTION
The adoption of new medical interventions depends nowadays on evidence of cost-ef-
fectiveness in addition to evidence of effectiveness. Consequently, economic data are in-
creasingly collected alongside clinical trials. We performed an economic trial to compare 
endovascular revascularization and supervised exercise training for patients with intermit-
tent claudication.174 Considerable uncertainty about the optimal cost-effective medical in-
tervention remained after analysis of the trial. Given this uncertainty, policy makers should 
address two separate decisions: which intervention should be reimbursed, and is more 
research	–	 for	example,	a	 larger	economic	 trial	–	 justified?14 More quantitative research 
could be justified, because a decision based on a trial with a finite sample size can be 
wrong: that is, the intervention that is identified as optimal may not be the actual optimal 
intervention. A future study could justify a change in current care which may result in an 
improvement in quality-adjusted life expectancy of future patients and a decrease in health 
care costs. However, the actual benefit of a future study is uncertain. Before embarking on 
an expensive study, funding agencies like to know the expected study cost. Money spent on 
such a study cannot be spent otherwise, for example, to fund another study, or reimburse 
a new treatment. The cost of a study is usually specified in a grant proposal. The expected 
benefit of a study typically receives little formal consideration. The challenge of deciding 
whether more research is justified is to make the cost-benefit tradeoff of future clinical re-
search prior to performing it. More research is justified only if the expected benefit exceeds 
the cost of a proposed study.
Value of Information (VOI) analysis provides a framework to guide the cost-benefit tradeoff 
of future cost-effectiveness research prior to performing it. VOI analysis estimates the ex-
pected benefit of a future study using available evidence (e.g., a previous randomized con-
trolled trial) about a decision. VOI analysis can guide the design of a study that maximizes 
the difference between the expected benefit for future patients and the expected cost of 
the study. This study is characterized by its design (e.g., randomized or observational), the 
subset of sampled parameters (e.g., quality-of-life only, or a selection of cost parameters), 
the sample size, and the associated study costs. Claxton et al. have demonstrated the fea-
sibility of VOI analysis to guide the research priority setting of the National Health Service 
in the United Kingdom.31
Most published VOI analyses involve decision models.28 Economic trials, however, are at-
tractive for VOI analysis because of their high internal validity. VOI analyses can be per-
formed in addition to conventional analyses of economic trials.6 They offer a sound alter-
native to significance testing when deciding if more research is needed. Moreover, VOI 
analysis provides a framework for sample size calculation. Based on patient-level data from 
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an economic trial VOI analysis can determine the optimal sample size of a future trial. The 
same methods can be used when patient-level data from a previous trial are not available, 
using elicited estimates with uncertainty intervals of the outcomes. Ideally, a VOI analysis 
is performed before and after a clinical trial.
The first objective of this article is to design the optimal study comparing endovascular 
revascularization and supervised exercise training for patients with intermittent claudica-
tion. The second objective is to demonstrate VOI analysis of patient-level data from an 
economic randomized controlled trial to guide future research. In the following section we 
briefly discuss the clinical problem, study design, and results of a previous trial of patients 
with intermittent claudication. Next, we explain the concepts and demonstrate the methods 
of the different VOI analyses, focusing on the application of VOI analyses to patient-level 
data from economic trials. The analyses are explained using mathematical notation (con-
form Ades)32 and step-by-step algorithms specifically for VOI analysis of patient-level data 
of economic trials. We used Monte Carlo simulation to obtain the VOI estimates. In appen-
dix 6 and 7 we present detailed instructions to perform VOI analyses on patient-level data 
using a spreadsheet such as Excel and statistical software such as R.175, 176
 
TREaTMENT Of INTERMITTENT ClaudICaTION
Randomized controlled trial
Intermittent claudication is the mildest form of peripheral arterial disease. Patients suffer 
from a limited walking distance due to inadequate circulation of the legs. The treatment 
goal for intermittent claudication is to improve health-related quality-of-life. The general 
consensus is to treat these patients initially with exercise training.177 Endovascular revas-
cularization seems an attractive alternative with the advantage of immediate clinical suc-
cess.178 However, the drawbacks of endovascular revascularization include procedure re-
lated morbidity and mortality as well as increased costs.179, 180
Between September 2002 and September 2005, 150 patients with intermittent claudi-
cation were randomly allocated to endovascular revascularization or supervised exercise 
training.174 During 12 months of follow-up all medical and non-medical costs (11 cost 
parameters) were assessed from the societal perspective and effects were measured with 
the	EuroQol-5D	questionnaire.	We	transformed	the	EuroQol-5D	values	into	utilities	using	
the Dutch scoring algorithm.181	 The	 improvement	 in	 quality-adjusted	 life	 years	 (QALYs)	
accumulated during the 12-month follow-up period was then used as effect measure in 
the cost-effectiveness analysis. We refer to the original article for more details on the study 
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design, analyses, and results.174 The original article presented results with adjustment for 
age and gender. Here we used unadjusted data for the value of information analyses. 
The	improvement	in	quality-adjusted	life	years	(QALYs)	was	higher	in	the	revascularization	
group than in the exercise group (mean difference 0.08; 95% CI 0.04, 0.12). The total 
mean cumulative cost per patient was also higher in the revascularization group than in the 
exercise group (mean difference €4254; 95% CI €1648, €7734). 
Cost-effectiveness analysis
We adopted the net benefit approach to cost-effectiveness analysis.5 A decision between 
two strategies based on both costs and effect can only be made if a trade-off is made be-
tween cost and effect by putting a monetary value on health. We used a societal willingness-
to-pay	 threshold	(WTP)	of	80,000	euro’s	per	QALY,	as	has	 recently	been	recommended	
by a Dutch governmental institute.182 Costs and effect (in this case, quality-adjusted life 
expectancy) are combined into a single outcome called net (monetary) benefit:
 net benefit = WTP*effect – costs
The net benefit is expressed in euro. The mean net benefit is denoted by B. The difference 
in mean net benefit between the two interventions is the incremental mean net benefit (IB). 
The uncertainty interval for the IB was estimated parametrically and non-parametrically.5 
The parametric intervals assume a normal distribution of the IB, justified by the central limit 
theorem. To check this assumption we also performed non-parametrical bootstrapping us-
ing 1 million bootstraps.24
Figure 1 The incremental net benefit (IB) for the revascularization strategy 
in euro with 95% uncertainty boundaries based on 1 million bootstraps of 
patientlevel net benefits, across a range of values for the willingness-to-pay 
threshold	(WTP)	in	euro/QALY.
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The revascularization group had a higher net benefit (€4486 versus €2316 per patient), but 
the difference in net benefit was not significant (mean difference €2170; 95% CI €-2818, 
€6685). Based on these results we can conclude that revascularization seems cost-effective, 
but considerable uncertainty remains. Figure 1 presents the incremental net benefit (IB) in 
euro	with	95%	uncertainty	interval	across	a	range	of	values	for	the	WTP	in	euro/QALY.	The	
bootstrapping results showed that assuming normal distributions was justified.
 
TOTal EvPI – ElIMINaTING uNCERTaINTY
VOI analysis starts with estimating the total expected value of perfect information (total 
EVPI). It is the expected benefit per patient of a study with an infinite sample size, resulting 
in perfect information about all (total) uncertain cost and effect parameters. Such a study 
would eliminate uncertainty about the net benefit of each intervention, but is of course hy-
pothetical. However, the total EVPI provides a ceiling level for the expected cost of a future 
study: studies with a finite sample size or studies that consider a subset of parameters all 
have a smaller expected benefit. Therefore, if the total EVPI does not exceed the fixed cost 
of research, more research is not justified. More research is potentially justified, if the total 
EVPI does exceed the fixed cost of research.
Total EVPI – equations and algorithm
The net benefit B(a,µ) of intervention a is a function of µ, where µ stands for the set of all 
unknown distributional cost and effect parameters involved. If all uncertainty about the pa-
rameters would be eliminated the actual net benefit of each intervention would be known. 
The cost of not knowing the actual net benefit of each intervention is the cost of uncertainty 
or the opportunity loss. It is defined as the difference between the maximum actual net 
benefit, and the actual net benefit of the supposedly optimal intervention (a*):
 opportunity loss = max
a
 B (a, µactual) { B (a*, µactual)
We cannot calculate the opportunity loss, because we don’t know the actual parameter val-
ues µactual. However, the expected opportunity loss is the expectation over the distribution of 
the parameters of each intervention. The total EVPI equals the expected opportunity loss:
 total EVPI = E
µ
 [max
a
 B(a, µ) {  B (a*, µ)]
To calculate the total EVPI, the parameters of each intervention must be characterized by a 
probability distribution based on the data of the initial trial. We can also use the probability 
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distribution of the mean net benefit B(a,µ) of each intervention. Although the net benefit 
may not be normally distributed in the population, the uncertainty about the mean net ben-
efit typically is (central limit theorem). As the distribution of the mean net benefit we take 
N (¹0; ¾pop / √n0), for each intervention; ¹0 is the estimated mean net benefit in the initial 
study, for each intervention; ¾pop is the estimated standard deviation in the initial study, for 
each intervention; and n0 is the sample size in the initial study, for each intervention. For 
simplicity ¾pop is treated as a known parameter, based on the initial study 
32 b
j
 is a random 
value of the distribution of the mean net benefit, for intervention a. The algorithm for the 
estimation of total EVPI involves the following steps:
1.  raw a value b
j
 for the net benefit from N (¹0; ¾pop / √n0), for each intervention a
2. calculate the opportunity loss: max
a
 ba
j
  { ba
j
*
3. repeat step 1 and 2 N times
4.  the total EVPI is estimated by averaging over the opportunity losses at step 2
The standard error of the mean opportunity loss (¾opp los / √N) reflects how precisely the 
total EVPI was estimated. The process of drawing a random value of each distribution (an 
iteration) is sometimes referred to as Monte Carlo simulation.
The example – total EVPI
Table 1 presents the results of the Monte Carlo simulation for 10 iterations. Each iteration 
consists of a random value of the distribution of the mean net benefit of each intervention. 
For each iteration the opportunity loss is calculated. For example, exercise was the optimal 
intervention in the first iteration, and revascularization was the optimal intervention based 
Table 1 – total EVPI (in euro): 10 iterations of Monte Carlo simulation
Iteration Revascularization Exercise opportunity loss
1 3348 4372 1024
2 7997 3198 0
3 3129 3311 182
4 2267 2991 724
5 -466 711 1177
6 3716 2276 0
7 3179 2220 0
8 5204 962 0
9 3543 2435 0
10 7679 4489 0
Mean 311
EVPI: expected value of perfect information
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on the initial trial results. Therefore, the opportunity loss of the first iteration equals €4372 
– €3348 = €1024. Based on these ten iterations only, the total EVPI is estimated by the 
mean opportunity loss of €311.
A total EVPI of €249 per patient was found with 10 million simulations in R. This means 
that after eliminating uncertainty we can expect an improvement in net monetary benefit 
of €249 per patient. Endovascular revascularization was the optimal intervention given 
the results of the initial trial, with an expected net benefit of 4486 euro per patient. With 
perfect information the expected net benefit of the optimal intervention (which could be 
endovascular	revascularization	or	exercise	training)	is	4486	+	249	=	€4735	per	patient.	
The total EVPI per patient should be extrapolated to the entire population that will benefit 
from the study results, to allow for comparison with the fixed study cost.
Population EVPI and study cost
The expected benefit of a study should include the benefit of all future patients from some 
predetermined perspective: single hospital, health insurance agency, country, or worldwide. 
The number of years (T) that future patients are expected to benefit from the results of 
a proposed study is difficult to determine. It depends on improvement in technology and 
future evidence. A sensitivity analysis can illustrate the importance of this uncertainty. The 
expected benefit to future patients is discounted by a discount rate of typically 3% per year: 
that is, each year further ahead a smaller benefit is assigned on behalf of these patients.157 
The population EVPI equals:
 population EVPI = total EVPI *
The study costs are typically estimated as fixed cost (e.g., salary of a PhD-student) and 
variable cost per patient in the study 15.
The example – population EVPI and study cost
Because the initial trial was funded by a national governmental agency, we used the na-
tional perspective for the annual population to benefit. This annual population was esti-
mated at 10,000 patients for The Netherlands. We assumed patients would benefit from 
the results for 5 years and discounted these benefits at 3% per year. We found a discounted 
population to benefit of about 46,000 patients and a population EVPI of 11 million euro. 
We estimated the fixed cost of an additional clinical study at 200,000 euro, based on the 
cost of our previous study. Because the EVPI for the population exceeds the expected costs 
of an additional study, it is potentially justified to perform some sort of additional study.
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TOTal EvSI – REduCING uNCERTaINTY
The total expected value of sample information (total EVSI) is an estimate of the expected 
benefit of studies with a finite sample size, collecting information on all cost and effect 
parameters. Instead of eliminating uncertainty, uncertainty about the mean net benefit of 
each intervention is only reduced. With increasing sample size, the total EVSI will reach a 
ceiling which equals the total EVPI, representing an infinite sample size.
Total EVSI – equations and algorithm
A proposed study provides data about all cost and effect parameters of n patients for each 
intervention. The study will improve the mean estimates of the parameter values, and con-
sequently of the net benefit of each intervention. Once we have observed the actual study 
data D, the expected benefit of treatment a* is Eµ/Dactual B (a*, µ). The best treatment then 
has expected benefit max
a
 Eµ/Dactual B (a, µ). Thus the current cost of uncertainty about the 
actual study data D is the opportunity loss:
 opportunity loss = max
a
 Eµ/Dactual B (a, µ) { Eµ/Dactual B (a*, µ) .
Because B is linear in µ this simplifies to:
 opportunity loss = max
a
 B (a, E(µjDactual)) { B (a*, E(µjDactual)).
We cannot calculate the opportunity loss, because we don’t know the actual data before 
performing the study. However, the expected opportunity loss is the expectation over all 
possible values of the new data. The total EVSI equals the expected opportunity loss:
 total EVSI = E
D
 [max
a
 B (a, E(µjD)) { B (a*, E(µjD))]
Again the analysis is simplified using the probability distribution of the mean net benefit N 
(¹0; ¾pop / √n0) , of each intervention a in the initial study. The data D of the proposed study 
is characterized by the sample size n1, the sample mean net benefit ¹1, and the standard 
error ¾pop / √n1 for each intervention.
32 ¹1 is unknown, but can be sampled from the distribu-
tion of the actual net benefit N (¹actual; ¾pop / √n1 for each intervention. ¹actual is also unknown, 
but can be sampled from the distribution of the mean net benefit of the initial trial N (¹0; 
¾pop / √n0 for each intervention. The algorithm for the estimation of the total EVSI involves 
the following steps:
1. choose a sample size n1 per intervention of the proposed study
2. draw a value ¹actual, j from N (¹0; ¾pop / √n0) , for each intervention
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3. draw a value ¹1, j from N (¹actual, j ; ¾pop / √n1) , for each intervention
4. calculate the posterior mean net benefit for each intervention a:  
5. calculate the opportunity loss: max
a
 ba
j
  { ba
j
*
6. repeat step 1 to 5 N times
7. the total EVSI is estimated by averaging over the opportunity losses at step 5
ENBS - the optimal sample size
The expected net benefit of sampling (ENBS) is defined as the difference between the total 
EVSI and the study cost. The optimal sample size is reached when the ENBS reaches a 
maximum. At this maximum the additional benefit of one more patient in the study equals 
the additional study costs of one more patient in the study.
In addition to the fixed cost and variable cost per patient, the cost of clinical trials should 
also include the forgone net benefit of each patient that is randomized to an intervention 
that is supposedly suboptimal. This amounts to the sample size of the inferior arm of the 
trial times the difference in net benefit based on the previous trial. 
The example – total EVSI, study costs, and ENBS
For a clinical trial collecting data on all parameters (total EVSI) we estimated a fixed cost of 
200,000 euro and a variable cost of €1000 per patient, both based on our previous (iden-
tical) study. The difference in net benefit between the revascularization and the exercise 
group was €2170 . The total cost in euro was therefore:
 total study costs = 200,000 + 1,000*2*n1 + 2170*n1
Note that n1 is the sample size per study arm and not the total sample size of the study. We 
used the same population to benefit of about 46,000 patients (see section on total EVPI). 
Figure 2 presents the study cost, the total EVSI, and the ENBS as a function of the sample 
size n1 per study arm. A maximum ENBS of €7.3 million is reached for a sample size of 
about 475 patients per study arm. The study cost of this study would be 2.2 million, of 
which 1.2 million is accounted for by the forgone net benefit of 475 patients assigned to 
the supposedly suboptimal intervention (supervised exercise training).
The ENBS of the proposed study is not the actual benefit of the study – which we will only 
learn after analyzing the results of the study – but the expected benefit, prior to perform-
ing the study. The actual benefit to an individual patient is zero if the new study does not 
lead to a change in current care, because the patient’s outcomes remain unchanged. 
The actual benefit to an individual patient is nonzero if the new study demonstrates that 
our initial decision was suboptimal and current care is changed accordingly. However, the 
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proposed study will almost always improve the precision of the outcomes and reduce the 
cost of uncertainty.
 
PaRTIal EvPI – ElIMINaTING uNCERTaINTY Of SOME 
PaRaMETERS
The partial EVPI estimates the expected benefit of eliminating uncertainty for individual pa-
rameters or subsets of parameters. Typically it is not justified to consider all parameters in a 
future study: a few key parameters are the source of most decision uncertainty. Eliminating 
uncertainty about the other parameters has no additional expected benefit or an expected 
benefit that does not justify the additional study costs.
Partial EVPI – equations and algorithm
For the estimation of partial EVPI, the parameters are divided into two groups: the param-
eters-of-interest µI are considered in a future study, the parameters-not-of-interest µC are 
not considered in a future study. If all uncertainty about the parameters-of-interest µI for 
each intervention would be eliminated, the actual values of these parameters would be 
known. The current cost of uncertainty of not knowing the actual values of the parameters-
of-interest µIactual of each intervention is called the opportunity loss. It is defined as the 
difference between the maximum expected net benefit given µIactual, and the expected net 
benefit given µIactual of the supposedly optimal intervention (a*). Because B(a,θ
C,θI) is linear 
in θC and θI we get:
 opportunity loss = max
a
 B (a, µI
actual
, E
µC
 (µCjµIactual)) { B (a*, µIactual, EµC (µCjµIactual))
Figure 2 Population EVSI, study costs and ENBS 
in million Euro for different sample sizes per 
study arm.The proposed study collects data on 
all parameters that were considered in the ini-
tial trial. The optimal sample size is about 500 
patients per study arm with an ENBS of €7.2 mil-
lion, and total study costs of €2.3 million.Of the 
total study costs, 1.1 million is accounted for by 
the forgone net benefit of 500 patients assigned 
to the supposedly suboptimal intervention (su-
pervised exercise training).
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We cannot calculate the opportunity loss, because we don’t know the actual values of the 
parameters-of-interest µI. However, the expected opportunity loss is the expectation over 
all possible values of the parameters-of-interest µI of each intervention. The partial EVPI 
equals the expected opportunity loss:
 partial EVPI = E
µI
 [max
a
 B (a, µI, E
µC
 (µCjµI)) { B (a*, µI, E
µC
 (µCjµI))]
Again, the analysis can be simplified by avoiding the distributions of individual parameters. 
Instead, we created distributions for the mean net benefit of the parameters-of-interest 
N (¹I0, ¾
I
pop / √n0) and the mean net benefit of the parameters-not-of-interest N (¹
I
0, ¾
I
pop / 
√n0), with correlation ½ , for each intervention. The partial EVPI is estimated in the fol-
lowing algorithm. The conditional mean net benefit of the parameters-not-of-interest µC is 
calculated in step 2 of the algorithm using the general equation for the conditional mean 
value of a bivariate normal distribution. 183
1. draw a value bI
j
 from N (¹I0, ¾
I
pop / √n0), for each intervention
2. calculate the conditional mean net benefit of µC, for each intervention:
3. calculate the mean net benefit for each intervention: b
j
 = bI
j
  + bC
j
 
4. calculate the opportunity loss: max
a
 ba
j
  { ba
j
*
5. repeat step 1 to 4 N times
6. the partial EVPI is estimated by averaging over the opportunity losses at step 4
Subsets of parameters
In theory we could estimate the partial EVPI for each subset of parameters. To evaluate 
whether more research regarding each subset is potentially justified, the partial EVPI is 
compared with the subset-specific fixed study costs. The number of required analyses, 
however, would explode for even a small number of parameters. In practice, investigators 
typically first estimate the partial EVPI for each individual parameter. Unfortunately, the 
partial EVPI of individual parameters doesn’t simply sum up to the partial EVPI of a subset 
of parameters. Even a subset of parameters with individual partial EVPIs of zero, together 
may have a nonzero partial EVPI. The subset of parameters with a nonzero EVPI or sub-
stantial individual partial EVPI seems a reasonable subset to consider for partial EVPI esti-
mation. Other relevant subsets are found by changing this subset. If the partial EVPI of this 
subset is close to the total EVPI, we can remove parameters with a small individual partial 
EVPI or a substantial associated increase in study costs (e.g., the quality-of-life parameter). 
If the partial EVPI is much smaller than the total EVPI, we can add parameters with small 
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additional study costs (e.g., a cost parameter that can be collected from administrative 
records).
The example – partial EVPI
Table 2 presents the partial EVPI of each individual parameter with 10 million simulations 
in R. Of the 12 parameters, only 4 had a nonzero individual partial EVPI. Together, these 
4 parameters had a partial EVPI of €248 per patient; almost the same as the total EVPI of 
249. The partial EVPI of the 3 parameters with the highest individual EVPI was also €248 
per patient. The two parameters with the highest individual partial EVPI together had a par-
tial EVPI of 244. For the subsets with 2 and 3 parameters we identified the optimal sample 
size in the next section. The partial EVPI of the subset of 8 parameters with an individual 
partial EVPI of zero, was still zero. Obtaining more information on these parameters is not 
justified, even for very small additional study costs.
Five cost parameters had a similar expected value, ranging from 437 euro to 742 euro per 
patient: the cost of material, personnel, overhead, treatment, and productivity loss. The 
partial EVPI of treatment cost was 6 euro per patient. The partial EVPI of the other four pa-
rameters together was zero. These results demonstrate that simply selecting the parameters 
with the highest expected value, or the parameters that differed most between treatments, 
is not a good alternative for partial VOI analysis.
Table 2 – Partial EVPIs
Individual parameters partial EVPI in euro
QALYs 104
additional admission costs 65
additional treatment costs 6
additional imaging costs 0.007
Subsets of parameters
all 12 parameters = total EVPI 249
all 4 with nonzero individual pEVPI 248
all 3 with individual pEVPI>1 248
all 2 with individual pEVPI>10 244
all 8 with zero individual pEVPI 0
all 11 cost parameters 69
EVPI,	expected	value	of	perfect	information;	QALYs,	quality-adjusted	life-years.
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PaRTIal EvSI – REduCING uNCERTaINTY Of SOME
PaRaMETERS
The partial expected value of sample information (partial EVSI) is an estimate of the ex-
pected benefit of studies with a finite sample size, collecting information on a subset of 
parameters. With increasing sample size, the partial EVSI will reach a ceiling: the partial 
EVPI, representing an infinite sample size.
Partial EVSI – equations and algorithm
A future study provides data   about the parameters-of-interest µI of n patients for each 
intervention. The study will improve the mean estimates of the parameters-of-interest µI, 
and consequently of the net benefit of each intervention. The current cost of not knowing 
the actual study data D
actual
 is called the opportunity loss. It is calculated as the difference 
between the maximum expected net benefit given D
actual
, and the expected net benefit 
given D
actual
, of the supposedly optimal intervention (a*):
opportunity loss =  max
a
 B (a, E
µ
I (µIjDactual), EµC (µCjµIjDactual))) { 
 B (a*, E
µ
I (µIjDactual), EµC (µCjµIjDactual)))
We cannot calculate the opportunity loss, because we don’t know the actual data before 
performing the study. However, the expected opportunity loss is the expectation over all 
possible values of the new data. The partial EVSI equals the expected opportunity loss:
partial EVSI =  E
D
 [max
a
 B (a, E
µ
I (µIjD), E
µC
 (µCj µIjD ))) { 
 B (a*, E
µ
I (µIjD), E
µC
 (µCj µIjD )))]
Analogous to estimating the partial EVPI, we used the observed distributions for the mean 
net benefit of the parameters-of-interest N (¹I0, ¾
I
pop / √n0) and the mean net benefit of the 
parameters-not-of-interest N (¹C0, ¾
C
pop / √n0), with correlation ½, for each intervention. The 
data of the proposed study is characterized by the mean net benefit of the parameters-of-
interest ¹I
1
 and the standard error ¾Ipop / √n1 for each intervention.
32 ¹I
1
 is unknown, but can 
be sampled from the distribution of the actual net benefit of the parameters-of-interest N 
(¹Iactual; ¾
I
pop / √n1), for each intervention. ¹
I
actual is also unknown, but can be sampled from 
the distribution of the mean net benefit of the parameters-of-interest observed in the initial 
study N (¹I0, ¾
I
pop / √n0), for each intervention. The partial EVSI is estimated in the following 
algorithm.
1. choose a sample size n
1
 per intervention of the proposed study
2. draw a value ¹Iactual, j from N (¹
I
0, ¾
I
pop / √n0), for each intervention
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3. draw a value ¹I
1j
 from N (¹Iactual, j; ¾
I
pop / √n1), for each intervention
4. calculate the posterior mean net benefit of µI, for each intervention:
5. calculate the conditional mean net benefit of µC, for each intervention:183
6. calculate the mean net benefit for each intervention: b
j
 = bI
j
  + bC
j
 
7. calculate the opportunity loss: max
a
 ba
j
  { ba
j
*
8. repeat step 1 to 7 N times
9. the partial EVSI is estimated by averaging over the opportunity losses at step 7
Although the proposed data collection sampled only the parameters-of-interest, the net 
benefit of each intervention is estimated using all available data of all parameters (step 6). 
The net benefit of the parameters-of-interest is estimated using data from both the initial 
study and the proposed data collection (step 4). The net benefit of the parameters-not-of-
interest is estimated using data from the initial study only, unless a correlation (½) exists 
with the parameters-of-interest (step 5).
The example - partial EVSI, study costs, and ENBS
We estimated the partial EVSI, for various sample sizes, for two subsets of parameters that 
were identified with the analysis of partial EVPI. These subsets include respectively three 
and two parameters with the highest individual partial EVPI. We estimated that collecting 
information on the quality-adjusted life expectancy represents 50% of the fixed and variable 
study costs: 100,000 euro and 500 euro per patient. Also collecting hospital admission 
costs implies searching administrative records: we estimated an increase in study costs 
of 10,000 euro plus 50 euro per patient. Also collecting the additional treatment costs 
requires more resources: we estimated an increase in study costs of 20,000 euro plus 100 
euro per patient. We used the same population to benefit of about 46,000 patients (see 
section on total EVPI).
For the subset of two parameters the optimal sample size was 525 patients per study arm 
and the ENBS was 7.6 million euro. For the subset of three parameters we found an opti-
mal sample size of 500 patients per study arm and an ENBS of also 7.6 million euro. While 
the expected benefit of the studies is equal, we prefer the former study because of lower 
study	costs.	This	optimal	study	design	obtains	data	on	the	QALY	and	additional	admission	
costs for 525 patients per study arm. The required study costs are 690,000 euro. Assign-
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Figure 3 (a) Sensitivity analysis for the 
willingness-to-pay threshold and the 
study costs.The proposed study collects 
information on the quality-adjusted life 
expectancy	(QALE)	and	the	additional	ad-
mission costs. The population to benefit 
is about 46,000 patients.The study costs 
estimates are: fixed 10,000 and variable 
100 euro (€); fixed 110,000 and variable 
550 (€€: base-case); and fixed 500,000 
and	 variable	 2000	 (€€€).The	 X	 presents	
the base-case willingness-topay threshold 
and study costs. (b) Sensitivity analysis for 
the population to benefit and the study 
costs. The proposed study collects infor-
mation	 on	 the	 QALE	 and	 the	 additional	
admission costs. The willingness-to-pay 
threshold is 80,000 euro/quality-adjusted 
life-years	 (QALY).The	 study	 costs	 esti-
mates are: fixed 10,000 and variable 100 
euro (€); fixed 110,000 and variable 550 
(€€: base-case); and fixed 500,000 and 
variable	 2000	 (€€€).	 The	X	 presents	 the	
base-case population to benefit of about 
46,000 patients. (c) Sensitivity analysis for 
the population to benefit and the willing-
ness-to-pay threshold. The proposed study 
collects	information	on	the	QALE	and	the	
additional admission costs.The study costs 
are €110,000 for fixed costs and €550 for 
the	 costs	 per	 patient.The	 X	 presents	 the	
base-case population to benefit.
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ing 525 patients to the supposedly suboptimal arm has an associated cost of 1.1 million 
euro. To estimate study costs we assumed a randomized controlled trial as optimal design 
to reassure validity of the results. Figure 3 presents several sensitivity analyses for the WTP 
threshold, the population to benefit, and the study costs.
alTERNaTIvE METhOdS
We performed VOI analysis assuming a normal distribution of the mean net benefit of each 
intervention, based on the central limit theorem. The total EVPI can also be estimated 
using bootstrapping techniques, which do not rely on the normality assumption.24 With 1 
million bootstraps in R we found a total EVPI of €264 per patient: very close to the €249 
that we found assuming a normal distribution of the mean net benefits. Unfortunately, it is 
not obvious how bootstrapping should be implemented to estimate partial value of infor-
mation and sample information. Other nonparametric methods for VOI analysis are being 
developed.32
We assessed the total EVPI using unadjusted estimates for the mean net benefit of each 
intervention. As another alternative, we used regression analysis in the net benefit frame-
work to obtain estimates of the mean net benefit adjusted for potential imbalances of 
baseline characteristics between the treatment groups. The resulting total EVPI was €119 
per patient. The adjusted outcomes probably underestimate the VOI; the unadjusted out-
comes may overestimate the VOI. The regression analysis ambiguously decomposes the 
total variance into components attributable to patient heterogeneity and uncertainty. Both 
uncertainty and estimates of the VOI will decrease, when more variation is attributed to 
heterogeneity.
Both Claxton and Willan estimated the total EVPI and total EVSI using closed form (analyti-
cal) methods that do not rely on simulation.15, 157 Using closed form solutions, Claxton also 
considered the VOI of trial designs assigning unequal sample sizes to each intervention.172 
Although closed form solutions for estimating the partial EVPI and partial EVSI are not 
available in the literature, it should be possible to derive such solutions. The advantages 
of closed form solutions are exact outcomes and negligible calculation time. Simulation, 
however, also has several advantages as compared to closed form solutions. The simula-
tions that we applied to our example can be easily modified to accommodate more than 
two comparators, prior distributions other than normal, and nonlinear functions of the 
parameters. Moreover, simulation has educational appeal: by following the steps of the 
simulation, the reader understands how it works.
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dISCuSSION
With value of information (VOI) analysis we found that more research is justified regard-
ing the choice between endovascular revascularization and supervised exercise training for 
patients with intermittent claudication. The optimal study design for a future study involves 
a randomized controlled trial collecting data on the quality-adjusted life expectancy and 
additional admission costs for 525 patients per treatment arm. The outcome of this trial 
could justify a change in current care. As a result, future patients may benefit from an 
increase in quality-of-life, or cost savings may allow the health care system to reimburse 
other (unrelated) beneficial interventions. Although we don’t know the actual benefit of the 
proposed study, the VOI analysis estimated an expected net benefit of sampling (ENBS) of 
7.6 million euro for The Netherlands, using the results of a previous trial. The study costs 
of 690,000 euro were accounted for in this estimate. No other study design had a higher 
ENBS. Sensitivity analyses demonstrated that the optimal sample size was fairly stable. 
It remained between 400 and 600 patients for a willingness-to-pay threshold between 
€30,000	and	€100,000	/QALY,	for	extreme	assumptions	about	the	study	costs,	and	for	a	
range of 3 to 7 years that future patients will benefit from the results of the proposed study. 
These results were used for a recent grant proposal. The €7.6 million of the proposed study 
can be compared with the ENBS of other (unrelated) study proposals. The ENBS can guide 
a funding agency to set priorities if the research budget is limited: study proposals with a 
higher ENBS should be reimbursed first. However, funding is justified for any study proposal 
with an ENBS exceeding zero.
An important assumption of VOI analysis is that health care costs and research costs are 
ultimately paid for from the same resources, which is largely true for The Netherlands. 
The appropriate perspective of the VOI analysis regarding the population to benefit from 
the results of a study proposal is not obvious. Because the initial trial of our example was 
funded by a national governmental agency, we used the national perspective. For a Eu-
ropean Union or world-wide perspective the population to benefit would increase at least 
20-fold, resulting in an optimal sample size of several thousand patients. The period that 
patients will benefit from the proposed data collection is also uncertain because of uncer-
tainty about future technological improvements and evidence from future studies. These 
ambiguities, however, are not drawbacks of VOI analysis in itself, but inherent to setting 
research priorities.
We demonstrated VOI analysis using patient-level data from a single clinical trial. We may 
have overestimated uncertainty and the value of information, because we didn’t consider 
all available evidence pertaining to the decision. A decision model can bring together evi-
dence from various sources and also extrapolate costs and effects beyond the follow-up 
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period in the initial trial. However, decision models also have several drawbacks. Many 
assumptions are required when building decision models, to the extent that for the same 
research question different models report diverging results.45 As a consequence the valid-
ity of models is often challenged. Moreover, building models is very time-consuming and 
requires expertise on both the clinical subject matter as well as the methodology of deci-
sion modelling. On the other hand, this investment of time may be worthwhile, because 
VOI analyses of such a decision model could conclude that more research is not justi-
fied. Finally, most decision models are nonlinear and require extremely computer-intensive 
nested VOI analyses.32 VOI analysis of patient-level data can avoid these nested analyses 
because the net benefit is a linear function of the cost and effect parameters. Clinical trials 
remain attractive because of their high internal validity and timeliness.6 For many clinical 
decisions a trial constitutes the best available evidence, not only to decide what medical 
intervention should be adopted, but also to address the question whether more research 
is needed. VOI analysis of trials is aimed at replacing the use of significance testing to de-
termine whether more research is justified; it is not aimed at replacing decision models to 
guide further research. Advocates for economic trials will emphasize their internal validity, 
while advocates for models stress their consideration of all available evidence. Whether a 
decision model is required to guide future research will depend on the methods and results 
of the initial study, as well as the importance of evidence from other sources.
A limitation of trials as compared to models is that clinical trials rarely have a lifetime 
follow-up of costs and effects. This is not only a drawback of VOI analysis of trials, but 
inherent to any analysis of a trial. Sometimes a model is used to extrapolate the trial data 
beyond the follow-up period.37 The follow-up of our initial trial was only 12 months. How-
ever, both interventions – endovascular revascularization and exercise training – give only 
temporary relief of symptoms. Improvement of quality-of-life in our study was more imme-
diate after revascularization, but at 12 months no difference was detected in quality-of-life. 
Like most interventions in surgery, the costs are largely incurred upfront. The base case 
analysis of a model based on our trial data would assume that no difference in costs and 
effects is anticipated beyond the follow-up of the trial.
We recommend a randomized controlled trial as the optimal design for the future study. Al-
ternatively, an observational study could collect data on quality-of-life and admission costs. 
The drawback of a nonrandomized design is that it is more difficult to avoid that differences 
in (known and unknown) baseline patient characteristics (i.e., confounders) are responsible 
for differences between the outcomes of interventions. Moreover, a randomized design is 
not necessarily associated with additional study costs.
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Few applications of VOI analysis to guide the design of clinical trials have been published. 
In 2005, a guidance document for designing and analyzing cost-effectiveness analyses 
conducted as part of clinical trials did not mention VOI analysis.6 However, the philosophy 
of a formal cost-benefit trade-off prior to experimental studies is not new. VOI analysis 
was introduced by Grundy29 in the late fifties and developed by Raiffa and Schlaifer.4 
Howard noted in 1966 that: “Placing a value on the reduction of uncertainty is the first 
step in experimental design, for only when we know what it is worth to reduce uncertainty 
do we have a basis for allocating our resources in experimentation designed to reduce the 
uncertainty.” In 1989 Detsky evaluated the effect of design choices made in the planning 
stages of a clinical trial on the costs and benefits derived from conducting the trial.184, 185 
Claxton introduced VOI analysis to the clinical audience of the Lancet.14 Moreover, he 
demonstrated VOI analysis to estimate the optimal sample size of a trial using hypothetical 
data.157 More recently, Willan applied VOI analysis to estimate the optimal sample size of 
a trial using patient-level data from a previous trial.186 Both studies used closed form solu-
tions that are not available in the literature for partial value of information analyses. Further 
research could find out closed form solutions for some partial value of information analy-
ses. 
Although the VOI analyses are relatively complex and technical, the fundamental ideas 
of VOI analysis is rather straightforward and may appear familiar to clinicians. A clear 
analogy exists between the Bayesian framework for VOI analysis and Bayesian diagnostic 
reasoning. A future trial can change the probability that an intervention is optimal, just as a 
diagnostic test can change the probability that a patient has a certain disease. Both a trial 
and a diagnostic test are costly and require a cost-benefit trade-off. The probability and 
the consequences of implementing a suboptimal intervention or misdiagnosing a patient 
determine whether more research or a diagnostic test is justified.
Clinical trials often show no statistically significant difference between the treatments com-
pared. We demonstrated that VOI analysis allows for a formal comparison of the expected 
benefit and the cost of a proposed study, before concluding whether or not more research 
is justified. Two erroneous conclusions are common about the need for more research 
when no significant difference is found. Some authors conclude that the decision has been 
settled: the interventions are assumed to be equivalent and more research is not needed. 
It has long been demonstrated, however, that a difference is often not found because the 
study was underpowered to detect even a large difference.11 In a famous quote, Altman 
warned that: “Absence of evidence is not evidence of absence”.12 Other authors conclude 
the exact opposite - more research is needed - when no significant difference is found. 
They seem to reason that there must be a difference and because it wasn’t found with the 
current study, another (larger) study is needed. Phillips pointed out that the conclusion 
143
value of information analysis of economic randomized controlled trails: the treatment of intermittent claudication
“more research is needed” requires some assessment of the expected benefit for future pa-
tients that would come from more research in comparison to the cost of research (e.g., VOI 
analysis). He observed that studies in health care typically conclude that “more research is 
needed” without such an assessment.13
If more research is justified, the investigators should decide on a sample size. We demon-
strated VOI analysis as an explicit framework to perform sample size calculations. Classical 
sample size calculations are based on arbitrary values for the minimal clinically significant 
difference in treatment effect, a type I error (typically ®=0.05) and a type II error (typi-
cally ¯=1-power=0.2). In practice the equation is often back-solved after substituting in 
a sample size that primarily reflects feasibility and cost. VOI analysis considers the actual 
harm to future patients of making a type I error (i.e., rejecting the null-hypothesis when 
it is true) and a type II error (not rejecting the null-hypothesis when it is false). The opti-
mal sample size is estimated by considering the marginal cost and benefits of sampling 
patients. Moreover, VOI analysis can conclude that more research is not justified.187 We 
recommend performing VOI analyses before and after an economic trial.
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Value of information analysis used 
to determine the necessity of 
additional research: MR imaging in 
acute knee trauma as an example
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abSTRaCT
Objective: To guide future outcomes research regarding the use of magnetic resonance 
(MR) imaging for patients with acute knee trauma in the emergency room setting, with use 
of prospective data from a randomized clinical trial and value of information analysis.
Methods: A total of 189 patients (123 male, 66 female; mean age 33.4 years) were ran-
domly assigned to undergo radiography alone (n=93) or radiography followed by MR im-
aging (n=96). Institutional review board approval and informed consent (parental consent 
for minors) were obtained. During 6-months of follow-up, data on quality of life and 39 
cost parameters were collected. Value of Information analysis was used to estimate the ex-
pected benefit of future research to eliminate the decision uncertainty that remained after 
trial completion. In addition, the parameters that were responsible for most of the decision 
uncertainty were identified, the expected benefits of various study designs were evaluated, 
and the optimal sample size was estimated.
Results: Only three parameters were responsible for most of the decision uncertainty: num-
ber of quality-adjusted life years, cost of overnight hospital stay, and friction costs. A study 
in which data on these three parameters are gathered would have an optimal sample 
size of 3500 patients per arm and would result in a societal benefit of €5.6 million, or 70 
quality-adjusted life years.
Conclusion: The optimal study design for use of MR imaging to evaluate acute knee trauma 
involves a trial in which there are 3500 patients per trial arm, and data on the number of 
quality-adjusted life years, cost of overnight hospital stay, and friction costs are collected. 
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INTROduCTION
Patients who present to the emergency room with acute knee trauma may benefit from im-
mediate magnetic resonance (MR) imaging. Moreover, the initial cost of the MR imaging 
may be offset by a reduction in the subsequent medical and societal costs because the pa-
tient may be able to return to work sooner than if MR imaging had not been performed. In 
a randomized controlled trial, we assessed the additional value of MR imaging in patients 
with acute knee trauma.188 After a 6-month follow-up of 189 patients we found no statisti-
cally significant difference in costs and a small transient significant difference in patient 
outcome. These results made us question whether a second larger trial, in which we would 
attempt to identify a difference in costs and a durable difference in patient outcome that 
may have remained undetected in our initial study, would be justified.
If study results show no significant differences between the primary outcomes, the re-
searchers invariably conclude that more clinical research is needed to reduce decision 
uncertainty.13 Uncertainty could result in the adoption of suboptimal medical interventions, 
which could harm patients or result in inefficient allocation of limited health care funds. 
More research – for example, another clinical trial – is expected to decrease this uncertainty 
and benefit patients, save money, or both. However, research is costly and money spent on 
one research project cannot be spent on another. Furthermore, while further research is 
being performed, a potentially cost-effective intervention is withheld from patients. These 
problems raise the question whether more research regarding an uncertain decision is a 
good value for the money. More clinical research is justified only if the expected benefit of 
this research exceeds the expected costs. Value of Information analysis is a method that 
expands on cost-effectiveness analysis and can be used to determine if more research is 
justified regarding a medical decision. This method is used to estimate the expected benefit 
of a proposed study given the currently available evidence. In addition, Value of Informa-
tion analysis can be used to identify the optimal study design and sample size. Use of Value 
of Information analysis has been embraced and recommended by the National Institute 
for Clinical Excellence (NICE) in the United Kingdom as a framework for setting research 
priorities in health care.14
The purpose of this study was to help guide future outcomes research regarding the use of 
MR imaging in patients with acute knee trauma in an emergency room setting, with use of 
prospective data from a randomized clinical trial and value of information analysis. 
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METhOdS
Randomized controlled trial
In a previously published diagnostic randomized controlled trial188, we (EHO, JJN) enrolled 
189 consecutive patients (123 male [mean age, 31.9 years; age range, 12.6-74.6 years], 
66 female [mean age, 36.1 years; age range, 16.6-72.9]) with a mean age of 33.4 years 
between August 1999 and May 2001. These patients had recent knee trauma and were re-
ferred to the radiology department for conventional radiography.188 Patients were randomly 
assigned to undergo conventional radiography alone (n=93) or radiography followed by a 
short dedicated MR imaging examination (n=96). Institutional review board approval and 
informed consent (parental consent for minors) were obtained for the randomized study.
During 6 months of follow-up, quality of life was measured four times with a valuative de-
vice	(EuroQol).	All	relevant	societal	costs	were	recorded	during	the	follow-up	period.	These	
costs included medical and non-medical costs. Medical costs consisted of costs of diag-
nostic procedures and treatment both inside and outside the hospital and were estimated 
with 36 resource-use parameters for each strategy. Nonmedical costs were estimated with 
3 parameters: patient travel costs, patient time cost, and friction costs. The latter was an 
estimate of societal production losses. In total, 40 parameters (39 cost parameters and 
quality of life) were sampled for each strategy. Mean values and 95% confidence intervals 
were calculated for costs and effects of both strategies. (See the original article188 for more 
details on study design and analysis.)
Cost-effectiveness analysis
To	perform	cost-effectiveness	analysis,	we	(BG,	JJN)	transformed	the	EuroQol	values	into	
utility values.189 For each patient an author (BG) calculated the overall number of quality-
adjusted life years during the study period as the effect parameter.38 
A choice of one of the two strategies that is based on both cost and effect can be made only 
if a trade-off between cost and effect is made by placing a monetary value on health. We 
used a societal willingness-to-pay of €80,000 per quality-adjusted life year, as recently rec-
ommended by a Dutch governmental institute.182 Subsequently we (BG, TS) combined cost 
and effect into one outcome, which we termed net (monetary) benefit.5 The net benefit 
was calculated by multiplying effect by willingness to pay and subtracting cost. The strategy 
with the maximum net benefit is the strategy that is preferred.
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Value of Information analysis
We (BG, TS) applied Value of Information analysis as described in the literature.27, 32, 81, 105, 
153 First, we estimated the total expected value of perfect information (EVPI) per patient. 
This is the value of collecting data about the effect parameter and all cost parameters in 
an infinitely large study. In other words, it is the value of removing all uncertainty related 
to the decision problem. 
Subsequently, we estimated the expected value for the entire patient population that can 
potentially benefit from more research (population EVPI). To calculate the population EVPI 
we (BG, MGMH) estimated the effective lifetime of the technology to be 10 years. Benefits 
to future patients were discounted at a rate of 3% per year.38 For the Netherlands perspec-
tive we estimated the annual population that could potentially benefit from the results of a 
future study to be 20,000 patients. We performed an additional analysis for the European 
Union perspective. By extrapolating the annual population of 20,000 patients to the Euro-
pean Union, we determined that an annual population of 561,000 patients could benefit 
from more research. If the population EVPI is substantial, it is of interest to estimate the 
EVPI for individual parameters, or sets of parameters. We termed this the partial EVPI. 
Partial EVPI is used to identify the parameters that have the highest informational value 
regarding decision uncertainty. 
If the total EVPI is substantial, we are interested to learn the expected benefit of reducing 
uncertainty by obtaining information from a future study with a finite sample size. This is re-
ferred to as the total expected value of sample information (EVSI). Moreover, we can assess 
the expected benefit of future studies with a finite sample size that collect information on a 
limited set of parameters. This is referred to as the partial EVPI. An author (BG) estimated 
the partial EVSI for several sets of parameters to assess various study designs. Comparing 
the EVSI with the costs of performing research enables us to determine whether an addi-
tional study is justified given the cost. Subtracting the cost of research from the EVSI results 
in the expected net benefit of sampling (ENBS). The optimal sample size is determined by 
calculating the sample size that maximizes the ENBS.
For a future multicenter trial with a 3-year duration (assuming the study requires 2 full-
time equivalent junior researchers and a senior researcher with 0.4 full-time-equivalent 
responsibility) we (BG, MGMH) assumed a fixed cost of €500,000 and a variable cost of 
€500 per patient if all parameters in the initial trial were to be measured. If data on only 3 
parameters (friction cost, overnight hospital stay, and quality-adjusted life years) were to be 
collected, we assumed a fixed cost of €250,000 and a variable cost of €250 per patient. 
These cost estimates were based on our current expenses for similar studies.
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Technical details
To allow for Value of Information analysis, we (BG, TS) represented the joint uncertainty 
about the mean values of all parameters by using a multivariable normal distribution, with 
variances equal to the estimated squared standard errors of the mean and correlations 
between the different parameters calculated from the dataset. The central limit theorem 
justified the normality assumption.
An author (BG) performed 10 million simulations for each analysis, resulting in standard 
errors in our estimates of about 1%. Nested simulations were not required to estimate par-
tial EVPI and EVSI because the relation between the net benefit and each parameter was 
linear and because the multivariable normal distribution allowed us to calculate conditional 
mean values.32, 183 To estimate EVSI, an author (BG) derived posterior normal distributions 
for the sampled parameters by using Bayesian updating of the prior normal distributions.190 
We (BG, TS) assumed that the standard deviations and correlations between parameters in 
future research would be the same as those in the initial trial. All analyses were performed 
with R software (version 1.7.1; R Foundation for Statistical Computing, Vienna, Austria) 
that can be accessed at http://www.r-project.org.175
 
RESulTS
Cost-effectiveness analysis
The combination of radiography and MR imaging was more effective (that is, it resulted in 
more quality-adjusted life years during the study period), was less costly, and had a higher 
net benefit than radiography alone (Table). The differences in effect and net benefit were 
statistically significant but the difference in costs was not.
Strategy 1: 
Radiography only
Strategy 2: 
Additional MRI
Difference: 
strategy 2 - 1
mean cost 
Euro (95% CI)
2231 (1561;2901) 1815 (1277;2353) -416 (-1275;443)
mean effect 
QALY	(95%	CI)
0.35 (0.34;0.36) 0.38 (0.36;0.39) 0.03 (0.01;0.04)
mean net benefit* 
Euro (95% CI)
25,848(24,696;27,000) 28,315(27,399;29,231) 2467 (515;4419)
Table Mean cost, effect, and net (monetary) benefit.
CI: confidence interval
QALY:	quality-adjusted	life	years
*Mean net benefit = effect x willingness-to-pay  –  cost, 
with	willingness-to-pay	=	80,000	Euro/QALY
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Population EVPI: overall importance of uncertainty
We found a total EVPI of €2.1 per patient. The resulting population EVPI was €365,000 for 
the Netherlands and €10.2 million for the European Union. These values have an equiva-
lent benefit of 5 quality-adjusted life years for the Netherlands and 128 quality-adjusted life 
years for the European Union. An effective lifetime of the technology of 5 years instead of 
10 years would reduce these benefits by approximately half.
Partial EVPI: important parameters
In the initial study, only two of the 40 collected data parameters had a non-zero partial 
EVPI. The partial EVPI of the quality-adjusted life year was €1.0 per patient; the partial 
EVPI of the friction cost was €0.01 per patient. These two parameters had a synergistic 
effect, and together they had a partial EVPI of €1.9 euro per patient. This synergistic ef-
fect was augmented by considering the cost of an overnight hospital stay. A future study in 
which data on the number of quality-adjusted life years, the cost of an overnight hospital 
stay, and the friction costs per patient would be gathered, would have a partial EVPI of €2.0 
per patient, which would be nearly equal to the total EVPI.
Total EVSI and ENBS: optimal sample size
We first considered the optimal sample size for a future study collecting data on all pa-
rameters. The population EVSI for a study from the perspective of the Netherlands did not 
exceed the study costs for any sample size. This meant that more research was not justified. 
The population EVSI for a study from the perspective of the European Union increased as 
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Figure 1 Population expected value of sample information for all parameters (popEVSI), study costs, and expected net benefit 
of sampling (ENBS). The ENBS curve reaches a maximum (equal to 3.8 million euro) at a sample size of 2500 patients per 
trial arm.
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the sample size increased until a plateau was reached; this plateau was equivalent to the 
population EVPI (Figure 1). The study costs increased linearly as the sample size increased. 
The maximum ENBS of €3.8 million was reached at a sample size of 2500 patients per trial 
arm. One should note, however, that there was a decreasing marginal gain in the ENBS: A 
study with 1500 patients per trial arm was expected to reach a net benefit of €3.4 million.
Partial EVSI and ENBS: optimal sample size
To calculate partial EVSI, we considered a study that would enable us to collect data on 
only the three most important parameters: quality-adjusted life years, cost of an overnight 
hospital stay, and friction costs per patient. The population (partial) EVSI for a study from 
the perspective of the Netherlands did not exceed the study cost for any sample size. The 
same study from the perspective of the European Union had a slightly lower population 
EVSI and substantially lower study costs compared with the study in which data were col-
lected for all parameters (Figure 2). Therefore, the ENBS was higher when only the three 
most important parameters were sampled. The optimal sample size was 3500 patients 
per trial arm, resulting in an ENBS of €5.6 million or 70 quality-adjusted life years. Again, 
because of the decreasing marginal gain, we found an ENBS of €5.1 million for a study 
with 2000 patients. 
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Figure 2 Population expected value of sample information (popEVSI) for three parameters (friction cost, overnight hospital 
stay, and quality-adjusted life time), study costs, and expected net benefit of sampling (ENBS). The ENBS curve reaches a 
maximum (of 5.6 million euro) at a sample size of 3500 patients in each trial arm.
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dISCuSSION
We found a population EVPI of €10.2 million for a study from the perspective of the Euro-
pean Union regarding the decision of whether to add an MR imaging to the current initial 
work-up of patients with acute knee trauma. This indicates that if we would eliminate all 
uncertainty regarding this decision, we could expect a societal financial benefit of €10.2 
million, which is equivalent to a societal health benefit of 128 quality-adjusted life years. 
Only three parameters were responsible for the decision uncertainty: the number of quality-
adjusted life years, cost of an overnight hospital stay, and friction costs per patient. Col-
lecting data on the other 37 cost parameters has almost no additional benefit. A study in 
which data on these three parameters were gathered would have an optimal sample size of 
3500 patients per trial arm, and it would be expected to result in a societal benefit of €5.6 
million or 70 quality-adjusted life years. From the perspective of The Netherlands, however, 
more research was not justified. 
It is important to realize that the calculated societal benefit of €5.6 million euro or 70 
quality-adjusted life years is an expected net benefit: It is a probability weighted average 
over all possible outcomes of a future study. We learn the actual benefit of a study only after 
we have initiated the study, collected the data, and analyzed the actual results. Often there 
is no actual benefit. The findings of the future study are more likely than not to confirm 
that the strategy that we believe to be optimal is indeed optimal. If a future study results 
in a change in the optimal strategy, the benefit may be a reduction in cost, an increase in 
quality-adjusted life years, or a combination of these benefits.
The expected societal benefit of €5.6 million should be compared with the expected soci-
etal benefit of other unrelated proposed clinical research projects to set research priorities. 
The decision uncertainty regarding imaging for patients with acute knee trauma turns out 
to be relatively small in comparison with other clinical problems that have been addressed 
in Value of Information analyses.31 More research regarding MR imaging in patients with 
acute knee trauma is justified, but other clinical studies are expected to result in up to a 
100-fold higher benefit. The prioritization of research studies will ultimately depend on the 
portfolio of potential studies submitted to a funding agency, their corresponding expected 
value of information, and the available research budget.
Our results were sensitive to the uncertain magnitude of the population expected to benefit 
from reducing decision uncertainty. This is, by definition, true for all Value of Information 
analyses. However, it is not a drawback but rather inherent to the assessment of the ex-
pected benefit of future research. Both the annual population that can potentially benefit 
from the research and the effective lifetime of the technology are influential and uncertain. 
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The annual population that can benefit from research depends on the perspective of the 
policy maker: For example, is it the perspective of the hospital, the state, the country, or 
something	even	larger?	When	research	proposals	are	compared,	they	need	to	be	judged	
and compared from one perspective. Furthermore, the effective lifetime of the technology 
is uncertain because we do not know when improvements in diagnosis and treatment will 
come about and how they will influence decision uncertainty.
A few limitations pertain specifically to our study. We applied Dutch medical and nonmedi-
cal costs to the entire European Union. This may have biased our results. Moreover, we 
assumed that medical care in the entire European Union was similar to that in the Neth-
erlands. In addition, in our analyses we assumed that the intervention has no effect on 
the costs and effects after the 6-months follow-up period. Although these limitations may 
affect the precise figure that results from the calculations, they are unlikely to have a sub-
stantial effect on our conclusions.
Our results imply that a Dutch funding agency seeking to maximize the future health in the 
Netherlands should not fund more research regarding the value of MR imaging in patients 
with acute knee trauma. A European agency, however, should consider funding a multi-
center trial with about 3500 patients per trial arm in which the friction costs, the cost of an 
overnight hospital stay, and the quality-adjusted life years are measured. However, other 
unrelated research proposals with a higher expected benefit should receive priority.
Value of Information analysis is an analytic tool that can help researchers decide whether 
more clinical research regarding an uncertain medical decision is justified. It is a logical 
initial step when clinical research is considered regarding a medical decision or when the 
results of a randomized clinical trial are inconclusive. Value of information analysis can 
be used to determine whether the decision uncertainty justifies the cost of the research. 
Decision uncertainty can be modeled by using all available evidence in the literature.38 Al-
ternatively, the results of a previous clinical study or meta-analysis can be used for value of 
information analysis, as in the current study. Ideally, the analysis should involve all compet-
ing strategies to include all decision uncertainty. If the expected benefit of more research is 
substantial, Value of Information analysis can be used to identify key parameters, evaluate 
various study designs, and estimate optimal sample sizes. Claxton et al. have demonstrated 
the feasibility of Value of Information analysis to help guide the research priority setting of 
the National Health Service in the United Kingdom.31, 191 Although the mathematics are 
relatively simple, we realize that it takes time to understand the concepts of Value of Infor-
mation analysis. To our knowledge, this is the only method with a theoretically sound basis; 
therefore, we foresee an important role for Value of Information analysis in guiding future 
research. The budget for clinical research is limited and money should be spent where the 
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expected benefits are greatest. Moreover, more clinical research is justified only if the ex-
pected benefit of more research exceeds the expected research costs.
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Making decisions about the care of individual patients is fundamental to health care. In 
daily practice, most medical decisions are based on experience and judgment. Medical 
decision making was developed because of concerns about human judgment, practice 
variation, and the proliferation of diagnostic and treatment options. The aim of medical de-
cision making is to perform a complete formal assessment of every aspect that is relevant 
for a decision. This assessment includes patient preferences, rare events, and health care 
costs, all of which are typically ignored within the evidence-based medicine framework. 
Considerable uncertainty about the optimal intervention typically remains after evaluat-
ing all available evidence. However, a decision between the interventions has to be made, 
regardless of the extent of uncertainty. Evaluation of uncertainty is particularly relevant to 
determine whether more quantitative research is justified. A future study could reduce deci-
sion uncertainty which is expected to benefit future patients, reduce health care costs, or 
both. Value of information (VOI) analysis was introduced to estimate the expected benefit 
of a future study. Moreover, VOI analysis can guide the design of a study by identifying key 
parameters as well as the optimal sample size. This dissertation concerns the analysis and 
presentation of uncertainty in medical decision making with a focus on VOI analysis.
In Chapter 2 we introduced cost-effectiveness analysis to a clinical audience of surgeons. 
New interventions in surgery typically provide small additional health benefits and are more 
expensive in comparison to current care. If a health care system cannot afford all benefi-
cial new interventions, cost-effectiveness analysis can help set priorities. The application 
of cost-effectiveness analysis faces several challenges, including credibility, generalizability, 
and ethical implications. Additional challenges more specific to surgery include the learn-
ing curve for new surgical interventions and the gradual improvement of surgical technolo-
gy. Adherence to guidelines for cost-effectiveness analyses could address some challenges; 
other challenges simply reflect the difficulty of making decisions under uncertainty. Despite 
these challenges, priorities have to be set.
Chapter 3 is a tutorial in which we demonstrated Monte Carlo simulation and VOI analysis 
to analyze stochastic uncertainty, parameter uncertainty, and patient heterogeneity in a 
decision model. First-order Monte Carlo simulation allows modeling of the influence of 
patient history on subsequent events. Second-order Monte Carlo simulation evaluates the 
joint effect of uncertainty about all estimated parameter values in the model. VOI analyses 
explore whether more research is justified, identify key parameters, and assess the opti-
mal sample size of a proposed study design. Increasing model complexity, often requiring 
microsimulation, is a major challenge for second-order Monte Carlo simulation and VOI 
analyses. We provided step-by-step algorithms for the nested analyses that are required in 
patient-level models and in nonlinear models for partial VOI analyses.
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Chapter 4 concerned the combined analysis of uncertainty and patient heterogeneity in 
medical decision models. When more than one type of uncertainty and heterogeneity is 
analyzed, the correct algorithm to obtain the model outcomes of interest can be compli-
cated. We distinguished eight model types, each dealing with a different combination of 
heterogeneity, parameter uncertainty, and stochastic uncertainty. Decision models are pri-
marily built to inform policy makers about the expected outcome of competing strategies. 
We demonstrated that the expected outcome and the distribution of the individual outcome 
can always be obtained in a single Monte Carlo simulation (i.e., without using nested Mon-
te Carlo simulations). Nested Monte Carlo simulations are inevitable if we are interested 
in the uncertainty about the expected outcome, reflecting lack of perfect knowledge, for 
a heterogeneous population or in microsimulation models. In addition, nested simulations 
are required to obtain the distribution of the expected outcome reflecting patient hetero-
geneity, both in microsimulation models and models with parameter uncertainty. These 
nested Monte Carlo simulations require intensive computer processing capabilities.
In Chapter 5 we clarified the limitations of acceptability curves for presenting uncertainty 
in cost-effectiveness analyses. Clinical journals increasingly illustrate uncertainty about the 
cost and effect of health care interventions using cost-effectiveness acceptability curves 
(CEACs). CEACs present the probability that each competing alternative is optimal for a 
range of values of the cost-effectiveness threshold. The limitations of CEACs arise because 
a CEAC is not sensitive to any change of the incremental joint distribution in the upper-left 
and lower-right quadrant of the cost-effectiveness plane, neither is it sensitive to radial shift 
of the incremental joint distribution in the upper-right and lower-left quadrants. As a result, 
CEACs are ambiguous to risk-averse policy makers, inhibit integration with risk-attitude, 
hamper synthesis with other evidence or opinions, and are unhelpful to assess the need 
for more research. Moreover, CEACs may mislead policy makers and can incorrectly sug-
gest medical importance. Both for guiding immediate decisions and for prioritizing future 
research, these considerable drawbacks of CEACs should make us rethink their use in com-
municating uncertainty.
In Chapter 6 we evaluated two different approaches for estimating the partial expected 
value of perfect information (partial EVPI) to identify key parameters in cost-effectiveness 
analysis. A method that is generally recommended assumes that the EVPI for a param-
eter is estimated as the reduction in expected opportunity loss instead of the increase in 
expected value. With analytic proof, we showed that this method is incorrect and results 
in biased partial EVPIs and incorrect importance ranking of parameters. We demonstrated 
the correct method to estimate partial EVPI, using a two-level Monte Carlo simulation. A 
computationally efficient one-level Monte Carlo simulation is mathematically equivalent if 
the outcome is a multilinear function of each parameter not of interest and — additionally 
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— the parameters not of interest are uncorrelated. Because Markov models are nonlinear, 
they require two-level simulations to obtain unbiased partial EVPIs.
VOI analysis was applied in Chapter 7 to a decision model comparing four imaging tests 
to diagnose coronary heart disease in patients with chest pain. We found that the optimal 
imaging test for patients with chest pain is uncertain for most subgroups of patients. The 
main objective was to design the optimal future study to reduce uncertainty regarding the 
optimal imaging test for patients with chest pain. We compared the partial EVPIs of eight 
study designs: four observational studies for test characteristics and quality-of-life weights, 
a cost study, and three clinical trials measuring treatment effects. The partial EVPI was 
highest for an observational study evaluating the quality-of-life weights for varying sever-
ity of chest pain. By comparing the expected net benefit of sampling (ENBS) for various 
sample sizes, we determined that the optimal sample size for this study would be 1500 
patients for each severity-level of chest pain.
In Chapter 8 we demonstrated VOI analysis using data from an economic clinical trial. 
Most published applications of VOI analysis use decision models or hypothetical trial data. 
We explained how VOI analysis using patient-level data on costs and effects is simplified us-
ing several justifiable assumptions. Step-by-step instructions in statistical software (R) and 
a spreadsheet (Excel) allows other investigators to apply VOI analysis to their patient-level 
data. We designed the optimal study comparing endovascular revascularization and super-
vised exercise training for patients with intermittent claudication, based on data from a re-
cent economic clinical trial. The optimal study should maximize the difference between the 
expected benefit of the anticipated study results for future patients and the expected cost 
of the study. The proposed study would be a randomized controlled trial collecting data 
on the quality-adjusted life expectancy and additional admission costs for 525 patients per 
treatment arm. Sensitivity analyses showed that the optimal sample size was fairly robust: 
it remained between 400 and 600 patients for a willingness-to-pay threshold between 
€30,000	and	€100,000	per	QALY,	for	extreme	assumptions	about	the	study	costs,	and	for	
a period in which future patients are expected to benefit from the results of the proposed 
study ranging from 3 to 7 years.
In Chapter 9 we applied VOI analysis to guide future outcomes research regarding the use 
of MR imaging for patients with acute knee trauma in the emergency room setting. An eco-
nomic clinical trial randomizing 189 patients with acute knee trauma to radiography only or 
radiography followed by MR imaging had found no significant difference in cost or effect. 
VOI analysis was performed to determine if more research was justified. From the perspec-
tive of only the Netherlands, the country that had funded the initial study, more research 
was not justified. From the perspective of the European Union, we found a population EVPI 
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of €10.2 million. VOI analysis further demonstrated that out of 40 parameters in the initial 
trial, only three parameters were responsible for most of the decision uncertainty: quality-
adjusted life time, cost of an overnight hospital stay, and friction costs. A study that gathers 
data on these three parameters would have an optimal sample size of 3500 patients per 
arm and would be expected to result in a societal benefit of €5.6 million, or 70 quality-
adjusted life years.
Some recommendations can be made based on the research presented in this disserta-
tion:
•	 Most	 cost-effectiveness	 analyses	 (whether	 decision	 models	 or	 clinical	 trials)	 can	 be	
improved by adhering to guidelines.
•	 The	 combined	 analysis	 of	 uncertainty	 and	 patient	 heterogeneity	 in	 decision	models	
requires careful selection of the correct algorithms to obtain the outcomes of interest.
•	 Uncertainty	in	cost-effectiveness	analysis	is	best	presented	by	uncertainty	intervals	for	
the incremental net benefit (when two interventions are compared) or the total EVPI.
•	 Methods	that	estimate	the	reduction	in	the	partial	EVPI	are	incorrect	and	should	not	be	
used to identify key parameters.
•	 The	analyses	of	a	probabilistic	decision	model	should	culminate	in	VOI	analysis	to	find	
the key parameters and optimal sample size of a future study.
•	 VOI	analysis	 should	be	 the	 first	 step	 in	designing	a	 clinical	 study,	 as	 it	 assesses	 the	
importance of decision uncertainty, the key parameters, and the optimal sample size.
Many topics on uncertainty in medical decision making remain unexplored, especially re-
garding VOI analysis. Future research could evaluate the feasibility of requiring a VOI 
analysis whenever a clinical study is considered for funding. In chapters 8 and 9, simula-
tion methods were used for partial VOI analyses of clinical trial data. In theory, closed form 
solutions should exist for these analyses. Most published VOI analyses consider both costs 
and health effects, while clinical research is mainly focused on health outcomes, such as 
mortality. Future research could explore the use of VOI analysis to prioritize clinical re-
search with outcomes such as mortality.
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Beslissingen nemen met betrekking tot de zorg voor individuele patiënten is een essentieel 
onderdeel van de gezondheidszorg. In de dagelijkse praktijk zijn de meeste beslissingen 
gebaseerd op de persoonlijke ervaring en beoordeling van de behandelend arts. Het vak-
gebied medische besliskunde is ontstaan om bezorgdheid over de feilbaarheid van deze 
beoordeling, verschillen in beleid tussen artsen en het toenemend aantal diagnostische en 
therapeutische mogelijkheden. Het doel van medische besliskunde is een formele evalu-
atie van alle aspecten die relevant zijn voor een bepaalde beslissing. In tegenstelling tot 
het vakgebied evidence-based medicine, worden ook de voorkeur van de patiënt, zeldzame 
complicaties en de kosten van de zorg expliciet meegewogen. Nadat al het beschikbare 
bewijs is meegewogen blijft het vaak onzeker welke interventie (diagnostische onderzoek 
of behandeling) het beste is voor een bepaalde patiënt. Echter, de arts moet een keuze 
maken, ongeacht hoeveel onzekerheid er is. De evaluatie van onzekerheid is met name 
van belang om te beoordelen of meer klinisch onderzoek gerechtvaardigd is. Door een 
toekomstige studie kan de onzekerheid afnemen, wat kan resulteren in betere uitkomsten 
voor toekomstige patiënten en/of een kostenreductie. Value of information (VOI) analyse is 
geïntroduceerd om de verwachte baten van een toekomstige studie te schatten. Bovendien 
kan VOI analyse de opzet van een studie begeleiden bij het selecteren van de belangrijkste 
parameters en het kiezen van het optimaal aantal patiënten in de studie. Dit proefschrift 
gaat over de analyse en presentatie van onzekerheid in de medische besliskunde met een 
focus op VOI analyse.
Hoofdstuk 2 is een introductie van kosteneffectiviteits analyse voor chirurgen. Nieuwe be-
handelingen in de chirurgie hebben vaak een kleine toegevoegde waarde voor de patiënt 
en zijn aanmerkelijk duurder dan de huidige zorg. Kosteneffectiviteits analyse kan helpen 
bij het stellen van prioriteiten als de gezondheidszorg zich niet iedere nieuwe interventie 
kan veroorloven. Het gebruik van kosteneffectiviteits analyse gaat gepaard met enkele uit-
dagingen, waaronder geloofwaardigheid, de toepasbaarheid op een specifieke patiënt, en 
ethische implicaties. Ook zijn er uitdagingen specifiek voor de chirurgie, zoals de leercurve 
voor nieuwe chirurgische behandelingen en de geleidelijke verbetering van chirurgische 
technologie. Het volgen van richtlijnen voor kosteneffectiviteits analyse lost sommige uit-
dagingen ten dele op; andere uitdagingen weerspiegelen dat het moeilijk is beslissingen te 
nemen in onzekerheid. Ondanks deze uitdagingen moeten keuzes worden gemaakt.
Hoofdstuk 3 is een tutorial waarin Monte Carlo simulatie en VOI analyse worden gede-
monstreerd om stochastische onzekerheid, parameter onzekerheid en patiënten heteroge-
niteit te analyseren in een besliskundig model. Eerste-orde Monte Carlo simulatie maakt 
het mogelijk om de invloed te modelleren van de voorgeschiedenis van een patiënt op 
toekomstige kansen en uitkomsten. Tweede-orde Monte Carlo simulatie evalueert het ge-
meenschappelijk effect van de onzekerheid van alle geschatte parameter waarden in het 
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besliskundige model. VOI analyses evalueren of meer klinisch onderzoek gerechtvaardigd 
is en stellen vast wat de belangrijkste parameters zijn evenals de optimale studie grootte. 
De toename van de complexiteit van besliskundige modellen, waardoor vaak microsimu-
latie nodig is, is een grote uitdaging voor tweede-orde Monte Carlo simulatie en VOI ana-
lyses. Algoritmes worden gepresenteerd voor de geneste analyses in besliskundige model-
len waarin individuele patiënten worden gesimuleerd en in niet-lineaire modellen voor de 
partiële VOI analyses.
Hoofdstuk 4 behandelt de gecombineerde analyse van onzekerheid en patiënten hetero-
geniteit in medische besliskundige modellen. Als meer dan één type onzekerheid of pati-
enten heterogeniteit wordt geanalyseerd, kan het moeilijk zijn vast te stellen wat het juiste 
algoritme is om de correcte uitkomsten van een model te verkrijgen. Onderscheid wordt 
gemaakt tussen acht model types die ieder een verschillende combinatie van patiënten he-
terogeniteit, stochastische onzekerheid en parameter onzekerheid beschouwen. Besliskun-
dige modellen worden met name gemaakt om de optimale interventie te kiezen op basis 
van de verwachte uitkomsten. We hebben laten zien dat de verwachte uitkomst en de dis-
tributie van de individuele uitkomst altijd verkregen kunnen worden met een enkele Monte 
Carlo simulatie (d.w.z. zonder een geneste simulatie). Geneste Monte Carlo simulaties zijn 
onvermijdelijk als we geïnteresseerd zijn in de onzekerheid (door gebrek aan bewijs) over 
de verwachte uitkomst, zowel als het gaat om beslissingen voor een heterogene populatie 
als om microsimulatie modellen. Ook is een geneste simulatie nodig als het gaat om de 
verdeling (door patiënten heterogeniteit) van de verwachte uitkomst, zowel in microsimu-
latie modellen als in modellen met parameter onzekerheid. Deze geneste Monte Carlo 
simulaties maken intensief gebruik van computer processor capaciteit.
Hoofdstuk 5 beschouwt de beperkingen van de kosteneffectiviteits acceptability curve 
(KEAC) voor het weergeven van onzekerheid in kosteneffectiviteits analyses. Klinische tijd-
schriften illustreren steeds vaker onzekerheid over de kosten en effecten van interventies 
in de gezondheidszorg met KEACs. Deze curves geven de kans weer dat een interventie 
kosteneffectief is voor bepaalde waarden van de kosteneffectiviteits drempel. De beper-
kingen van KEACs ontstaan doordat KEACs niet gevoelig zijn voor veranderingen van de 
incrementele gezamelijke verdeling van kosten en effecten in de kwadranten linksboven en 
rechtsonder van het kosteneffectiviteits vlak. Hierdoor zijn KEACs niet eenduidig voor be-
sluitvormers met een risico aversie, maken zij het onmogelijk ander bewijs en opinies mee 
te nemen in de besluitvorming, en zijn ze ongeschikt om te beoordelen of meer klinisch 
onderzoek gerechtvaardigd is.
Bovendien kunnen KEACs beleidsmakers misleiden door ten onrechte een groot medisch 
belang te suggereren. Gezien deze beperkingen voor het communiceren van onzekerheid 
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moet het gebruik van KEACs heroverwogen worden, zowel voor het besluit om een nieuwe 
interventie te implementeren, als voor de beoordeling of meer klinisch onderzoek gerecht-
vaardigd is.
Hoofdstuk 6 evalueert twee verschillende methoden voor het schatten van de partiële ex-
pected value of perfect information (EVPI) om de belangrijkste parameters te vinden in een 
kosteneffectiviteits analyse. Een veel gebruikte methode veronderstelt dat de EVPI van een 
parameter berekend kan worden met de reductie in de EVPI in plaats van met de toename 
in expected value. We bewezen analytisch dat deze methode onjuist is en leidt tot foutieve 
waarden voor de partiële EVPI en een foutieve rangschikking van de parameters. De juiste 
methode voor het berekenen van de partiële EVPI werd gedemonstreerd met behulp van 
geneste Monte Carlo simulaties. Een snellere methode met behulp van een enkele Monte 
Carlo simulatie leidt tot dezelfde partiële EVPI mits de parameters die niet in de voorge-
stelde studie worden gemeten ongecorreleerd zijn en bovendien de uitkomst van het model 
een multilineaire functie is van deze parameters. In Markov modellen is een geneste simu-
latie onvermijdelijk omdat deze modellen niet-lineair zijn.
In hoofdstuk 7 is VOI analyse toegepast op een besliskundig model waarin vier beeldvor-
mende onderzoeken, voor het diagnosticeren van coronair lijden bij patiënten met pijn op 
de borst, worden vergeleken. Het meest kosteneffectieve beeldvormende onderzoek voor 
patiënten met pijn op de borst bleek onzeker voor de meest subgroepen van patiënten. Het 
doel in dit hoofdstuk was om de optimale klinische studie op te zetten ter vermindering van 
onzekerheid met betrekking tot de keuze van een beeldvormend onderzoek voor patiënten 
met pijn op de borst. We vergeleken de partiële EVPI van acht studie opzetten: vier obser-
vationele studies naar de testkarakteristieken en de kwaliteit van leven, een kostenstudie 
en drie klinische trials voor de behandeling van coronair lijden. De partiële EVPI was het 
hoogst voor een observationele studie naar de kwaliteit van leven voor patiënten zonder 
pijn op de borst, met milde en met ernstige pijn op de borst. De expected net benefit of 
sampling werd berekend voor verschillende waarden van de studie grootte. De optimale 
studie grootte was 1500 patiënten per patiëntengroep.
Hoofdstuk 8 demonstreert VOI analyse met data van een economische klinische studie. De 
meeste gepubliceerde toepassingen van VOI analyse gebruiken besliskundige modellen of 
hypothetische klinische data. Met behulp van enkele veronderstellingen is het mogelijk om 
VOI analyse toe te passen op patiënten data met kosten en kwaliteit van leven uitkomsten. 
Met onze stap-voor-stap instructies in statistische software (R) en in een spreadsheet (Excel) 
kunnen anderen VOI analyse toepassen op hun eigen patiënten data. Op basis van patiën-
ten data van een recente economische klinische studie hebben we de optimale studie op-
gezet om endovasculaire revascularisatie te vergelijken met gesuperviseerde looptraining 
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voor patiënten met intermitterende claudicatie klachten. De optimale studie maximaliseert 
het verschil tussen de verwachte baten van de studieresultaten voor toekomstige patiënten 
en de kosten van de studie. De optimale studie was een gerandomiseerde studie naar de 
twee belangrijkste parameters, kwaliteit van leven en de kosten van ziekenhuisopname, 
voor 525 patiënten per studie arm. Gevoeligheids analyses lieten zien dat de optimale stu-
die grootte vrij stabiel was: de studie grootte bleef tussen de 400 en 600 patiënten voor een 
willingness-to-pay drempel tussen de €30.000 en de €100.000 voor een kwaliteit gecor-
rigeerd levensjaar, voor extreme waarden voor de kosten van de studie, en voor een periode 
waarin toekomstige patiënten profiteren van de studieresultaten van drie tot zeven jaar.
Hoofdstuk 9 is een toepassing van VOI analyse om toekomstig onderzoek op te zetten naar 
de waarde van MRI voor patiënten op de spoed-eisende hulp met acuut knieletsel. Een 
economische klinische studie randomiseerde 189 patiënten met acuut knieletsel tussen 
alleen een röntgenfoto en een röntgenfoto gevolgd door een MRI. Deze studie vond geen 
significant verschil in kosten en effecten. VOI analyse werd toegepast om te evalueren of 
meer klinisch onderzoek gerechtvaardigd was.Vanuit het perspectief van de gezondheids-
zorg in Nederland, van waaruit de eerdere klinische studie was gefinancierd, was meer 
klinisch onderzoek niet gerechtvaardigd. Vanuit het perspectief van de Europese Unie werd 
een population EVPI gevonden van €10,2 miljoen. VOI analyse toonde ook aan dat van 
de veertig parameters in de eerdere studie slechts drie parameters verantwoordelijk waren 
voor het overgrote deel van de onzekerheid: kwaliteit van leven, de kosten van ziekenhuis-
opname, en de frictiekosten. Een toekomstige studie naar deze drie parameters heeft een 
optimale studie grootte van 3500 patiënten per studie arm en een verwachte opbrengst 
voor de maatschappij van €5,6 miljoen, of 70 voor kwaliteit gecorrigeerde levensjaren.
Op basis van het onderzoek in dit proefschrift kunnen enkele aanbevelingen worden ge-
daan:
•	 De	 meeste	 kosteneffectiviteits	 analyses	 (zowel	 besliskundige	 modellen	 als	 klinische	
studies) kunnen worden verbeterd door het strict volgen van richtlijnen.
•	 Voor	 de	 gecombineerde	 analyse	 van	 onzekerheid	 en	 patiënten	 heterogeniteit	 in	
besliskundige modellen is het van belang het juiste algoritme te kiezen om de correcte 
uitkomst te berekenen.
•	 Onzekerheid	 in	 kosteneffectiviteits	 analyse	 kan	 het	 best	 worden	 gepresenteerd	met	
betrouwbaarheids intervallen voor de incrementele net benefit (als twee interventies 
worden vergeleken) of de totale EVPI.
•	 Methoden	die	de	 reductie	 in	de	partiële	EVPI	berekenen	zijn	onjuist	en	moeten	niet	
worden gebruikt om vast te stellen welke parameters het belangrijkst zijn.
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•	 VOI	 analyses	 om	 de	 belangrijkste	 parameters	 vast	 te	 stellen	 evenals	 de	 optimale	
studie grootte, zijn een essentieel onderdeel van de analyse van een probabilistisch 
besliskundig model.
•	 VOI	analyses	moeten	de	eerste	stap	zijn	bij	het	opzetten	van	een	klinische	studie	om	de	
mate van onzekerheid met betrekking tot een keuze tussen interventies vast te stellen, 
evenals de belangrijkste parameters en de optimale studie grootte.
Veel onderwerpen over onzekerheid in de medische besliskunde verdienen meer aandacht, 
met name op het gebied van VOI analyse. Toekomstig onderzoek kan evalueren of het 
haalbaar is om een VOI analyse te verplichten voor iedere subsidie aanvraag voor een kli-
nische studie. In de hoofdstukken 8 en 9 werd patiënten data gebruikt om partiële EVPIs 
te berekenen met simulatie methoden. Toekomstig onderzoek kan de formules vinden 
waarmee deze partiële EVPIs eenvoudiger zijn te berekenen. In de literatuur worden VOI 
analyses meestal toegepast in het kader van kosteneffectiviteits studies, terwijl de meeste 
klinische studies zich richten op uitkomsten zoals mortaliteit. Toekomstig onderzoek kan 
het gebruik van VOI analyses evalueren om prioriteiten te stellen voor onderzoek met der-
gelijke uitkomsten.
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Knowing how little you know
Uncertainty is an essential aspect of medical decision making: the optimal intervention 
for a patient is typically uncertain to some extent. Knowing how little you know — that 
is, knowing the extent of uncertainty — has long been recognized as a sign of wisdom.115 
Socrates went so far as to say: “As for me, all I know is I know nothing”.207 Interestingly, 
the extent of uncertainty has no immediate relevance when deciding on the optimal inter-
vention for a patient. A decision has to be made, no matter how little you know. Moreover, 
while doubt may be a sign of wisdom, indecisiveness can be detrimental, especially in 
medical emergencies.
Knowing how little you know is especially relevant when considering if more research is 
justified to decrease uncertainty about a decision. Less uncertainty is expected to benefit 
patients. An estimate of the extent or importance of uncertainty is required to set priori-
ties among clinical studies competing for funding. In this dissertation value of information 
(VOI) analysis was demonstrated as a set of methods to determine the importance of un-
certainty and guide future quantitative research. Through VOI analysis you can know how 
little you know.
The analysis of uncertainty
The analysis of uncertainty in cost-effectiveness analyses is the initial focus of this thesis. 
Organizations, journals, and experts increasingly recommend the analysis of parameter 
uncertainty and patient heterogeneity.110, 208 However, most published cost-effectiveness 
analyses, for example in surgery, use deterministic models (Chapter 2). For stochastic un-
certainty, experts disagree about the use of microsimulation in decision models: some con-
sider it an avoidable obstacle to perform probabilistic sensitivity analyses; others point out 
that cohort analyses often fail to reflect real-life complexity.90, 209, 210 Fortunately, increasing 
computer performance continues to facilitate nested analyses in microsimulation models. 
The analysis of patient heterogeneity is complicated because no unambiguous method 
exists to decompose the total variance of a parameter into components attributable to 
parameter uncertainty and to patient heterogeneity. The methodological complexity of the 
combined analysis of stochastic uncertainty, parameter uncertainty, and patient heteroge-
neity presents a barrier for their application. The appropriate algorithms and step-by-step 
instructions in Chapters 3 and 4 have addressed this difficulty.
The presentation of uncertainty
The debate about the optimal presentation of uncertainty in cost-effectiveness analysis 
(CEA) has not been settled. Uncertainty intervals for the incremental cost-effectiveness 
ratio and separate hypothesis testing for costs and effects have been discredited and are 
currently rarely presented. We demonstrated the serious limitations of cost-effectiveness 
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acceptability curves (CEACs; Chapter 5), which often appear in clinical journals such as the 
British Medical Journal. As Howard stated: “No theory that involves just the probabilities of 
outcomes without considering their consequences could possibly be adequate in describing 
the importance of uncertainty to a decision maker.”30 Nevertheless, CEACs continues to 
have their advocates.211 
For the comparison of two interventions, we recommend the presentation of the incremen-
tal distribution on the cost-effectiveness plane, the uncertainty interval of the incremental 
net benefit, and the total expected value of perfect information (total EVPI). The CE-plane 
and uncertainty intervals of the net benefits overestimate the extent of uncertainty when 
more than two interventions are compared, because the outcomes are typically positively 
correlated in decision models. Therefore, the total EVPI is the only unambiguous measure 
of decision uncertainty for the comparison of more than two interventions. The total EVPI is 
a new concept for most clinicians and policy makers. However, the total EVPI is no harder 
to estimate or understand than a CEAC. Both the total EVPI and the CEAC are straight-
forward to calculate from the results of a probabilistic sensitivity analysis (Chapter 3).
VOI analysis – methods
Value of information (VOI) analysis is the second focus of this thesis. The framework of 
cost-effectiveness analysis requires that health care interventions are cost-effective; analo-
gously, VOI analysis requires that quantitative health care research is cost-effective. Phillips 
observed that studies in health care typically conclude that “more research is needed” 
without some assessment of the expected benefit for future patients that would come from 
more research.13 VOI analysis evaluates uncertainty resulting in a formal comparison of the 
expected benefit and the cost of a proposed study.
Our initial explorations of VOI analysis were held back because two different methods 
to estimate the partial EVPI were applied in the VOI literature. In Chapter 6 we demon-
strated that methods to estimate the partial EVPI as reduction in EVPI are conceptually and 
mathematically incorrect. Brennan et al. confirmed our conclusion.82 All VOI applications 
published in the last few years have applied the correct methodology for estimating partial 
EVPI.
VOI analysis – decision models
Yokota’s comprehensive overview of VOI analyses in 2004 28, as well as the more recent 
literature, shows that most published VOI studies are limited to estimating total (popula-
tion) EVPI and sometimes partial EVPIs.33, 34, 212, 213 Such analyses are relevant to evaluate 
the importance of overall uncertainty and identify key parameters responsible for decision 
uncertainty. However, they are insufficient to justify and guide further research. Estimation 
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of the partial expected value of sample information (partial EVSI) is required to compare 
a study’s expected benefit with the expected study costs across a range of sample sizes, to 
find the optimal sample size. In Chapter 7, we compared the partial EVPI of various study 
designs. Next, we demonstrated the feasibility of finding the optimal sample size for a study 
design using VOI analysis in a decision model. For the decision between diagnostic tests for 
patients with chest pain, the quality-of-life weights for varying severity of chest pain were 
the most important parameters. The optimal study design was an observational study with 
1500 patients for each level of chest pain severity.
VOI analysis – clinical trials
Most published applications of VOI analysis use decision models or hypothetical trial data.28 
Decision models are often preferred for cost-effectiveness, and VOI analyses because of 
their external validity and consideration of all available evidence. However, a randomized 
controlled trial constitutes the best available evidence for many clinical decisions, not only 
to decide what medical intervention should be adopted, but also to guide future research. 
Currently, a non-significant difference between the study outcomes typically results in a call 
for a larger trial.13 In Chapters 8 and 9, we developed and demonstrated VOI methods to 
use patient-level data on costs and effects from randomized controlled trials. For the treat-
ment of intermittent claudication and for the use of MR imaging for acute knee injury, we 
identified the key parameters and optimal sample size. Chapter 8 includes programming 
syntax and step-by-step instructions to allow other investigators to apply VOI analyses to 
their clinical trial data. 
VOI analysis – assumptions and challenges
While we anticipate a bright future for VOI analysis, we acknowledge several assumptions 
and limitations. VOI analyses are typically performed in a cost-effectiveness analysis set-
ting. As a consequence, VOI analysis has the same assumptions and limitations associated 
with	cost-effectiveness	analysis,	such	as	the	use	of	QALYs.214 Moreover, VOI analysis deter-
mines that more research is justified if the expected benefit of a proposed study exceeds the 
study costs. This trade-off assumes that health care costs and research costs are ultimately 
paid from the same resources. The extent to which this assumption holds is different in 
different countries.
The populationVOI, which is compared with the study costs, depends greatly on the future 
population benefiting from the acquired information. The annual population to benefit 
depends on the appropriate perspective of the VOI analysis. Typically the appropriate per-
spective (e.g., national or worldwide) is not obvious. The period that patients will benefit 
from the proposed data collection is also uncertain because of uncertainty about future 
technological improvements and evidence from future studies. These ambiguities about 
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the population to benefit, however, are not drawbacks of VOI analysis in itself, but are in-
herent to identifying research priorities.
VOI analyses often result in recommending study designs with very large sample sizes, up 
to several thousand patients. Such sample sizes may seem unfeasible, especially for a sin-
gle-center study. On the other hand, some multinational trials in cardiology have managed 
to randomize thousands of patients. Moreover, Altman has pointed out that the sample size 
of controlled trials is generally inadequate.12 Using VOI analyses, funding agencies may 
select a few large multinational studies for funding, instead of many studies with each an 
inadequate sample size.
VOI analyses in decision models can be challenging for both the analyst and the computer. 
First, the analyst needs to build a probabilistic model. A probabilistic sensitivity analysis is 
then required to estimate the total EVPI. Moreover, a nested simulation is required to esti-
mate the total EVPI for microsimulation models. In Chapter 6, we explained that a nested 
(two-level) simulation is also required to estimate the partial EVPI or EVSI, because typically 
parameters which are not of interest are not a multilinear function of the model outcome. 
Step-by-step algorithms are now available for these complicated analyses. Unfortunately, 
the nested simulations require a great deal of computer-processing capabilities. Obtain-
ing a precise and unbiased estimate in complex models using dedicated decision making 
software may take weeks of simulation. More time-efficient methods, such as Gaussian 
process modeling, have been developed, but few applications have been published.91 The 
importance of such time-efficient methods will depend on the balance between increasing 
model complexity and increasing computer performance.
VOI analysis – recommendations and future research
VOI analysis can help set clinical research priorities by comparing the expected benefit 
and the study costs of proposed study designs. Detsky developed methods to estimate the 
benefit of clinical trials after they were carried out, and he compared the benefit with the 
cost of these trials.184 VOI analysis allows this comparison before the study is performed. 
Informally, some comparison of the expected benefit and the costs of proposed study de-
signs is also made without a VOI analysis. Funding proposals typically include an estimate 
of the study costs and of the population that is expected to benefit from the results of the 
proposed study. The main novelty of VOI analysis is the estimation of the importance of 
uncertainty per patient, based on evidence available before the study is performed. VOI 
analysis can replace significance testing (e.g., p-values < 0.05) to evaluate whether more 
research is justified. Moreover, VOI analysis can determine the optimal sample size of a 
proposed study, replacing more arbitrary conventional sample size calculations.
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Analysts increasingly incorporate parameter uncertainty into their decision models. VOI 
analysis is the main justification of building such a probabilistic model, since the analysis 
of uncertainty is especially relevant to guide future research.27 Analysts should therefore 
proceed to identify the optimal study design of a future study, if the total EVPI exceeds the 
study costs. This optimal study is characterized by its design (e.g., randomized or observa-
tional), the subset of sampled parameters (e.g., test characteristics or treatment effects), 
the sample size, and the associated study costs.
We used simulation methods for partial VOI analyses of clinical trial data. In theory, it 
should be possible to derive closed form solutions for these analyses. We recommend 
finding these solutions facilitating VOI analysis of clinical trial data to guide future clinical 
research.
Most published VOI analyses consider both costs and health effects. However, most clinical 
research considers only health outcomes such as mortality. VOI analysis could be applied to 
set priorities among studies with mortality as the principle outcome. For example, the total 
EVPI could be estimated as a 2% expected reduction in mortality with perfect information. 
For a population-to-benefit of 10,000 patients, the associated expected population benefit 
of perfect information could be expressed as 200 averted deaths. Applying VOI analyses 
to studies with multiple health outcomes (e.g., mortality as well as quality-of-life or various 
adverse events) requires integration of the outcomes into a single outcome such as quality-
adjusted life expectancy. We recommend exploring the feasibility of such VOI analyses to 
guide priority setting for clinical research with only health outcomes.
In general, we recommend evaluating the feasibility of requiring a VOI analysis whenever 
a clinical study is considered for funding. The VOI analysis could be performed within a 
decision model (Chapter 7) or using data from a previous clinical study (Chapters 8 and 
9). Alternatively, VOI analyses can be performed using expert estimates of the uncertainty 
intervals of costs and effects of each intervention (e.g., using Delphi methods). The latter 
requires less time than building a decision model, but is more susceptible to bias. Currently, 
most study proposals include an estimate of the study costs and of the population which will 
benefit from the results of the study. Study proposals based on VOI analyses also include 
estimates of the expected population benefit given the optimal sample size. Proposed stud-
ies with a higher population benefit should receive priority. As Howard noted: “Placing a 
value on the reduction of uncertainty is the first step in experimental design, for only when 
we know what it is worth to reduce uncertainty do we have a basis for allocating our re-
sources in experimentation designed to reduce the uncertainty.”30
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aPPENdIX 1 – ChaPTER 3
Notation
x : model parameter
f(x) : model outcome for a value of x
E[f(x)] : expected outcome of model
E[x] : expected value of x
Numerical example of nonlinearity
            is a nonlinear function of x.
If x has a discrete distribution, being 0.1 or 0.3 both 
with 50% probability, then:
                                             , which is not equal to:
                                  .
 
aPPENdIX 2 – ChaPTER 3
Notation
We used a notation similar to Ades et al.32 The notation is slightly modified to allow for 
stochastic uncertainty and patient heterogeneity.
Notation
µ : stochastic variable for model parameters
µI : parameters of interest in partial value of information analyses
µC  : parameters not of interest in partial value of information analyses
X : stochastic variable for covariates
t  : strategy
t* : baseline optimal strategy; i.e., prior to collecting more data
B(t;µ;X) : stochastic variable for patient-level model outcome (e.g., lifetime)
                                        : expected outcome of cohort analysis (e.g., life expectancy)
D : data collection on parameters of interest in proposed future study
E : expectation
max : maximization
P : probability distribution
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Stochastic uncertainty
Models with no parameter uncertainty and no patient heterogeneity.
The expected outcome of the optimal strategy is: max
t
 [E
B
 (B (t))],
estimated by:                           .
Parameter uncertainty
Models with parameter uncertainty, and no patient heterogeneity.
Markov cohort model
The expected outcome of the optimal strategy is:                            ,
estimated by:                                .
The distribution of the expected outcome of strategy a is:                 .
Patient-level model
The expected outcome of the optimal strategy is: max
t
 [E
B;µ
 (B (t;µ))],
estimated by:                                      .
The distribution of the expected outcome of strategy a is: P
µ
{E
B
 (B (t;µ))},
estimated by:   
TOTAL EVPI
Markov cohort model with parameter uncertainty, and no patient heterogeneity.
                                                                                              ,
estimated by:                                                     .
See Box 2 for a step-by-step algorithm. See Groot Koerkamp et al. for a proof that the fol-
lowing is mathematically equivalent:105
                                                                             .
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PARTIAL EVPI
Markov cohort model with parameter uncertainty, and no patient heterogeneity.
                                                                                   ,
estimated by:   
See Box 4 for a step-by-step algorithm. If the model is a multilinear function of uncorrelated 
BC, and a linear function of correlated BC, the equations simplify to:
 
                                                                                              ,
estimated by:                                                                                .
See Box 3 for a step-by-step algorithm.
Variability
Markov cohort model with patient heterogeneity, and no parameter uncertainty.
The expected outcome of a heterogeneous population is:                    ,
estimated by:                     .
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aPPENdIX 3 – ChaPTERS 3 aNd 7
Table 1 includes parameter values related to exercise echocardiography and exercise 
SPECT that were not considered in the model of chapter 3.
nr. parameter mean 
(in %)
95% confidence limits source
angiography: short-term risks
1  myocardial infarction if 0-VD‡ 0.02 0.02 0.03 192
2  myocardial infarction if 1-VD 0.06 0.05 0.07 192
3  myocardial infarction if 2-VD 0.08 0.07 0.10 192
4  myocardial infarction if 3-VD 0.08 0.07 0.09 192
5  myocardial infarction if LMD§ 0.17 0.15 0.18 192
6  die if 0-VD 0.02 0.01 0.02 193
7  die if 1-VD 0.05 0.04 0.06 193
8  die if 2-VD 0.07 0.06 0.08 193
9  die if 3-VD 0.12 0.11 0.13 193
10  die if LMD 0.55 0.52 0.58 193
CTCA*
11  Sensitivity 99 95 100 194
12  Specificity 88 59 100 194
13  percentage uninterpretable 1.69 0.04 6.16 194
14  percentage morbidity 0.05 0.04 0.06 expert opinion
exercise echocardiography
15  Sensitivity 85 83 87 195
16  Specificity 77 74 80 195
17  percentage uninterpretable 5 0 10 196
18  percentage morbidity 0.05 0.04 0.06 expert opinion
19  percentage mortality 0.005 0.004 0.006 expert opinion
exercise SPECT
20  Sensitivity 87 86 88 195
21  Specificity 64 60 68 195
22  percentage uninterpretable 2 0 4 expert opinion
23  percentage morbidity 0.05 0.04 0.06 expert opinion
24  percentage mortality 0.005 0.004 0.006 expert opinion
25 pre-test probability of CHD given 
age, gender, and chest pain type
see Table 3
Table 1A Model parameters – test characteristics and pre-test 
probability of CHD
‡ VD = vessel disease
§ LMD = left main disease
* CTCA = computed tomographic coronary angiography
chapter 12
184
nr. Parameter mean credible interval ‡ source
cost tests
26  cost angiography 3186 2230 4141 Medicare (30% inpatient)
27  cost CTCA 705 494 917 Medicare
28  cost echocardiography 241 169 313 Medicare
29  cost SPECT 599 419 779 Medicare
cost treatments
30  cost CABG 23052 16136 29968 Medicare
31  cost PCI 11795 8257 15334 Medicare (70% stents)
cost events
32  cost myocardial infarction 6690 4683 8697 Medicare
annual costs chest pain patient
33  no, abnormal LVEF 3870 2709 5031 Medicare
34  mild, abnormal LVEF § 5689 3982 7395 Medicare
35  mild, normal LVEF 1818 1272 2363 Medicare
36  severe, abnormal LVEF 9148 6403 11892 Medicare
37  severe, normal LVEF 4105 2874 5337 Medicare
Table 1B	Model	parameters	–	costs	in	US$.
‡ For costs we assumed a ±30% credible interval on Medicare estimates.
§ LVEF = left ventricular ejection fraction
nr. Parameter mean 95% confidence limits source
utilities chest pain states
38  No 0.87 0.80 0.92 197
39  Mild 0.81 0.76 0.86 197
40  Severe 0.67 0.56 0.77 197
disutilities (in days lost)
41  CABG 30 24 36 expert opinion
42  Angiography 1 0.8 1.2 expert opinion
43  myocardial infarction 10 8 12 expert opinion
44  PCI 2.5 2 3 expert opinion
Table 1C Model parameters – utilities.
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nr. parameter ‡ mean 95% confidence limits source
effects medical treatment only
45  risk myocardial infarction with 0-VD 1.0 0.7 1.5 198
46  risk myocardial infarction with 1/2-VD 2.1 1.5 2.9 198
47  risk myocardial infarction with 3-VD / LMD 2.7 2.1 3.5 198
48  relative risk die with 1/2-VD * 2.3 1.9 2.8 199
49  relative risk die with 3-VD * 3.6 3.1 4.1 199
50  relative risk die with LMD * 9.6 6.2 14.3 199
51  % for annual transitions between chest pain 
 states after medical treatment
see Table 2
52  risk future procedure 0-VD 0.5 0.2 1.0 200
53  risk future procedure 1-VD 1.0 0.5 1.7 200
54  risk future procedure 2-VD 4.2 3.0 5.5 200
55  risk future procedure 3-VD/LMD 7.5 6.0 9.2 200
56  % CABG of future procedures 0/1-VD 16 13.8 18.3 200
57  % CABG of future procedures 2-VD 58 55 61 200
58  % CABG of future procedures 3-VD/LMD 87 85 89 200
LVEF (treatment independent) §
59  risk abnormal LVEF with 0-VD 0.5 0.4 0.7 198
60  risk abnormal LVEF with 1-VD 2.0 1.7 2.3 198
61  risk abnormal LVEF with 2-VD 5.0 4.5 5.5 198
62  risk abnormal LVEF with 3-VD 6.0 5.5 6.5 198
63  risk abnormal LVEF with LMD 6.0 5.5 6.5 198
Table 1D Model parameters – medical treatment.
‡ All risks – except relative risks – are annual risks and expressed in %. 
§ LVEF = left ventricular ejection fraction
* Relative risks of dying are in comparison to life table mortality.
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nr. parameter ‡ mean 95% confidence limits source
short-term risks with PCI
64  myocardial infarction if 1-VD 3.5 2.7 4.4 201
65  myocardial infarction if 2-VD 5.2 4.3 6.2 201
66  die if 1-VD 0.2 0.1 0.5 202, 203
67  die if 2-VD 0.9 0.5 1.4 202, 203
effects PCI
68  reduction in myocardial infarction 17 12 22 204
69  reduction in mortality if 1/2-VD 15 0 50 200
70  % for annual transitions between 
 chest pain states after PCI
see Table 2
71  relative risk chest pain 
 improvement of PCI vs. CABG
0.85 0.80 0.90 200
72  relative risk of reprocedure 
 for stent vs. PTCA§
0.5 0.2 0.8 205
73  % eligible for PCI 76 61 91 205
74  annual risk of reprocedure after PCI 4 2 5 200
75  % CABG of reprocedures 22 19 25 200
Table 1E. Model parameters – PCI.
‡ All values are expressed in %, except the relative risks
§ PTCA = percutaneous transluminal coronary angioplasty
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nr. parameter ‡ mean 95% confidence limits source
short-term risks CABG
76  myocardial infarction if 3-VD 7.0 5.9 8.2 201
77  myocardial infarction if LMD 7.0 5.9 8.2 201
78  die if 35yr male 2.3 0.2 6.6 206
79  die if 35yr female 2.9 0.1 10.9 206
80  die if 45yr male 2.7 1.6 4.2 206
81  die if 45yr female 3.5 1.6 6.1 206
82  die if 55yr male 3.2 2.3 4.2 206
83  die if 55yr female 4.1 2.6 5.8 206
84  die if 65yr male 4.4 3.5 5.4 206
85  die if 65yr female 5.7 4.1 7.5 206
86  die if 75yr male 6.3 5.1 7.6 206
87  die if 75yr female 8.0 6.0 10.3 206
effects CABG
88  reduction in myocardial infarction 42 29 55 198
89  reduction in mortality if 3-VD 48 29 64 199
90  reduction in mortality if LMD 67 40 84 199
91  % from mild to no angina 60 55 65 198
92  % from severe to mild angina 70 65 75 198
93  % from severe to no angina 10 7 13 198
94  % for annual transitions between 
 chest pain states after CABG
see Table 2
95  annual risk of reprocedure 
 after CABG
2 1 3 200
96  % CABG of reprocedures 7 5 9 200
Table 1F. Model parameters – CABG.
‡ All values are expressed in %.
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Table 2
Dirichlet distributions were 
used to represent uncertainty 
about the annual transition 
probabilities between chest 
pain severity states. These 
transitions depend on the ex-
tent of vessel disease and the 
treatment. The parameters of 
the dirichlet distributions are 
the number of patients that 
transit to each health state. 
For example, for patients with 
1 vessel disease, medical 
treatment, and no chest pain, 
26 out of 164 patients had 
mild chest pain at the end of 
the year. These numbers were 
derived and extrapolated from 
the CASS-registry.85, 198
sample size none mild severe
Medical treatment, 1-VD
 none 164 136 26 2
 mild 309 46 244 19
 severe 20 5 7 8
CABG/PCI, 1-VD
 none 263 226 34 3
 mild 188 43 134 11
 severe 18 5 6 7
Medical treatment, 2-VD
 none 193 154 37 2
 mild 449 49 359 40
 severe 42 8 10 23
CABG/PCI, 2-VD
 none 428 376 47 4
 mild 262 34 225 3
 severe 14 3 4 8
Medical treatment, 3-VD/LMD
 none 202 135 65 2
 mild 360 86 259 14
 severe 31 3 3 25
CABG/PCI, 3-VD/LMD
 none 316 262 51 3
mild 208 31 164 12
severe 15 4 5 6
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Table 3
Dirichlet distributions repre-
senting uncertainty about pre-
test probability of CHD were 
based on observational study 
results.85 The probabilities de-
pend on gender, age, and type 
of chest pain. For example, 
249 men with non-specific 
chest pain were observed of 
whom 5 had one vessel dis-
ease.
subgroup sample size 0-VD 1-VD 2-VD 3-VD LMD
NON-SPECIFIC
Men
 30-39 249 242 5 0 2 0
 40-49 391 344 35 8 4 0
 50-59 440 361 48 18 4 9
 60-69 129 94 15 12 6 1
 >70 22 8 2 7 5 0
Women
 30-39 135 130 3 1 0 1
 40-49 425 408 13 4 0 0
 50-59 585 550 23 12 0 0
 60-69 215 194 15 2 2 2
 >70 23 23 0 0 0 0
ATYPICAL
Men
 30-39 171 92 32 31 12 3
 40-49 568 244 131 80 85 28
 50-59 919 267 221 221 147 64
 60-69 434 95 91 104 100 43
 >70 46 3 10 11 15 7
Women
 30-39 39 31 4 2 0 2
 40-49 257 177 46 18 5 10
 50-59 414 290 54 37 25 8
 60-69 264 137 58 34 24 11
 >70 34 15 5 5 8 1
TYPICAL
Men
 30-39 66 11 25 15 10 5
 40-49 402 48 109 105 96 44
 50-59 840 42 168 244 269 118
 60-69 539 27 86 129 199 97
 >70 67 2 6 10 33 16
Women
 30-39 10 3 1 3 2 1
 40-49 70 31 15 12 12 0
 50-59 161 52 35 31 31 13
 60-69 137 26 19 34 44 14
 >70 23 1 5 2 13 2
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aPPENdIX 4 – ChaPTER 4
Example calculation of 10-year risk for base case patient:
base case patient: men 60 yr, average total cholesterol (212.5), average HDL (44.9), aver-
age (treated) SBP (129.7), nonsmoker, nondiabetic
=	3.061*(log(60)-3.856)+1.124*(log(212.5)-5.342)-0.933*(log(44.9)-
	 3.769)+1.933(0-4.354)+1.999*(log(129.7)-0.502)+0.655*(0-0.352)+
 0.574*(0-0.065)=0.7517
 
Note:
For the analysis of parameter uncertainty we assumed that the regression coefficients of 
“SBP if treated” and “SBP if untreated” had a correlation of 1. We used the standard equa-
tion for the conditional random value of a bivariate normal distribution:                               . 
x and y represent the correlated beta’s.
 
aPPENdIX 5 – ChaPTER 6
We will prove equation 10, showing that the total expected value of perfect information 
(total EVPI) is independent of the path in Figure 1. We want to show that:
Total EVPI =  pEVPI(µ
I
) + E
µI
 pEVPI(µC|µI).
Substituting the definitions of total and partial EVPI (equations 4 and 5), we get:
E
µ
 max
a
 B(a,µ) - max
a
 E
µ
 B(a,µ) = 
[E
µI
 max
a
 E
µC|µI B(a,µ) - maxa Eµ B(a,µ)]	+
E
µI
 [E
µC maxa EµI|µC B(a,µ) - maxa Eµ B(a,µ)].
Collecting and canceling terms leads to:
E
µ
 max
a
 B(a,µ) = E
µI
 max
a
 E
µI|µC B(a,µ)	+	Eµ maxa B(a,µ)
- E
µI
 max
a
 E
µI|µC B(a,µ),
which proves the equality we set out to prove.
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SYNTAX FOR EXCEL
The algorithms for the VOI analyses are described using a spreadsheet such as Excel. The 
analyses are easier and faster using visual basics for Excel. We didn’t use visual basics, 
because many are not familiar with it. Moreover, if you’re used to writing syntax, we recom-
mend R because it is much faster than visual basics.
general preparation for VOI analyses
1. Create a separate worksheet for the data of each intervention. 
2. Set up the data with patients in rows and parameters in columns. The first row is the 
header.
3. Set costs as negative values. 
4. The last column of the datasheet should contain the monetarized values of the quality-
adjusted life expectancy: choose a value for the WTP threshold (e.g., 80,000 euro/
QALY),	and	multiply	each	quality-adjusted	life	expectancy	with	the	WTP.	
5. Calculate the net monetary benefit for each patient in the column on the right of the 
datasheet.
The syntax below assumes a total of 12 parameters in columns A to L, with patient-level 
data on 75 patients for each intervention. Column M of the datasheet contains the net 
monetary benefit. We perform the analyses for 10,000 simulations. Each algorithm is per-
formed in a separate sheet. We refer to the cells in a bold capital and number followed by 
a colon. 'PTA data'! refers to the worksheet named PTA data.
preparation for total EVPI and total EVSI analyses
A1: =AVERAGE('PTA data'!M2:M76) # mean net benefit of PTA
B1:	=AVERAGE('EX	data'!M2:M76)	 #	 mean	net	benefit	of	EX
A2:	=SQRT(VAR('PTA	data'!M2:M76)/75)	 #	 standard	error	of	the	mean	net	
  benefit of PTA
B2:	=SQRT(VAR('EX	data'!M2:M76)/75)	 #	 standard	error	of	the	mean	net
	 	 	benefit	of	EX
total EVPI – in Excel
A4:	=NORMINV(RAND(),A$1,A$2)	 #	 step	1
B4:	=NORMINV(RAND(),B$1,B$2)
C4:	=MAX(A6:B6)-IF(A$1>B$1,A6,B6)	 #	 step	2
copy cells A4, B4, and C4 to rows 5 to 10003 # step 3
C1: =AVERAGE(C4:C10003) #step 4
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total EVSI – in Excel
D1: =500 # step 1
A4:	=NORMINV(RAND(),A$1,A$2)	 #	step	2
B4:	=NORMINV(RAND(),B$1,B$2)
C4:	=NORMINV(RAND(),A4,SQRT(VAR('PTA	data'!M$2:M$76)/D$1))	 #	step	3
D4:	=NORMINV(RAND(),B4,SQRT(VAR('EX	data'!M$2:M$76)/D$1))
E4:	=(A$1*75+C4*D$1)/(75+D$1)	 #	step	4
F4:	=(B$1*75+D4*D$1)/(75+D$1)	 #	step	4
G4:	=MAX(E6:F6)-IF(A$1>B$1,E6,F6)	 #	step	5
copy cells A4, B4, C4, D4, E4, F4, and G4 to rows 5 to 10003 # step 6
C1: =AVERAGE(G4:G10003) # step 7
preparation for partial EVPI and partial EVSI analysis
A1: =AVERAGE('PTA data'!M2:M76) # mean net benefit of PTA
B1:	=AVERAGE('EX	data'!M2:M76)	 #	 mean	net	benefit	of	EX
A4 to A15: “select value 1 or 0 for each cell” # PTA: 1= µI, 0= µC
B4	to	B15:	“select	value	1	or	0	for	each	cell”	 #	 EX:	1=	µI, 0= µC
C4: =IF(A4=1,0,1) # PTA: 0= µI, 1= µC
D4:	=IF(B4=1,0,1)	 #	 EX:	0=	µI, 1= µC
copy cells C4 and D4 to rows 5 to 15
E4: =MMULT('PTA data'!A2:L76,A4:A15) # matrix multiplication
select cells E4 to E78, press F2, press ctrl-shift-enter # net benefit per patient of PTA
  for µI
E1: =AVERAGE(E4:E78) # mean NB of PTA for µI
E2: =sqrt(var(E4:E78)/75) # sem of mean NB of PTA for µI
F4:	=MMULT('EX	data'!A2:L76,B4:B15)	 #	 matrix	multiplication
select	cells	F4	to	F78,	press	F2,	press	ctrl-shift-enter	 #	 net	benefit	per	patient	of	EX	
  for µI
F1:	=AVERAGE(F4:F78)	 #	 mean	NB	of	EX	for	µI
F2:	=sqrt(var(F4:F78)/75)	 #	 sem	of	mean	NB	of	EX	for	µI
G4: =MMULT('PTA data'!A2:L76,C4:C15) # matrix multiplication
select cells G4 to G78, press F2, press ctrl-shift-enter # net benefit per patient of PTA
  for µC
G1: =AVERAGE(G4:G78) # mean NB of PTA for µC
G2: =sqrt(var(G4:G78)/75) # sem of mean NB of PTA for
  µC
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H4:	=MMULT('EX	data'!A2:L76,D4:D15)	 #	 matrix	multiplication
select	cells	H4	to	H78,	press	F2,	press	ctrl-shift-enter	 #	 net	benefit	per	patient	of	EX
  for µC
H1:	=AVERAGE(H4:H78)	 #	 mean	NB	of	EX	for		
H2:	=sqrt(var(H4:H78)/75)	 #	 sem	of	mean	NB	of	EX	for	µC
partial EVPI – in Excel
I4:	=NORMINV(RAND(),E$1,E$2)	 #	 step	1
J4:	=NORMINV(RAND(),F$1,F$2)
K4:	=G$1+((CORREL(E$4:E$78,G$4:G$78)*G$2*(I4-E$1))/E$2)	 #	 step	2
L4:	=H$1+((CORREL(F$4:F$78,H$4:H$78)*H$2*(J4-F$1))/F$2)
M4:	=I4+K4	 #	 step	3
N4:	=	J4+L4
O4:	=MAX(M4:N4)-IF(A$1>B$1,M4,N4)	 #	 step	4
copy cells I4, J4, K4, L4, M4, N4, and O4 to rows 5 to 10003 # step 5
O1: =AVERAGE(O4:O10003) # step 6
partial EVSI – in Excel
D1: =500 # step 1
I4:	=NORMINV(RAND(),E$1,E$2)	 #	 step	2
J4:	=NORMINV(RAND(),F$1,F$2)
K4:	=NORMINV(RAND(),I4,SQRT(VAR(E$4:E$78)/D$1))	 #	 step	3
L4:	=NORMINV(RAND(),J4,SQRT(VAR(F$4:F$78)/D$1))
M4:	=(E$1*75+K4*D$1)/(75+D$1)	 #	 step	4
N4:	=(F$1*75+L4*D$1)/(75+D$1)
O4:	=G$1+(CORREL(E$4:E$78,G$4:G$78)*G$2*(M4-E$1))/E$2	 #	 step	5
P4:	=H$1+(CORREL(F$4:F$78,H$4:H$78)*H$2*(N4-F$1))/F$2
Q4:	=M4+O4	 #	 step	6
R4:	=N4+P4
S4:	=MAX(Q4:R4)-IF(A$1>B$1,Q4,R4)	 #	 step	7
copy	cells	I4,	J4,	K4,	L4,	M4,	N4,	O4,	P4,	Q4,	R4,	and	S4	to	rows	5	to	10003	 #	 step	8
S1: =AVERAGE(S4:S10003) # step 9
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SYNTAX FOR R
The R syntax is presented for each step of the algorithms. We used vectors to create n ran-
dom draws in one step, avoiding computer-intensive loops.
preparation for VOI analyses
Set up (e.g., in Excel) the data with patients in rows and parameters in columns. The first 
row is the header. The last parameter is the quality-adjusted life expectancy. Create a sepa-
rate file for each intervention. Save the file with extension txt (tab delimited). The syntax 
below assumes a total of 12 parameters, and 75 patients per treatment group. 
general preparation
library("MASS", character.only=TRUE) # open statistical package
pta<-read.delim("d:/r/PTA.txt",header=TRUE) # import data from folder d:/r
ex<-read.delim("d:/r/Ex.txt",header=TRUE)
pta<-as.matrix(pta) # allow for matrix calculations
ex<-as.matrix(ex)
WTP<-80000 # select a WTP
pta[,12]<-pta[,12]*WTP	 #	 monetarize	QALYs	
ex[,12]<-ex[,12]*WTP
pta[,1:11]<- -pta[,1:11] # set costs as negative values
ex[,1:11]<- -ex[,1:11]
nbPTA<-	pta[,12]+	apply(pta[,1:11],1,sum)	 #	 create	vector	for	net	benefit
nbEX<-	ex[,12]+	apply(ex[,1:11],1,sum)
N<-100000 # select number of simulations
preparation for partial EVPI and partial EVSI analysis
PTAi<- c(0,0,0,0,0,0,0,0,0,1,0,1) # vector to select µI of PTA with 1
EXi<-	c(0,0,0,0,0,0,0,0,0,1,0,1)	 #	 vector	to	select	µI	of	EX	with	1
PTAc<-c(1,1,1,1,1,1,1,1,1,1,1,1)-PTAi # vector to select µC of PTA with 1
EXc<-c(1,1,1,1,1,1,1,1,1,1,1,1)-EXi	 #	 vector	to	select	µC	of	EX	with	1
nbPTAi<-pta%*%PTAi # total NB for µI of PTA
nbEXi<-ex%*%EXi	 #	 total	NB	for	µI	of	EX
nbPTAc<-pta%*%PTAc # total NB for µC of PTA
nbEXc<-ex%*%EXc	 #	 total	NB	for	µC	of	EX
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The	parameters	of	interest	can	be	changed	in	the	definitions	of	PTAi	and	EXi.	In	the	current	
setting the parameters-of-interest are parameter number 10 and 12 of both interventions.
total EVPI – algorithm in R
rPTA<-rnorm(N,mean(nbPTA),sqrt(var(nbPTA)/75)) # step 1
rEX<-rnorm(N,mean(nbEX),sqrt(var(nbEX)/75))
VPI<-apply(cbind(rPTA,rEX),1,max)-	rPTA	 #	 step	2
EVPI<-mean(VPI) # step 4
Step 3 is skipped because at step 1 a vector of n random values is drawn. The last term of 
step	2	should	be	replaced	with	rEX	if	exercise	is	the	optimal	treatment	given	the	WTP.
total EVSI – algorithm in R
nEVSI<-500 # step 1
rPTA<-rnorm(N,mean(nbPTA),sqrt(var(nbPTA)/75)) # step 2
rEX<-rnorm(N,mean(nbEX),sqrt(var(nbEX)/75))
rPTAs<-rnorm(N,rPTA,sqrt(var(nbPTA)/nEVSI)) # step 3
rEXs<-	rnorm(N,rEX,sqrt(var(nbEX)/nEVSI))
pPTA<-(mean(nbPTA)*75+	rPTAs*nEVSI)/(75+nEVSI)	 #	 step	4
pEX<-(mean(nbEX)*75+rEXs*nEVSI)/(75+nEVSI)
VSI<-apply(cbind(pPTA,pEX),1,max)-pPTA	 #	 step	5
EVSI<-mean(VSI) # step 7
Step 6 is skipped because at step 2 a vector of n random values is drawn. The last term of 
step	5	should	be	replaced	with	pEX	if	exercise	is	the	optimal	treatment	given	the	WTP.
partial EVPI – algorithm in R
rPTAi<-rnorm(N,mean(nbPTAi),sqrt(var(nbPTAi)/75)) # step 1
rEXi<-rnorm(N,mean(nbEXi),sqrt(var(nbEXi)/75))
rPTAc<-mean(nbPTAc)+cor(nbPTAi,nbPTAc)*sqrt(var(nbPTAc))*
(rPTAi-mean(nbPTAi))/sqrt(var(nbPTAi)) # step 2
rEXc<-mean(nbEXc)+cor(nbEXi,nbEXc)*sqrt(var(nbEXc))*
(rEXi-mean(nbEXi))/sqrt(var(nbEXi))
rPTA<-rPTAi+rPTAc	 #	 step	3
rEX<-rEXi+rEXc
VPI<-apply(cbind(rPTA,rEX),1,max)-rPTA	 #	 step	4
pEVPI<-mean(VPI) # step 6
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Step 5 is skipped because at step 1 a vector of n random values is drawn. The last term of 
step	4	should	be	replaced	with	rEX	if	exercise	is	the	optimal	treatment	given	the	WTP.
partial EVSI – algorithm in R
nEVSI<-500 # step 1
rPTAi<-rnorm(N,mean(nbPTAi),sqrt(var(nbPTAi)/75)) # step 2
rEXi<-rnorm(N,mean(nbEXi),sqrt(var(nbEXi)/75))
rPTAs<-rnorm(N,rPTAi,sqrt(var(nbPTAi)/nEVSI)) # step 3
rEXs<-rnorm(N,rEXi,sqrt(var(nbEXi)/nEVSI))
pPTAi<-(mean(nbPTAi)*75+rPTAs*nEVSI)/(75+nEVSI)	 #	 step	4
pEXi<-(mean(nbEXi)*75+rEXs*nEVSI)/(75+nEVSI)
pPTAc<-mean(nbPTAc)+cor(nbPTAi,nbPTAc)*sqrt(var(nbPTAc))*
(pPTAi-mean(nbPTAi))/sqrt(var(nbPTAi)) # step 5
pEXc<-mean(nbEXc)+cor(nbEXi,nbEXc)*sqrt(var(nbEXc))*
(pEXi-mean(nbEXi))/sqrt(var(nbEXi))
pPTA<-	pPTAi+pPTAc	 #	 step	6
pEX<-pEXi+pEXc
VSI<-apply(cbind(pPTA,pEX),1,max)-pPTA	 #	 step	7
pEVSI<-mean(VSI) # step 9
Step 8 is skipped because at step 2 a vector of n random values is drawn. The last term of 
step	7	should	be	replaced	with	pEX	if	exercise	is	the	optimal	treatment	given	the	WTP.
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